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 General Introduction
10 | Chapter 1 
In psychiatry, diagnostic classification is an important way to organize 
information concerning signs and symptoms of individuals. Since such 
classification entails far-reaching consequences for the individual patient, it 
calls for both reliability and validity. A few decades ago, this was believed by 
many to be a utopian goal. However, publication of the Feighner-criteria 
(Feighner et al., 1972) for 14 psychiatric diagnosis made it possible to base 
the third edition of the Diagnostic and Statistical Manual (DSM-III) on 
empirical research rather than on theoretical starting-points. Moreover, 
these criteria instigated the construction of standardized diagnostic 
interviews. With these developments, the reliability issue of psychiatric 
diagnosis seemed to be largely solved (Robins & Barrett, 1989). On the 
other hand, the validity of psychiatric diagnosis still seemed to be a 
different matter. 
Diagnostic validity refers to the extent to which diagnostic categories 
are related to the clinical reality of patients. Valid diagnoses help in making 
treatment decisions, in knowing something about the etiology of the 
patient’s disorder, and in predicting the course of the patient’s problems 
(Blashfield, 1989). Since specific etiologies or specific biological defects that 
cause susceptibility for a disorder are still rarely available for psychiatric 
illnesses, “the trick is to find indirect indicators that a diagnostic definition 
maps closely onto the ‘real’ underlying disorder” (Robins & Barrett, 1989, p. 
vi).  
Robins and Guze (1970) were the first to provide guidelines for 
establishing (mainly the external) validity of psychiatric diagnoses through 
these indirect indicators. They proposed five phases for achieving diagnostic 
validity in psychiatric illness: clinical description, laboratory study, 
exclusion of other disorders, follow-up study, and family study. Kendler 
(1980, 1990) expanded these criteria into three classes of potential external 
validators for psychiatric diagnoses: antecedent validators (family studies, 
premorbid personality, demographic factors, and precipitating factors), 
concurrent validators (biological and psychological tests that are not part of 
the diagnostic criteria being assessed), and predictive validators (diagnostic 
consistency over time, course of illness, and response to treatment). Over 
the years, as the neuroscience base supporting psychiatric science 
advanced, the need for a validation system not based solely on the surface 
features mentioned above evolved. Andreasen (1995) emphasized an 
additional group of external validators that could be used to link symptoms 
and diagnoses to their neural and genetic substrates: molecular genetics 
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and molecular biology, neurochemistry, neuroanatomy, neurophysiology, 
and cognitive neuroscience.  
The years following the introduction and expansion of the criteria for 
establishing diagnostic validity have given rise to many validation studies 
for different psychiatric disorders. For Attention Deficit Hyperactivity 
Disorder (ADHD), the results of these validation studies have recently been 
reviewed by Faraone (2005). He concluded that converging evidence from 
many different perspectives as denoted by Robins and Guze (1970) supports 
the diagnostic validity of the disorder, at least for children. Far fewer 
studies have been conducted to establish the validity of ADHD in adults. 
This seems only logical when one considers the fact that until relatively 
recently, children with ADHD were believed to grow out of their problems 
with attention, hyperactivity, and impulsivity once they reached adulthood. 
Only a few decades ago, it started to become evident that up to 50% of 
children with the disorder might still meet the requirements for the 
diagnosis in adulthood, leading to considerable functional impairment in 
areas of academics, employment, and personal relationships (for reviews see 
Wilens & Dodson, 2004; Wilens, Faraone, & Biederman, 2004). The social 
and societal costs of untreated as well as treated ADHD are substantial, 
which justifies the growth of research into the adult form of the disorder. 
Similar doubts about the validity of the disorder in children that still 
existed in the late seventies of the last century (Shaffer & Greenhill, 1979) 
have been expressed about the adult version of the diagnosis in more recent 
years. Moreover, the diagnosis in adults comes with additional difficulties of 
retrospectively judging symptoms from before age seven, overlap of 
symptoms with other disorders, and self-diagnoses due to extensive media 
attention (Shaffer, 1994; Barkley, 1998; Faraone, 2000; Spencer, 
Biederman, Wilens, & Faraone, 1994). According to Biederman et al. (1993), 
validity of ADHD in adults would be indicated by similarity to the childhood 
disorder with regard to patterns of psychiatric and cognitive findings. In 
reviews of validity studies (Faraone, 2000; Herpers & Buitelaar, 1996; 
Spencer et al., 1994; Spencer, Biederman, Wilens, & Faraone, 1998), it has 
been tentatively concluded that evidence for the external validators of 
Robins and Guze (1970) is available for adults with ADHD: the clinical 
correlates are very similar to those seen in children with the disorder, as are 
the co-morbid disorders. Family studies have shown that parents of 
children with ADHD children have a significantly increased risk for having 
the disorder themselves; treatment studies have indicated that stimulants 
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are also reasonably effective in ADHD in adults. Laboratory studies have 
established similar neuropsychological dysfunctions in adults and children 
with ADHD, brain-imaging studies showed abnormalities of brain regions 
that have been implicated in the etiology of ADHD in studies with children, 
and molecular genetic studies have implicated similar genes in adults and 
children with ADHD.  
Notwithstanding this mounting evidence for validity of ADHD in 
adults, there still is a paucity of studies compared to the abundance of 
papers in children. Performing a literature search in PsycINFO with the 
keyword ‘ADHD’ leads to 6640 hits, whereas the combination of ‘ADHD’ and 
‘adult’ only comes up with 715 results. Moreover, as Brinberg and McGrath 
(1985) stated: “Validity is not a commodity that can be purchased with 
techniques. Validity, as we will treat it, is a concept designating an ideal 
state – to be pursued, but not to be attained.”.  
Overall Aim of this Thesis 
The current thesis encompasses a number of empirical, clinical studies into 
various aspects of ADHD in adults. Each study has its own background in 
the literature in terms of theoretical perspectives and prior data, which will 
be expatiated on in the separate chapters. Beyond that, the common theme 
of the studies and thereby the overall aim of this thesis is to further 
substantiate the external validity (especially the concurrent and predictive 
validity) of the diagnosis ADHD in adults. 
Introduction to Separate Chapters 
The thesis commences with research into neuropsychological correlates of 
ADHD in adults, to underpin the concurrent validity of the disorder by 
psychological laboratory tests. For many years, psychological research into 
ADHD has focused on attention problems as the core deficit (Douglas, 
1999). More recently, many authors see the symptoms of ADHD as the 
consequence of disturbances in executive functioning (EF). Welsh and 
Pennington (1988) defined EF as follows: "... the ability to maintain an 
appropriate problem solving set for attainment of a future goal (p. 201)". 
Following this definition, Pennington and Ozonoff (1996) indicated five 
domains of EF: fluency (the ability to generate different solutions for a 
problem), planning (the ability to plan the steps needed to reach a solution 
for a problem), working memory (the ability to keep information online while 
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performing), inhibition (the ability to inhibit or withhold one’s actions), and 
set shifting (the ability to shift to another action or problem solving set 
when necessary). To establish which of the above mentioned EFs poses a 
problem in adults with the disorder, we conducted a meta analysis of 
studies utilizing neuropsychological tests in adult ADHD samples 
(presented in Chapter 2) and an empirical study with an extensive battery of 
neuropsychological tests comparing adults with ADHD with normal controls 
(Chapter 3). 
In Chapter 4 we offer a study into the predictive validity of ADHD in 
adults, in the form of a double blind, cross-over, placebo controlled 
medication trial with methylphenidate. This stimulant is one of the most 
effective and safest medications for the treatment of ADHD both in children 
(Schachter, Pham, King, Langford, & Moher, 2001) and in adults (Wilens, 
Spencer, & Biederman, 2002; Faraone, Spencer, Aleardi, Pagano, & 
Biederman, 2004). Methylphenidate has been shown to improve the 
executive function ‘inhibition’ on several neuropsychological laboratory 
tasks in children with ADHD (Losier, McGrath, & Klein, 1996; Scheres et 
al., 2003; Tannock, Schachar, & Logan, 1995; Tannock, Schachar, Carr, 
Chajczyk, & Logan, 1989), but information on the effect of the stimulant on 
inhibition and other cognitive variables in an adult ADHD population is still 
limited. 
Chapter 5 contains research performed with actigraphs, again 
intended to serve as building stone for the concurrent validity of the 
disorder. The chapter may provide evidence for the predictive validity of the 
disorder as well, since the actigraphs were also deployed during the 
medication trial mentioned above. Actigraphs are small devices, usually 
worn around the wrist, that detect and store movement for later analysis of 
levels of activity, sleep and wake parameters, and circadian rhythm 
parameters (Ancoli-Israel et al., 2003). Actigraphy has been utilized in 
studying children with ADHD, but it has hardly ever been employed in 
adults with the disorder. 
Finally, Chapter 6 will possibly provide another underpinning for the 
concurrent validity of ADHD in adults, by relating neuropsychological 
functioning to genetics. The above-mentioned executive functions have been 
related to the frontal lobes (e.g., Fassbender et al., 2004; Miller, 2000; Rose 
& Colombo, 2005) and to dopaminergic neurotransmitter systems (for a 
review see Coull, 1998). Precisely these are indicated in the etiology of the 
symptoms in ADHD, both by imaging studies (for a review see Durston, 
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2003) and by medication studies (for a review see Solanto, 2002). The exact 
origin of these deviations is yet unknown, but there is increasing evidence 
for a strong genetic background (see Thapar, Holmes, Poulton, & 
Harrington, 1999 for a review). Several researchers have tried to find a link 
between genes implicated in the etiology of ADHD and neuropsychological 
findings, to help define cognitive endophenotypes for molecular genetic 
studies of psychiatric disorders (Leboyer et al., 1998; Skuse, 2001). These 
endophenotype studies have so far only been performed in children with 
ADHD, but Chapter 6 provides the reader with the results of a first study in 
adults with the disorder. 
 
Next to adding to the validity of the diagnosis, the studies presented in this 
thesis also play a part in building theoretical and etiological knowledge at 
several levels of the disorder. Neuropsychological findings contribute to the 
description and therefore the phenotype of patients with the disorder, and 
to possible endophenotypes as well (Doyle, Faraone et al., 2005; Doyle, 
Willcutt et al., 2005). Especially with the use of an extensive battery of 
tests, with the inclusion of control tasks for functions that may underlie 
performance on executive functioning (EF) measures, and with the 
utilization of experimental tasks from cognitive psychology, the results will 
add to the already existing neuropsychological literature in the field. A 
similar contribution is expected from the actigraphy data. Actigraphs are a 
very new research tool in the field of adult ADHD and their use may provide 
us with some interesting new venues as well as adding to the description 
(phenotype) of the disorder. In researching the effects of one of the most 
widely used medications for ADHD on neuropsychological tests and 
actigraphic parameters, the papers also build the knowledge of the disorder 
in ways that have not often been utilized in adults with the disorder. Last 
but not least, we hope to contribute to the latest development in the 
research field of ADHD: the genetics of the disorder. By looking for the 
relationship between genetic polymorphisms and performance on 
neuropsychological tests we trust to assist in the search for endo-
phenotypes to aid the venture of laying out the genetics of ADHD. 
  
 
Boonstra, A.M., Oosterlaan, J., Sergeant, J.A., & Buitelaar, J.K. (2005). Executive 
functioning in adult ADHD: a meta-analytic review. Psychological Medicine, 
35(8), 1097-1108. 
Executive functioning in adult ADHD:
A meta-analytic review.
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ABSTRACT 
Background: Several theoretical explanations of ADHD in children have focused on 
executive functioning as the main explanatory neuro-psychological domain for the 
disorder. In order to establish if these theoretical accounts are supported by 
research data for adults with ADHD, we compared neuropsychological executive 
functioning and non-executive functioning between adults with ADHD and normal 
controls in a meta-analytic design. 
Method: We compared thirteen studies that 1) included at least one executive 
functioning measure, 2) compared the performance of an adult ADHD group with 
that of an adult normal control group, 3) provided sufficient information for 
calculation of effect sizes, and 4) used DSM-III-R or DSM-IV criteria to diagnose 
ADHD. 
Results: We found medium effect sizes both in executive functioning areas [verbal 
fluency (d=.62), inhibition (d=.64 and d=.89), and set shifting (d=.65)] and in non-
executive functioning domains [consistency of response (d=.57), word reading 
(d=.60) and color naming (d=.62)].  
Conclusions: Neuropsychological difficulties in adult ADHD may not be confined to 
executive functioning. The field is in urgent need of better-designed executive 
functioning tests, methodological improvements, and direct comparisons with 
multiple clinical groups to answer questions of specificity. 
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INTRODUCTION 
For many years, psychological research into Attention Deficit Hyperactivity 
Disorder (ADHD) has focused on attention problems as the core deficit 
(Douglas, 1999). More recently, some authors see the symptoms of ADHD 
as the consequence of disturbances in executive functioning (EF). Welsh 
and Pennington (1988) defined EF as follows: “... the ability to maintain an 
appropriate problem solving set for attainment of a future goal (p. 201)”. 
Following this definition, Pennington and Ozonoff (1996) indicated five 
domains of EF: fluency (the ability to generate different solutions for a 
problem), planning (the ability to plan the steps needed to reach a solution 
for a problem), working memory (the ability to keep information online while 
performing), inhibition (the ability to inhibit or withhold ones actions), and 
set shifting (the ability to shift to another action or problem solving set 
when necessary). 
Pennington and Ozonoff (1996) concluded that ADHD is associated 
with deficits in behavioral inhibition. In Barkley’s (1997b) theory of ADHD, 
a core deficit in inhibition causes difficulties with many other EFs, such as 
working memory, self-regulation, and motor control. Many researchers have 
indeed noted poorer performance on neuropsychological tasks designed to 
measure EF. Sergeant, Geurts, & Oosterlaan (2002) reviewed studies using 
EF tasks in children with ADHD and related disorders. They reported clear 
evidence for EF deficits in ADHD in children, although they questioned the 
specificity of EF problems for this disorder, since many other childhood 
psychiatric disorders (e.g., oppositional defiant disorder, conduct disorder) 
are also related to deficits in EF. 
In a recent qualitative review, Woods, Lovejoy, & Ball (2002) discussed 
studies in which EF measures were used with an adult ADHD sample. They 
concluded, “… that adults with ADHD demonstrate subtle impairments on 
select measures of attention and executive functions, auditory-verbal list 
learning, and complex information processing speed relative to normal 
controls (p.12)”. They further concluded “The most prominent and reliable 
measures that differentiate adults with ADHD from healthy control samples 
were the various Stroop tasks, verbal letter fluency, auditory-verbal list 
learning, and continuous performance tests (p. 28)”. 
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However much we commend the qualitative and narrative review of Woods 
et al. (2002), refinement of their conclusions can be found in a statistical or 
quantitative review of the literature. It is for this reason that we conducted 
the current meta-analytical review to quantitatively establish the difference 
between adults with ADHD and normal controls (NC) in EF. We compared 
studies using EF tests in a group of adults with ADHD and a group of NC 
adults. Since many of these tests also provide information on non-EF 
neuropsychological functions (e.g., speed of information processing, verbal 
memory) and since there are indications that not only EF is impaired in 
ADHD (e.g., Woods et al., 2002), we decided to also include non-EF 
variables from the EF tasks in our meta-analysis. 
METHOD 
Papers for consideration were identified through a literature search in 
PsycINFO, MEDLINE, and Current Contents from 1970 (around this time 
adult ADHD was first mentioned in the literature) through September 2003.  
 
To be included in the analysis, studies had to meet the following criteria: 
 Each study had to include at least one EF measure in one or more of 
five domains, as stated by Pennington and Ozonoff (1996). 
 Studies had to compare the performance of an adult ADHD group (age 
above 18 years) with a group of NC participants. 
 Sufficient information for calculation of effect sizes (ES) had to be 
available either directly from the paper, or through the contacting 
author of the study. 
 ADHD diagnoses had to be made according to either DSM-III-R or 
DSM-IV criteria. 
 
We included only EF measures that had formerly been shown to rely on 
functioning of the frontal cortex, either in patient studies or by use of 
neuro-imaging techniques. Further, an EF measure was only included in 
the study if at least four studies with an adult ADHD sample provided 
information on the same version of the test and on the same dependent 
variables, either directly in the paper or through contacting authors. Next to 
this criterion of four studies, both the total number of ADHD participants 
and the total number of NC participants in all studies had to exceed 50 for 
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each dependent measure, in order to obtain enough power (.80) to find 
significant results for at least medium effect sizes (Cohen, 1988).  
EF Measures 
Controlled Oral Word Association (COWAT) 
The COWAT (Spreen & Benton, 1977) is a test for verbal fluency. It assesses 
the capacity to produce different words starting with a specific letter within 
a specified time interval. The dependent variable used in this meta-analysis 
was the total number of correct words generated for three letters (F, A, and 
S, or C, F, and L) in one minute per letter.  
Continuous Performance Test (CPT) 
The version of the CPT used for our analyses is the Multi Health System 
Standard Task (Conners, 1995). The task requires participants to press the 
space bar as quickly as possible when they are presented with a letter on a 
computer screen. They have to do this for every letter except for the letter X, 
in which case they are to withhold their response. The most often reported 
(and therefore chosen for our analyses) dependent variables are: 1) mean 
reaction time for hits (hit RT; to measure the latency of the response 
execution process); 2) the standard error of the mean hit reaction time (SE 
hit RT; an indication of the consistency with which respondents can focus 
their attention); 3) the number of commission errors (COM), measuring 
inhibitive behavior (high error rates indicate poor inhibitive control); 4) the 
number of omission errors (OM; indicating poor vigilance); 5) attentiveness 
(d’; usually termed 'sensitivity' in signal detection theory), which is an 
indication of the ability to discriminate between targets (X) and non-targets 
(other letters); 6) Risk taking (β). This variable notifies a person’s response 
tendency: higher values point to cautious response styles.  
WAIS Digit Span (DS) 
In the Wechsler Adult Intelligence Scale - Revised (WAIS-R; Wechsler, 1981) 
subtest DS, participants are to repeat a series of digits read aloud by the 
experimenter. In DS-Forwards (DS-F), the participant has to repeat the 
series in the same order it was read. This is a direct measure of verbal 
memory, with few EF connotations. In DS-Backwards (DS-B) the series has 
to be repeated backwards. This manipulation requires working memory. 
20 | Chapter 2 
Series of increasing difficulty level are presented. Dependent variables can 
be calculated separately for DS-F and DS-B by counting the number of 
correctly repeated series for each condition. 
Stroop Color Word Test (Stroop) 
In this measure of interference or mental inhibition (first developed by 
Stroop in 1935), a participant is shown three different cards. The first two 
cards require reading color names (card W) and naming colors (card C). The 
third card (color word: CW) is the actual interference card, which consists of 
color names, printed either in the denoted color (RED printed in red ink) or 
in a different color (RED printed in green ink). Participants are to name the 
color of the ink rather than the name of the color. Often, the number of 
correctly named colors on card CW is chosen to represent interference. This 
is one of the dependent measures chosen in this meta-analysis. However, 
one could question the validity of this variable as an indication of 
interference, since performance on the first two cards may influence scores 
on the CW card. Hammes (1971) has therefore suggested correcting the 
score on the CW card for color naming performance. We calculated this 
interference score with the raw mean data and included it as a second 
dependent variable in our analyses.  
Trailmaking Test (TMT) 
This test (Reitan & Wolfson, 1985) requires participants to connect series of 
circles. In part A (TMT-A), the circles contain numbers (1 through 25) and 
participants are instructed to connect them in counting order. This part 
requires serial information processing, visual scanning, and motor speed. 
Part B (TMT-B) contains circles with numbers and circles containing letters. 
The instruction is to connect the circles by alternating between numbers 
and letters (i.e., 1-A-2-B, etcetera). TMT-B can be considered a measure of 
both working memory and interference control (inhibition). The dependent 
variables for both part A and B are the number of seconds needed to 
complete the sequence.  
Calculation of Effect Sizes and Tests of Homogeneity 
All data were analyzed using the program Comprehensive Meta Analysis 
(Borenstein & Rothstein, 1999). We report Cohen’s d (Cohen, 1988), which 
is defined as the difference between two means divided by standard 
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deviation of either group. We corrected for sample size-bias with Hedges’ 
formula (Hedges & Olkin, 1985). Our effect sizes are therefore slightly more 
conservative than uncorrected ones, although differences between corrected 
and uncorrected indices are usually slight (Kulik & Kulik, 1989). The closer 
Cohen’s d comes to zero, the smaller the difference between two groups. For 
each dependent variable, the effect sizes from each study are combined into 
a grand mean estimate of the difference in performance between ADHD 
participants and NC participants. In accordance with Cohen (1988), we 
consider values between 0.2 and 0.5 as small, between 0.5 and 0.8 as 
medium, and above 0.8 as large.  
In a meta-analysis, one assumes that all effect sizes are derived from 
a single population. The amount of variation (i.e., heterogeneity) within the 
established effect sizes is reflected by the Q-statistic (Hedges & Olkin, 
1985). If effect sizes are homogeneous, this Q-statistic will not exceed a 
critical value associated with an a priori established alpha level (in this 
study p=.05). If effect sizes are not homogeneous, this could imply that 
other factors than chance and EF have influenced the results. An overview 
of these potential moderator variables will be provided in the Results 
section. 
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RESULTS 
Executive Functions 
We obtained data on five EF tests in 13 different studies that met our 
criteria for inclusion (see Table 2.1). 
 
Table 2.1 
Studies included in the current meta-analysis 
Study Subjects (% males in sample) 
Age 
M (SD) Test & dependent variable 
Barkley et al. 
(1996) 
 
 
ADHD n = 25 (64%) 
NC n = 23 (61%) 
ADHD  22.5 (4.0) 
NC  22.0 (4.0) 
COWAT 
CPT Hit Reaction Time 
CPT SE Reaction Time 
CPT Omissions 
CPT Attentiveness (d’) 
CPT Commissions 
CPT Risk Taking (β) 
Dinn et al. 
(2001) 
 
ADHD n = 25 (36%) 
NC n = 11 (45%) 
ADHD  35.6 (15.9) 
NC  35.4 (9.9) 
COWAT 
 
Epstein et al. 
(1998) 
ADHD n = 60 (57%) 
NC n = 72 (58%) 
 
ADHD  35 (11) 
NC  25 (10) 
CPT Hit Reaction Time 
CPT SE Reaction Time  
CPT Omissions 
CPT Attentiveness (d’) 
CPT Commissions 
CPT Risk Taking (β) 
Epstein et al. 
(2001) 
ADHD n = 25 (40%) 
NC n = 30 (50%) 
 
ADHD  33.6 (-) 
NC  33.4 (-) 
CPT Hit Reaction Time 
CPT SE Reaction Time  
CPT Omissions 
CPT Attentiveness (d’) 
CPT Commissions 
CPT Risk Taking (β) 
Holdnack et al. 
(1995) 
ADHD n = 25 (60%) 
NC n = 30 (63%) 
ADHD  30.6 (8.5) 
NC  26.7 (6.7) 
Trailmaking Test – A 
Johnson et al. 
(2001) 
 
 
ADHD n = 56 (71%) 
NC n = 38 (63%) 
 
ADHD  33.3 (8.42) 
NC  40.8 (10.24) 
COWAT 
Stroop Word 
Stroop Color 
Stroop Color Word 
Stroop Interference 
Trailmaking Test – A 
Trailmaking Test – B 
Lovejoy et al. 
(1999) 
 
 
ADHD n = 26 (50%) 
NC n = 26 (50%) 
 
ADHD and NC range 21-55, 
median 41 
COWAT 
Trailmaking Test – A 
Trailmaking Test – B 
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Table 2.1 (continued) 
Studies included in the current meta-analysis 
Study Subjects (% males in sample) 
Age 
M (SD) Test & dependent variable 
Murphy (2002) ADHD n = 18 (100%) 
NC n = 18 (100%) 
ADHD range 27-58 
NC range 25-59 
Trailmaking Test – A 
Trailmaking Test – B 
Murphy et al. 
(2001) 
 
 
ADHD n = 105 (75%) 
NC n = 64 (69%) 
 
ADHD  21.1 (2.7) 
NC  21.2 (2.4) 
COWAT 
CPT Hit Reaction Time  
CPT SE Reaction Time 
CPT Omissions 
CPT Attentiveness (d’) 
CPT Commissions 
CPT Risk Taking (β) 
WAIS DS Forwards 
WAIS DS Backwards 
Rapport et al. 
(2001) 
 
 
ADHD n = 35 (69%) 
NC n = 32 (59%) 
 
ADHD  32.9 (10.8) 
NC  33.2 (13.2) 
COWAT 
Trailmaking Test – A 
Trailmaking Test – B 
Riordan et al. 
(1999) 
 
 
ADHD n = 21 (81%) 
NC n = 15 (47%) 
 
ADHD 31.8 (11.8) 
NC 36.5 (10.8) 
COWAT 
Stroop Word 
Stroop Color 
Stroop Color Word 
Stroop Interference 
WAIS DS Forwards 
WAIS DS Backwards 
Trailmaking Test – A 
Trailmaking Test – B 
Taylor & Miller 
(1997) 
ADHD n = 211 (-) 
NC n = 28 (-) 
 
- Stroop Word 
Stroop Color 
Stroop Color Word 
Stroop Interference 
Trailmaking Test – A 
Trailmaking Test – B 
Walker et al. 
(2000) 
 
ADHD n = 30 (83%) 
NC n = 30 (67%) 
ADHD  25.8 (8.7) 
NC  25.8 (6.8) 
COWAT 
CPT Hit Reaction Time 
CPT SE Reaction Time  
CPT Omissions 
CPT Commissions 
Stroop Word 
Stroop Color 
Stroop Color Word 
Stroop Interference 
WAIS DS Forwards 
WAIS DS Backwards 
Trailmaking Test – A 
Trailmaking Test – B 
Note. Dashes indicate that information was not provided in original paper. ADHD = Attention Deficit Hyperactivity Disorder; 
COWAT = Controlled Oral Word Association; CPT = Continuous Performance Test; NC = Normal Control; SE = Standard Error; 
WAIS DS = WAIS Digit Span. 
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The results of the analyses of the EF measures are summarized in Table 
2.2. Positive effect sizes (Cohen’s d) indicate a better performance for the NC 
group, while negative effect sizes point toward an advantage for those with 
ADHD. As can be concluded from values of the Q-statistic in Table 2.2, 
heterogeneity in effect sizes was found for the COWAT, CPT risk taking, and 
Stroop CW.  
For the COWAT, we found a medium positive ES of .62 (p=.00). This 
indicates that NC participants generated more words during this verbal 
fluency task than ADHD participants. An also medium positive ES of .55 
(p=.00) was established for attentiveness (d’) on the CPT, denoting that the 
NC group showed a better ability to distinguish important from non-
important information on a stimulus level. ADHD participants showed 
worse inhibition as measured by commission errors on the CPT, reflected in 
a medium positive ES of .64 (p=.00) for this variable. For risk taking (β) on 
the CPT, there was a non-significant (p=.26) small negative ES of -.22. This 
indicates that there was no difference in response style (impulsive versus 
cautious) between the ADHD and the NC group. The ADHD group 
performed much worse on interference control as measured by the Stroop 
CW card, as indicated by a large positive ES (d=.89, p=.00). However, when 
we controlled the score on the CW card for color naming (the score on card 
C), there was no difference between the two groups, as indicated by the 
positive ES of .13 (p=.26). On Trails B, a medium positive ES of .65 (p=.00) 
could be established, indicating that the NC participants performed better 
at this set shifting measure than the ADHD participants. Finally, we found 
a small positive ES of .44 (p=.01) for WAIS DS BW, implying that the ADHD 
group has more problems with verbal working memory than the NC group. 
Non-Executive Functions 
The results of the analyses of the non-EF measures are summarized in 
Table 2.3. Q-values indicated homogeneity for all but two non-EF effect 
sizes (Stroop W and Stroop C). 
For Hit RT on the CPT, there was a non-significant ES of -.03 (p=.79), 
which indicates that there were no differences in reaction time speed for 
correct responses between the ADHD and the NC group. The ADHD group 
showed more variability in reaction times than the NC group, as shown by 
the medium positive ES of .57 (p=.00) for HIT RT SE. The medium positive 
ES of .50 (p=.00) for omission errors on the CPT points out that the ADHD 
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participants made more of this type of errors, suggesting worse vigilance in 
this group. Both for the Stroop W card and the Stroop C card we observed 
medium positive effect sizes of .60 (p=.02) and .62 (p=.01), respectively. 
These values imply that the ADHD group had more difficulties than the NC 
group on both color name reading and color naming. The small positive ES 
of .46 (p=.00) for TMT-A denotes that the ADHD group performed poorer 
than the control group on this measure of serial information processing, 
visual scanning, and motor speed. A small positive ES of .29 (p=.02) for 
WAIS DS FW indicates that there is only a small, but significant advantage 
for the NC group as far as verbal memory span is concerned. 
Moderator Variables 
A major problem in meta-analytic research is the fact that factors other 
than chance and the cognitive processes under study (EF and non-EF) may 
influence the difference between groups, especially in the case of 
heterogeneity in effect sizes. Statistical correction for these factors in a 
meta-analysis is only sensible with a larger number of studies than was 
included in the present paper. Therefore, we now discuss several potential 
moderator variables (see Table 2.4). 
 
First of all, the studies differed with respect to the diagnostic procedures for 
ADHD. One of the problems in diagnosing adult ADHD is that symptoms 
have to have started before the age of seven. This means retrospectively 
establishing those symptoms, which raises questions of reliability and 
validity of the diagnosis. Another concern is the reliability of patient self-
reports about their symptoms (Barkley, Fischer, Smallish, & Fletcher, 
2002). Therefore, to reduce the chance of both false positives and false 
negatives, it is best if more than one informant is consulted (e.g., the 
patient, a parent, a spouse) and if more than one type of measurement is 
used (e.g., self-report questionnaires, clinical interviews, structured 
interviews; Weiss & Murray, 2003). Next to heterogeneity between samples, 
ADHD in itself is a heterogeneous diagnosis with many different symptoms 
leading to several different subtypes, which also complicates comparing 
studies.  
Another confounder can be found in the fact that approximately 75% 
of adults with ADHD suffer from other psychiatric disorders as well 
(Biederman et al., 1993). Many of these disorders may also be attended with 
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cognitive disabilities, so that it is hard to conclude if established difficulties 
in cognitive areas are related to the ADHD or to the co-existing disorder. 
Ideally, participants should be tested for co-existing disorders and there 
should be some form of statistical correction for this co-morbidity.  
Thirdly, men and women differ in their cognitive abilities (Kimura, 
1996), so if the composition of the ADHD group and the NC group differs 
with respect to sex, this may influence the results. Also, it may not be 
possible to compare studies when some have included only men, and others 
have also tested women.  
A fourth possible moderator variable is the intelligence level of 
participants. There is continuing debate in the current literature as to 
whether EF data should be corrected for overall IQ level (Denckla, 1996). 
Especially in children with ADHD, many researchers have noted a 
correlation between EFs and IQ (e.g., Ardila, Pineda, & Rosselli, 2000), 
indicating at least a relation between the two. Other researchers (e.g., Nigg, 
2001) have argued that controlling for IQ might remove some of the 
variance that is related to ADHD. Ideally, researchers should therefore 
report their EF results with and without controlling for overall IQ 
performance (Barkley, 1997b). This was done in only two of the 13 studies 
used for this meta-analysis (Johnson et al., 2001; Murphy, Barkley, & 
Bush, 2001).  
Next, the medication of choice for ADHD (methylphenidate) is known 
to have an effect on several cognitive abilities, both in children (e.g., 
Tannock et al., 1995) and in adults with the disorder (e.g., Kuperman et al., 
2001). However, in three studies included in this review, it was not even 
mentioned whether ADHD participants were taking medication or not 
(Epstein, Conners, Sitarenios, & Erhardt, 1998; Murphy, 2002a; Taylor & 
Miller, 1997).  
Finally, one would preferably want to compare the ADHD group with a 
group of NCs that, in line with the argumentation for other moderating 
variables, shows no signs of psychopathology, does not take any kind of 
psychotropic medication, and is of similar gender, age and IQ as the ADHD 
group. The NC groups in the studies included here vary largely. In some 
studies, the criteria for the NC groups remain vague (Dinn, Robbins, & 
Harris, 2001; Epstein et al., 1998). Most researchers clearly state that NC 
participants were not allowed to score above a certain cut off score on some 
measure for ADHD, although childhood ADHD was not always an exclusion 
criterion (Johnson et al., 2001). Neurological conditions or events and other 
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psychiatric diagnoses were usually reason for exclusion, although studies 
varied in the ways of establishing these other diagnoses (by clinical 
interview, structured interview, self-report or questionnaires). In the study 
by Taylor & Miller (1997), the ‘No Diagnoses’ group consisted of people who 
were self referred for evaluation of ADHD, but who did not meet DSM-IV 
criteria for ADHD. One could of course question how compatible this latter 
group was to other NC groups, and even if this group would not be more 
like the ADHD group than like a NC group.  
DISCUSSION 
We conducted the present study to establish a quantitative account of the 
difference in EF between adults with ADHD and NCs. We included non-EF 
dependent variables from the EF tasks, in order to determine whether 
deficits are specific to EF or not. As far as we know, this study is one of the 
first quantitative reviews of this topic, and based on the average number of 
subjects for each analysis, the analyses had enough power to be able to 
draw some firm conclusions. 
Our results in the EF domain are in agreement with the child-
literature on ADHD, where differences between children with ADHD and 
NCs in the areas of verbal fluency, inhibition, and set shifting have been 
reported consistently (Sergeant et al., 2002). In their qualitative review, 
Woods et al. (2002) concluded that Stroop tasks, verbal letter fluency, 
auditory verbal list learning, and continuous performance tests 
discriminate best between adult ADHD and NC samples. Our data provide 
no answers with respect to auditory verbal list learning, since insufficient 
data were available for these analyses. With respect to Stroop tasks, our 
data demonstrated that people with ADHD show worse performance than 
NCs on all three cards of the Stroop, not just on the interference (CW) card. 
When controlling for performance on the Color card, the effect size for the 
Color Word card was no longer significant. Therefore, we cannot conclude 
that adults with ADHD show poor selective visual attention and/or 
prepotent response inhibition, as Woods et al. (2002) suggested. Future 
research including the Stroop Color Word Test should correct for 
performance on at least the Color card when reporting interference results 
for this test. With respect to the Trailmaking Test, Woods et al. (2002) 
concluded that many studies have shown differences on part A, and not so 
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much on part B. According to these authors, this may be related to the 
initial novelty of the task. Our quantitative analyses are partly in agreement 
with this point, since we found a small ES for TMT-A. However, we found a 
larger ES for part B, indicating more robust differences on this part of the 
test. Based on our data, one might conclude that there is a set shifting 
problem in adult ADHD, and not just a problem with novelty. To be able to 
draw firmer conclusions in this area, it will be necessary to correct 
performance on part B for performance on part A, as was done with the 
Stroop Color Word Test. However, the data to perform these analyses were 
not available. It would make sense for future studies to correct performance 
on part B for performance on part A, by looking at difference scores. The 
same advice holds for WAIS Digit Span, where one should correct 
performance on DS Backwards for performance on DS Forwards, before 
conclusions with respect to working memory can be drawn, based on 
performance on this test. With respect to verbal fluency tests, our data are 
in agreement with the conclusion by Woods et al. (2002), however we do not 
feel that these tests “demonstrate great promise in discriminating adults 
with ADHD from comparison groups” (p.22), since other psychiatric groups 
have been shown to perform poorly on this type of measure and it thus 
lacks specificity (e.g., Harvey et al., 1997).  
In the non-EF domain, variability in reaction times has been noted 
before in relation to ADHD, both in adults (Tinius, 2003) and in children 
(Scheres, Oosterlaan, & Sergeant, 2001). Inconsistency has also been noted 
in other areas of performance in ADHD, such as motor timing (Rubia, 
Taylor, Taylor, & Sergeant, 1999). This ‘consistent inconsistency’ may well 
be related to the recent suggestion of an endophenotype (intermediate 
construct between genes and behavior) in ADHD related to variability in 
performance (Castellanos & Tannock, 2002). Although this endophenotype 
is connected to inter-individual variability, rather than variability between 
subjects, it is noteworthy that the measures with large effect sizes (COWAT 
and Stroop) are also the measures with significant Q-values. This indicates 
that also within ADHD as a group, performance may not be consistent. 
Poorer performance on the other tasks (Stroop, CPT Omissions, TMT-A, 
WAIS DS FW) has been noted before in children and adults with ADHD. 
Many of these variables seem to point towards general slowing on more 
cognitive responses (like reading, color naming, and visual search), even 
though motor response as measured by CPT HIT RT is not slower. This 
general cognitive slowing, as opposed to motor slowing, is in line with 
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earlier research (e.g., Aldenkamp et al., 2000). Verbal memory deficits 
(WAIS DS FW) have also been noted in ADHD before (Quinlan & Brown, 
2003).  
In light of the current emphasis on EF in ADHD research, we feel that 
the most striking outcome of this review is the similarity in effect sizes 
between the EF domain and the non-EF domain. Simply averaging the effect 
sizes for both domains yielded a mean ES of .40 for the EF variables (we 
excluded Stroop CW in this calculation) and a mean ES of .43 for the non-
EF domain. The total sample size of the groups compared was large enough 
to be able to conclude that these figures do not suggest a specific deficit in 
the EF realm for adults with ADHD. Rather, they suggest that in 
comparison with NC adults, adults with ADHD show disabilities in various 
areas of cognitive functioning, including EF. This conclusion needs to be 
strengthened by analyzing other tests specifically designed to measure non-
EF functions, rather than including non-EF dependent variables from EF 
tests. Nevertheless, the lack of difference between EF and non-EF effect 
sizes calls into question models of ADHD that depend heavily upon EF for 
their explanatory power, such as the model by Barkley (1997b). 
Another striking result from our study, which supports the last 
statement, is the fact that we found only one large ES, for interference 
control as measured by the Stroop CW card. However, this ES was no 
longer significant when we controlled for another function necessary to 
perform appropriately on this test (color naming). So in fact we only 
detected medium effect sizes. Cohen (1988) noted that values of f as large as 
.50 (corresponding with d-values of 1.00) are not common in behavioral 
science, but one might expect an area that has received so much attention 
in research during the past decade to yield larger effect sizes. Moreover, the 
largest effect sizes were also the ones that were accompanied by significant 
Q-values, indicating heterogeneity in results. This points to the fact that 
although EF problems are part of ADHD in adults, they are not so in every 
study and every sample. Again the question rises: should we continue the 
quest for EF difficulties in ADHD? 
The issue of specificity in EF research also underlines this last 
question. Sergeant et al. (2002) concluded that the EF problems are not 
specific for ADHD in children, since other psychopathological groups also 
showed problems with these abilities. Unfortunately, there are only very few 
studies in adult ADHD that have included clinical comparison groups. The 
few studies available suggest lack of specificity in adult ADHD as well 
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(Epstein, Johnson, Varia, & Conners, 2001; Taylor & Miller, 1997; Walker, 
Shores, Trollor, Lee, & Sachdev, 2000). It is well known that many other 
psychiatric disorders are accompanied by EF deficits, such as 
schizophrenia (Velligan & Bow-Thomas, 1999), and depression (Ottowitz, 
Dougherty, & Savage, 2002). Future research urgently needs to employ 
multiple clinical groups. Especially disorders that either have symptoms in 
common with ADHD (like depression or mania) or that share involvement of 
neurotransmitters or frontal areas with ADHD (e.g., schizophrenia) should 
be compared with ADHD.  
EFs have played a major role in many theoretical accounts of ADHD. 
Although these accounts have not been specifically proposed for ADHD in 
adults, one would expect them to be applicable to the adult version of the 
disorder. In line with Pennington & Ozonoff (1996), we would expect 
primarily deficits in the realm of behavioral inhibition and working memory, 
whereas according to the theory by Barkley (1997b), a core deficit in 
inhibition would lead to problems in all other areas of EF. Our data support 
neither view. Various researchers have made other suggestions with regard 
to a theoretical explanation of ADHD. As mentioned before, some have 
suggested general slowing as an explanation. This suggestion seems to be 
backed up by our data. Other researchers have suggested motivational 
issues and delay aversion, either on itself or in combination with inhibition 
(Sonuga-Barke, 2002), and the role of reward (Douglas, 1999). 
Unfortunately, no studies have been performed in this area with an adult 
ADHD population. This also holds for the role of energetics, which has been 
suggested by Sergeant and Van der Meere (1990). More recently, 
Castellanos and Tannock (2002) argued that one of the key characteristics 
of ADHD might be the temporal and contextual variability in performance, 
related to cerebellar dysfunction. Our results support variability in 
responses (medium ES for CPT standard error of reaction time). 
We do not believe that our similar results in the EF and non-EF 
domains indicate that we should discard the possible EF explanation for 
ADHD altogether, but it seems high time for some changes in the field. For 
one thing, it seems, now more than ever, necessary to develop reliable and 
valid measures of EF. As long as we do not have improved EF measures at 
our disposal, researchers could improve their efforts by using tests that 
include different levels of difficulty (like the Tower of London), or that 
manipulate different functions at the same time. Another way of improving 
research in this area, is by including control tasks for skills that are not 
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related to EF per se, but that are necessary to perform an EF test anyway. It 
would also be an improvement to use tasks that are based on theoretical 
accounts of specific cognitive processes, rather than tasks that have been 
defined as EF task based on lesion studies. Examples of such tasks are the 
Stop Signal Test (Logan, Cowan, & Davis, 1984), and the Self Ordered 
Pointing Test (Petrides & Milner, 1982).  
To conclude this discussion, we would like to point out some 
limitations of our study. The first one can be found in the potential 
moderator variables, of which we provided a detailed overview in our 
Methods section. Without statistical controls for the effects of the variables, 
their impact is not quantified and their possible influence should be kept in 
mind while interpreting our results. Future studies of adult ADHD should 
aim for careful diminution of methodological differences by taking these 
issues into account. The second limitation can be found in another well-
known problem in meta-analysis: the ‘file drawer problem’. This refers to 
the fact that studies without significant group differences tend to remain in 
file drawers rather than to get published. This may of course greatly limit 
the conclusions one can draw. Finally, our inclusion criteria of at least four 
studies with an adult ADHD population and a total number of participants 
exceeding 50 led to exclusion of some interesting and important papers in 
the field, of which we hope that they will stimulate further research (e.g., 
McLean et al., 2004). 
 
In sum, in this meta-analytic review we showed differences between adult 
ADHD and NC in both areas of EF and areas of non-EF. This result raises 
doubts about the current emphasis on EF research in ADHD. We feel that 
we should not view the EF research venue as a dead end yet, but that the 
field is in need of some important methodological changes before we can 
decide in favor of or against the EF hypothesis of ADHD. 
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ABSTRACT 
Forty-nine carefully diagnosed adults with Attention Deficit Hyperactivity Disorder 
were compared to 49 normal controls matched for age and gender on a large 
battery of tests in five domains of executive functioning (inhibition, fluency, 
planning, working memory, and set shifting) and several other neuropsychological 
functions to control for non-executive test demands. After stringent controls for 
non-executive function demands and IQ, adults with ADHD showed problems in 
inhibition and set shifting, but not in any of the other domains tested. These 
results imply that adult ADHD may be mainly a disorder of inhibition. 
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INTRODUCTION 
After many years of focusing on attention problems as the core deficit of 
Attention Deficit Hyperactivity Disorder (ADHD; Douglas, 1999), more and 
more researchers now see the symptoms of ADHD as the consequence of 
disturbances in executive functioning (EF). EF is a wide-ranging construct, 
with as many as 33 different definitions posed in the literature (Eslinger, 
1996). One possible definition is that of Welsh and Pennington (1988): "... 
the ability to maintain an appropriate problem solving set for attainment of 
a future goal (p. 201)". Following this definition, Pennington and Ozonoff 
(1996) have included the following domains to be shared under the wings of 
EF: fluency (the ability to generate different solutions for a problem), 
planning (the ability to plan the steps needed to reach a solution for a 
problem), working memory (the ability to keep information online while 
performing), inhibition (the ability to inhibit or withhold ones actions), and 
set shifting (the ability to shift to another action or problem solving set 
when necessary).  
Barkley (1997b) introduced EF in a unifying theory of ADHD. In his 
view, a core deficit in inhibition causes secondary difficulties in all other 
domains of EF, since all these other functions are dependent on the first 
executive, self-regulatory act of inhibition. He further postulated a 
subdivision for the crucial domain of inhibition, consisting of three 
interrelated processes: 1) inhibition of a pre-potent response (the ability to 
withhold the most obvious reaction to a stimulus); 2) inhibition of an 
ongoing response; and 3) interference control (the ability to resist 
distraction, whether it be in- or external). Barkley’s theory has been 
subjected to empirical studies in children with ADHD (e.g., Geurts, Verte, 
Oosterlaan, Roeyers, & Sergeant, 2004; Scheres et al., 2004), but to our 
knowledge there are currently no studies that have specifically tested the 
validity of his theoretical accounts in adults with the disorder. 
Many researchers have however noted poorer performance on 
neuropsychological tasks designed to measure EF, both in children with 
ADHD and in adults with the disorder. Pennington and Ozonoff (1996) 
reviewed several studies utilizing EF tasks in child psychiatric samples and 
they concluded that ADHD is mainly associated with deficits in the realm of 
behavioral inhibition. More recently, Sergeant et al. (2002) reviewed studies 
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using EF tasks in children with ADHD and related disorders. They reported 
clear evidence for several EF deficits within the five domains mentioned by 
Pennington and Ozonoff (1996) in ADHD in children. In adult ADHD, fewer 
studies into EF have been performed. In a recent qualitative review, Woods 
et al. (2002) discussed studies in which EF measures were used with an 
adult ADHD sample. They concluded, “… that adults with ADHD 
demonstrate subtle impairments on select measures of attention and 
executive functions, auditory-verbal list learning, and complex information 
processing speed relative to normal controls (p.12)”. 
However, several imperfections can be noted in earlier studies on EF 
in adult ADHD. First of all, as far as we know no study has included tasks 
tapping into all five domains of EF as denoted by Pennington and Ozonoff 
(1996) in a sufficiently large sample of adults with ADHD. Secondly, 
performance on EF tasks is dependent on several non-EF cognitive 
processes, such as perception, attention, and memory (Eslinger, 1996), 
which makes controlling for these latter functions important (Denckla, 
1996; Sergeant et al., 2002). In order to conclude that EF deficits exist in 
adults with ADHD, it should therefore be shown that these difficulties are 
independent of non-EF functions. Although some studies have included 
tasks for non-EF neuropsychological abilities, no study has controlled for 
non-EF abilities in EF tasks. Thirdly, IQ could confound EF results, since 
there seems to be a relationship between IQ and neuropsychological 
performance (Dodrill, 1999; Mahone et al., 2002). Whether IQ should be 
controlled for is a major issue of debate in the current literature. As of 
today, it remains unclear whether difficulties with EF in ADHD may be 
explained by lower levels of general cognitive ability rather than by the 
disorder, or whether the converse is more accurate: IQ deficits in ADHD 
could be a function of the impaired EF associated with the disorder. In case 
of the latter possibility, statistically controlling for IQ in the data analyses 
might well remove some of the variation in EF that is due to ADHD itself 
(Nigg, 2001). Until this controversy is resolved, it has been recommended 
that studies report their findings both ways (Barkley, 1997a). Nevertheless, 
we feel that a stronger case for the sensitivity of EF deficits in ADHD could 
be made when these deficits remain after controlling for possible differences 
in IQ. 
A fourth, relatively ignored, issue in adult ADHD studies is the effect 
of co-morbid disorders on neuropsychological functioning. ADHD in adults, 
like in children, usually co-exists with other psychiatric disorders. In 
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adults, mood and anxiety disorders are most frequently noted in connection 
with ADHD (Biederman, 2004). These disorders have been established to go 
hand in hand with neuropsychological deficits themselves (Lautenbaucher, 
Spernal, & Krieg, 2002; Ottowitz et al., 2002). If EFs are specific to ADHD, 
one would not expect ADHD with co-morbid mood and anxiety disorders to 
perform differently on EF tasks from adults with ADHD but without these 
co-morbid disorders. 
Following from the above, we conducted this study to test three main 
hypotheses. First of all, we expected adults with ADHD to show difficulties 
with all three of Barkley’s forms of inhibition. We secondly hypothesized 
these difficulties with inhibition lead to problems in the four other areas of 
EF as denoted by Pennington and Ozonoff (1996): fluency, working memory, 
planning, and set shifting. Our third and last prediction was that, since EFs 
are said to be crucial to the nosology of ADHD, problems in this domain 
would remain for our ADHD group after stringent controls for IQ and non-
EF performance. Moreover, we expected no differences on EF task 
performance between ADHD participants with and without co-morbid 
anxiety and/or mood disorders. 
METHOD 
Participants 
Forty-nine adults with ADHD between 18 and 55 years of age, 21 men and 
22 women, participated in this study. The average age was 38.7 years (SD 
9.7), and the average IQ was 100.6 (SD 17.8). Two of the participants were 
diagnosed with ADHD hyperactive/impulsive subtype, the other 47 were 
diagnosed with ADHD combined subtype. 
ADHD participants were closely matched on gender and age with 49 
normal control (NC) participants, 26 men and 23 women, between the ages 
of 18 and 55. The average age of the NCs was 38.1 years (SD 9.3), and their 
average IQ was 107.7 (SD 16.5). 
Selection of ADHD Participants 
The ADHD participants were self-referred or referred to an outpatient clinic 
in The Netherlands for assessment of ADHD. Prior to inclusion in the study, 
participants underwent a standardized clinical assessment consisting of a 
42 | Chapter 3 
psychiatric evaluation by one of two experienced psychiatrists. Details of 
the diagnostic procedure and of inclusion criteria have been provided 
elsewhere (see Chapter 4 of this thesis; Kooij et al., 2004). Data for several 
diagnostic measures are provided in Table 3.1. 
 
Table 3.1 
ADHD Group Characteristics on Diagnostic Measures 
 
measure value 
Number of currently endorsed DSM-IV criteria for ADHD (ADHD Rating Scale) M = 15.5 
SD = 2.1 
Number of DSM-IV criteria for ADHD endorsed in childhood (DIS-L) M = 12.2 
SD = 4.0 
Sheehan Disability Scale (minimum 0, maximum 30) M = 22.9 
SD = 3.2 
Global Assessment of Functioning (minimum 0, maximum 100) * M = 56.9 
SD = 5.9 
Lifetime Axis I co-morbid disorders (CIDI) 
 Any co-morbid disorder 
 Multiple co-morbid disorders (≥ 2) 
 
Current Axis I co-morbid disorders (during the last 6 months) 
 Any co-morbid disorder 
 Multiple co-morbid disorders (≥ 2) 
 Any anxiety disorder 
 Any mood disorder 
 
79.6 % 
55.1 % 
 
 
61.2 % 
32.7 % 
38.8 % 
22.45 % 
Axis II co-morbid disorders (IPDE) 
 Antisocial Personality Disorder 
 Borderline Personality Disorder 
 
12.2 % 
16.3 % 
Note. CIDI = Composite International Diagnostic Interview; DIS-L = Diagnostic Interview Schedule-section L;  
IPDE = International Personality Disorder Examination. 
* Scores above 70 indicate normal functioning. 
 
 
Selection of Normal Control Participants 
Controls were recruited through advertisements on the local hospital 
intranet and in local papers. They were paid €100,- for their participation 
and in addition they received a report on their test performance. Inclusion 
of NCs proceeded in three stages. Subjects were first screened for ADHD 
and other psychiatric disorders by telephone. During the second stage of 
screening they filled out the Dutch version of the ADHD-Rating Scale (Du 
Paul, Power, Anastopoulos, & Reid, 1998). NC participants had to obtain a 
score below the 60th percentile found in a Dutch epidemiological study 
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(Kooij et al., 2004). NC participants were not allowed to show evidence of 
childhood ADHD on three additional items assessing childhood ADHD. 
Participants also filled out the General Health Questionnaire (Goldberg & 
Williams, 1988), on which their score had to be five or lower, based on the 
suggested cut-off in the manual. In addition, participants were excluded if 
they consumed more than 15 units of alcohol per week for women or 21 
units per week for men (in accordance with the Dutch guide-lines for safe 
use of alcohol), if they used any form of drugs or psychotropic medication 
(including sleep medication), if they had ever in their life received a 
psychiatric diagnosis (including substance abuse), and if they had been in 
touch with any kind of care for mental health problems (including burn out) 
during the last three years. During the third phase, participants were 
screened for childhood ADHD with section L of the Dutch version of the 
Diagnostic Interview Schedule (Robins, Cottler, Bucholz, & Compton, 1995) 
and for lifetime and current Axis I psychiatric disorders with the Dutch 
version of the Composite International Diagnostic Interview (CIDI, version 
2.1, lifetime; Robins et al., 1988). In case of childhood ADHD on section L or 
CIDI Axis I diagnoses during the last three years, participants were 
excluded. If, during neuropsychological testing, IQ turned out to be below 
75, participants were excluded after all.  
The local Medical Ethical Committee approved the study, and all 
subjects completed a written informed consent form before inclusion in the 
study. 
Materials 
Table 3.2 provides an overview of the tests used in this study. In order for a 
task to be included in this study, the original measurement purpose of the 
task had to be related to one of the five EF domains as denoted by 
Pennington & Ozonoff (1996). Besides, the discriminative validity of the 
tests had to be shown in childhood ADHD samples. Furthermore, as much 
as possible we included tasks with a proven relationship to prefrontal 
functioning in neuro-imaging studies. Some tasks, such as the Tower of 
London and the Self Ordered Pointing Test, were included because they 
allowed manipulation of EF load within individual participants. Non-EF 
tests were tailored to EF tests, to control for the main non-EF ability in the 
latter. We required non-EF tests to show as little EF connotation as 
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possible. For detailed information on the tests, the reader is referred to 
manuals and former publications. 
EF Tasks 
Fluency 
Verbal fluency was tested by means of a Dutch category fluency test 
(Categories; Luteijn & Van der Ploeg, 1983) in which animals and 
professions have to be named. The dependent variable was the total number 
of correct responses for both categories. Next to category fluency, we also 
tested letter fluency by means of the Controlled Oral Word Association Test 
(Benton & Hamsher, 1989). The dependent variable was the total number of 
correct responses for four letters (U, N, K, and A, which are the standard 
letters used for this test in The Netherlands). We assessed non-verbal 
fluency by means of the Ruff Figural Fluency Test (Ruff, 1988). The 
dependent variable used in this study was the total number of unique 
designs. 
Planning 
To map out planning, we used the Tower of London – Revised (Schnirman, 
Welsh, & Retzlaff, 1998). This is a revision of the original task described by 
Shallice (1982) and Krikorian, Bartok, and Gay (1994). The included version 
of the test consists of 30 problems, ten of which have to be solved in four 
steps, ten in five steps, and ten in six steps. In accordance with Geurts et 
al. (2004) and Scheres et al. (2004) we took difficulty level (4, 5, or 6 steps) 
into account in calculating the dependent variable. It was expected that 
there would be a linear relationship between difficulty level and number of 
errors. Therefore, we calculated individual regression coefficients (beta 
weights), with difficulty level (three levels) as predictor and number of errors 
as dependent variable. The individual beta weights for errors were used as 
the dependent variable. We expected larger beta weights for errors for 
ADHD participants than for NCs, since larger beta weights indicate more 
errors (i.e., planning problems) with increasing difficulty level. 
Inhibition 
We included tests for three different forms of inhibition, according to the 
division proposed by Barkley (1997b). 
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Inhibition of a pre-potent response - For this form of inhibition we 
included two different tests. Firstly, the Change Task (Logan & Burkell, 
1986). This is an extension of the Stop Signal Test (Logan, Cowan, & Davis, 
1984). The Stop Signal Test merely requires participants to withhold a 
response to a visual stimulus when they hear a stop signal, whereas the 
extended Change Task requires an additional, different response after 
inhibiting the original (pre-potent) response. This additional response is 
called the Change Response, and is used in this study to measure set 
shifting. The main dependent measure for inhibition as measured by this 
task is the Stop Signal Reaction Time. This is an estimate of the latency of 
the inhibition process. Stop Signal Reaction Time cannot be measured 
directly, but it can be estimated using the Race Model (Logan, 1994). For 
information on the calculation of the Stop Signal Reaction Time, one is 
referred to Logan et al. (1984). For details on the version used in this study, 
see Chapter 4 of this thesis. 
Secondly, we included Conners’ Continuous Performance Test 
(Conners, 1995). This version differs from more traditional paradigms 
(Rosvold, Mirsky, Sarason, Bransome, & Beck, 1956) in that the response 
required for the target stimulus X is to withhold a discrete and repetitive 
motor response, rather than to respond to it. For all other stimuli, a 
response of pressing the space bar is required. To represent inhibition, we 
chose the number of commission errors as the dependent variable, with 
higher error rates indicating poor inhibitive control. 
 
Ongoing response inhibition - We included the Circle Drawing Test 
(Bachorowski & Newman, 1990) to operationalize this form of inhibition. 
The dependent variable used (referred to as ‘inhibition time’) was the 
number of seconds used to trace the circle under inhibition instructions 
minus the tracing time in a neutral condition. The larger the inhibition 
time, the better a participant is able to inhibit (slow down) the continuous 
tracing response. 
 
Interference control - To assess interference control, we included the 
Stroop Color Word Test (Stroop, 1935; Dutch version: Hammes, 1971). The 
dependent variable for this task was the interference score, calculated by 
subtracting the speed of color naming (number of seconds needed to 
complete the Color card) from the number of seconds needed to complete 
the interference (Color-Word) card. The larger this score, the worse the 
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interference control, since a larger score indicates more slowing by the 
interfering information. 
Set Shifting 
To measure set shifting we included two tests. Firstly, we included a 
measure from the Change Task (Logan & Burkell, 1986), namely the mean 
reaction time of the Change Response (see under Inhibition). The second 
test for set shifting was the Wisconsin Card Sorting Test (Grant & Berg, 
1948). We used the paper and pencil version, with a computer based 
scoring program (Harris, 1990). We chose the percentage of perseverative 
errors as our dependent variable. A perseverative error is an error based on 
a principle that is no longer correct.  
Working Memory 
Verbal working memory was mapped out with two tasks from the Dutch 
version of the Wechsler Adult Intelligence Scale-III (WAIS; Wechsler, Van 
der Steene, Vertommen, Bleichrodt, & Uterwijk, 2000): Digit Span-
Backwards and Letter Number Sequencing. For Digit Span-Backwards, the 
dependent variable was the number of correctly backwardly repeated series. 
For Letter Number Sequencing, the dependent variable was the number of 
correctly repeated series.  
We assessed spatial working memory by means of Visual Memory 
Span Backwards from the Wechsler Memory Scale-Revised (Wechsler & 
Stone, 1987). The dependent variable was the number of correctly repeated 
series. A second tests used for non-verbal working memory was the abstract 
version of the Self Ordered Pointing Task (Petrides & Milner, 1982). As with 
the Tower of London, individual beta weights were calculated as dependent 
variables, since the demand on working memory increases with the number 
of designs on the cards. Each beta weight was derived by performing 
individual regression analyses with difficulty level (6, 8, 10, or 12 designs) 
as predictor and number of errors as dependent variable. We expected beta 
weights to be larger for the ADHD group, since larger beta weights are 
indicative of working memory difficulties. 
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Non-EF Control Tasks 
We included several neuropsychological tests for functions that are required 
to perform EF tests, but that are not tapping EF functions per se. In this 
manner, we could control for the non-EF demands in the EF tasks. Which 
control test is used for which EF measure is clarified in Table 3.2. 
Wechsler Adult Intelligence Scale-III 
We estimated the IQ of participants based on four subtests of the Dutch 
version of the WAIS-III (Wechsler et al., 2000): Vocabulary, Arithmetic, 
Block Design, and Picture Arrangement. The reliability of this short form 
has not been established for the WAIS-III yet, but for the WAIS-R 
correlations of these four tests Full Scale IQ range from .93 to .95 
(Silverstein, 1982). The subtests Vocabulary and Block Design were also 
included in separate analyses as non-EF control tasks.  
Benton Visual Retention Test – Copy & Memory 
The Benton Visual Retention Test (Sivan, 1992) was included to measure 
immediate visual memory abilities (Memory condition, Administration A) 
and perceptual-motor skills (Copy condition, Administration C). For each 
condition, the dependent measure was the number of correctly reproduced 
designs. 
Purdue Pegboard 
The Purdue Pegboard (Tiffin, 1968) was included to measure dexterity and 
manual proficiency. Scores on two of the conditions of the test were 
included as dependent variables in this study: the number of pegs placed 
with both hands during 30 seconds (to measure manual proficiency), and 
the number of elements used to construct assemblies according to certain 
rules in 60 seconds (to measure alternating hand movements). 
California Verbal Learning Test 
We included the Dutch adaptation (Mulder, Dekker, & Dekker, 1996) of the 
California Verbal Learning Test (Delis, Kramer, Kaplan, & Ober, 1987) to 
assess verbal memory and learning. We included ‘level of achievement on 
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list A’ as the dependent variable. This is an overall index for verbal memory 
and learning capacities. 
Finger Tapping Test 
We included the Finger Tapping Test (Halstead, 1947) as a general measure 
of motor speed. We used the average number of taps per ten-second trial 
over five or ten trials (depending on the dispersion of trial scores) for the 
dominant hand as the dependent variable. 
Sorting Test 
The subtest Sorting from the Groninger Intelligence Test (Luteijn & Van der 
Ploeg, 1983) was designed to measure the ability to sort cards according to 
a certain principle. The dependent variable was the number of correctly 
sorted items. 
Procedure 
We tested participants during two three-hour sessions on two separate 
days, one morning and one afternoon session. Two 15-minute breaks were 
included in each session. In order to control for effects of fatigue, the tasks 
during each session were administered in two different orders that were 
randomly assigned to the participants. We used standardized instructions 
for each of the tasks. Tasks were administered and scored by the first 
author or by master students trained by the first author. 
Statistical Approach 
First, we calculated correlations between the dependent variables of the EF 
tasks to investigate whether use of composite scores to reduce the number 
of dependent variables was justified. Second, we performed two overall 
MANOVAs (with group, ADHD versus NC, as between subjects factor) on all 
dependent EF variables and on all dependent non-EF variables, to guard 
against type I errors. If these MANOVAs were significant, we proceeded to 
separate ANOVAs for separate dependent variables. Third, we compared the 
groups on the EF measures while controlling for IQ and non-EF 
performance, by means of ANCOVAs. Fourth, we compared performance on 
EF tasks between ADHD participants with and without co-morbid anxiety 
or mood disorders by means of a MANOVA. Finally, we conducted a 
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discriminant analysis to determine the predictive power of 
neuropsychological tests for a diagnosis of ADHD. 
Several researchers (Bezeau & Graves, 2001; Zakzanis, 2001) have 
encouraged emphasizing effect sizes rather than just reporting p-values, 
since p-values are dependent on power issues. We therefore decided to not 
adjust our alpha level for separate ANOVAs for the many statistical tests 
used, but to focus on effect sizes in interpreting our results. As a 
consequence, our ANOVA alpha level was set at .05. However, we 
considered results with small effect sizes (below .06) to be negligible. In 
keeping with Cohen (1988), we further considered effect sizes (partial η2, 
further referred to simply as η2) between .06 (including .06) and .14 as 
medium, and above .14 (including .14) as large.  
Missing Data and Extreme Results 
Technical difficulties or clerical errors led to missing data for some 
variables. Therefore, degrees of freedom may differ for different tests. We 
ran all ANOVAs with and without extreme cases (defined by values that 
deviated more than three box lengths from the upper or lower edge of the 
box in a box plot), and found no differences in the significance of the 
results. Therefore, we decided not to exclude extreme cases from our 
analyses. 
RESULTS 
Correlations between dependent variables 
The mean correlation between the dependent variables of the EF tasks was 
rather low (r=.23, SD=.12, range r=|.01|to|.62|). This indicates there is 
little common variance between the EF variables, which was to be expected 
since tests were selected to represent different EFs. The correlations do not 
justify using a composite EF score for the main analyses. Moreover, the 
pattern of correlations within EF domains does not warrant use of 
composite scores within domains either, although most of the correlations 
between tests intended to measure the same ability were higher than the 
mean EF correlation.  
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Group Comparisons 
Our matching procedure lead to a similar gender distribution in the ADHD 
and NC groups (each group contained 26 men and 23 women) and to 
similar ages in both groups (t(96)=.27, p=.79). However, the NC group had a 
higher IQ than the ADHD group (t(96)=-2.06, p=.04). The order in which 
tests were administered did not have an effect on the results of the EF and 
non-EF tasks, as shown with a MANOVA with all dependent EF and non-EF 
variables (Wilks’Λ=.26, F(27,62)=1.22, p=.26). Hence, subsequent analyses 
were conducted without taking test order into account. An overall MANOVA 
with all dependent EF variables demonstrated a large effect of group 
(Wilks’Λ=.62, F(14,81)=3.62, p=.00, η2=.39). Consequently, follow up 
ANOVAs and ANCOVAs seemed justified. This was also the case for the 
non-EF variables (Wilks’Λ=.73, F(13,84)=2.41, p=.01, η2=.27). 
EF Domains 
Raw means and standard deviations for EF tasks are provided in Table 3.3. 
Fluency 
For the Controlled Oral Word Association Test (verbal fluency) we 
established a significantly worse performance of the ADHD group compared 
to the NC group (F(1,96)=7.95, p=.006, η2=.08). After covarying for IQ, this 
difference remained significant (F(1,95)=4.56, p=.039), but the 
accompanying effect size was lowered to .04, which can be considered 
small. Controlling for just Vocabulary converted the difference to non-
significant (F(1,95)=3.15, p=.079, η2=.03). For Categories, no group 
differences between ADHD and NC were found (F(1,96)=1.61, p=.207, 
η2=.02). These results did not alter after covarying for IQ (F(1,95)=.20, 
p=.658, η2=.002), or Vocabulary separately (F(1,95)=.00, p=.995, η2=.00). 
 For non-verbal fluency, we found a worse performance of the 
ADHD group in comparison with the NC group (F(1,96)=5.13, p=.026). 
However, the accompanying effect size was only small (η2=.05). When 
covarying for IQ, the group difference disappeared (F(1,95)=1.96, p=.165, 
η2=.02). Covarying for non-EF performance did not alter the results 
(F(1,95)=4.91, p=.029, η2=.05). 
52 | Chapter 3 
Table 3.3 
Raw Group Means and Standard Deviations for EF Measures 
 ADHD NC 
EF Domains & EF Measures M SD M SD 
Verbal fluency 
 Categories 
 COWAT 
 
48.29 
47.37 
 
10.52 
15.18 
 
51.08 
56.37 
 
11.26 
16.41 
Non-verbal fluency 
 RFFT 
 
93.35 
 
20.95 
 
102.76 
 
20.19 
Planning 
 TOL 
 
.51 
 
1.05 
 
.52 
 
.90 
Inhibition of pre-potent response 
 CPT 
 ChT-SSRT 
 
Ongoing response inhibition 
 CDT 
 
Interference control 
 SCWT 
 
15.51 
248.34 
 
 
242.86 
 
 
37.39 
 
7.42 
100.67 
 
 
206.06 
 
 
15.57 
 
9.04 
191.99 
 
 
317.10 
 
 
25.10 
 
6.29 
67.86 
 
 
230.84 
 
 
11.14 
Set shifting 
 ChT-CR 
 WCST 
 
516.08 
11.89 
 
105.27 
6.13 
 
440.80 
12.22 
 
63.02 
10.09 
Verbal working memory 
 WAIS-DS-B 
 WAIS-LNS 
 
Spatial working memory 
 VMS-B 
 SOP 
 
5.71 
9.84 
 
 
8.02 
.67 
 
1.50 
2.10 
 
 
1.56 
.82 
 
7.02 
11.35 
 
 
8.69 
.64 
 
2.46 
2.66 
 
 
1.64 
.73 
Note. ADHD = Attention Deficit Hyperactivity Disorder; CDT = Circle Drawing Task; COWAT = Controlled Oral 
Word Association Test; CPT = Continuous Performance Test; ChT = Change Task (CR = Change Response; SSRT = 
Stop Signal Reaction Time); EF = Executive Function; NC = Normal Controls; RFFT = Ruff Figural Fluency Test; 
SOP = Self Ordered Pointing Test; SCWT = Stroop Color Word Test; TOL = Tower of London-Revised; VMS-B = 
Visual Memory Span-Backwards; WAIS = Wechsler Adult Intelligence Scale (DS-B = Digit Span-Backwards; LNS = 
Letter & Number Sequencing); WCST = Wisconsin Card Sorting Test. 
Planning 
We could not establish a difference between the ADHD and the NC group in 
planning abilities (F(1,95)=.003, p=.960, η2=.00). These results did not 
change when we reran the analyses while covarying for IQ (F(1,94)=.24, 
p=.626, η2=.00) or non-EF performance (F(1,94)=.04, p=.842, η2=.00). 
Inhibition 
Inhibition of a pre-potent response - The ADHD participants were 
significantly slower in inhibiting their pre-potent response on the Change 
Task than the NC group (F(1,96)=10.56, p=.002, η2=.10). This result 
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remained similar after controlling for IQ (F(1,95)=7.20, p=.009, η2=.07). 
Covarying for non-EF abilities was not necessary in this instance, since 
response speed is already taken into account in the calculation of the 
dependent variable. On the Continuous Performance Test, the ADHD group 
performed worse than the NC group (F(1,96)=21.69, p=.000, η2=.18). This 
effect remained large after controlling for IQ (F(1,95)=18.41, p=.000, η2=.16). 
After covarying for initial differences in response speed (mean reaction time 
on the same test), the effect became even larger (F(1,95)=28.41, p=.000, 
η2=.23). 
 
Ongoing response inhibition - We did not obtain any significant 
differences on the Circle Drawing Test, neither in the primary ANOVA 
(F(1,96)=2.82, p=.096, η2=.03), nor in the subsequent ANCOVA with IQ 
(F(1,95)=1.70, p=.195, η2=.02). Covarying for non-EF abilities was not 
necessary for this test, since initial motor speed on the neutral condition 
was already included in the dependent variable. 
 
Interference Control - The ADHD group showed larger Interference 
Times on the Stroop Color Word Test than the NC group (F(1,96)=20.17, 
p=.000, η2=.17). Covarying for IQ did not change this result (F(1,95)=16.56, 
p=.000, η2=.15). Covarying for non-EF abilities again was not necessary, 
since performance on the Color Naming Card was already included in de 
dependent variable. When we performed an exploratory ANCOVA with 
Interference Time as dependent variable and performance on the Word 
Naming Card as covariate (to see if differences in reading speed accounted 
for the effect), the NCs still outperformed the ADHD group (F(1,95)=17.48, 
p=.000, η2=.16). 
Set Shifting 
The ADHD group performed worse on the Change Response of the Change 
Task than the NC group (F(1,96)=18.45, p=.000, η2=.16). This difference 
remained highly significant after covarying for differences in IQ 
(F(1,95)=14.75, p=.000, η2=.13) and alternating movements (F(1,95)=14.26, 
p=.000, η2=.13). The Wisconsin Card Sorting Test did not yield any 
significant group results, neither in the primary ANOVA (F(1,95)=.039, 
p=.843, η2=.00), nor in subsequent ANCOVAs with IQ (F(1,94)=.99, p=.322, 
η2=.01) and sorting abilities (F(1,94)=23, p=.636, η2=.00). 
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Working Memory 
Verbal working memory - For Digit Span-Backwards, we detected a 
medium effect of group (η2=.10), with the NC group scoring significantly 
better than the ADHD group (F(1,96)=10.06, p=.002). Covarying for IQ did 
not substantially alter these results (F(1,95)=6.54, p=.012, η2=.06). 
Covarying for verbal short-term memory with results on the California 
Verbal Learning Test did not change the results either (F(1,95)=4.45, 
p=.037, η2=.05). For Letter and Number Sequencing we observed a medium 
group effect (η2=.09). The NC group showed better verbal working memory 
abilities than the ADHD group (F(1,96)=9.76, p=.002). After controlling for 
differences in IQ these results did not become considerably different 
(F(1,95)=6.18, p=.015, η2=.06). Covarying for verbal short term memory with 
the California Verbal Learning Test however, resulted in an only marginally 
significant difference (F(1,95)=3.97, p=.049, η2=.04). When we performed an 
explorative analysis for both verbal working memory tasks with 
performance on Digit Span-Forwards as a covariate (since this may be a 
purer measure of short-term verbal memory), the above-mentioned 
differences disappeared for both tasks (Digit Span-Backwards: 
F(1,95)=1.78, p=.185, η2=.02; Letter & Number Sequencing: F(1,95)=1.71, 
p=.195, η2=.02). 
 
Spatial working memory - The NC group performed better than the 
ADHD group on Visual Memory Span-Backwards (F(1,96)=4.35, p=.040), 
although this effect was only small (η2=.04). Covarying for IQ made this 
slight difference disappear (F(1,95)=2.12, p=.149, η2=.02). Controlling for 
visual short-term memory also annulled the original results (F(1,95)=2.82, 
p=.096, η2=.03). We perceived no group differences on the Self Ordered 
Pointing Test (F(1,96)=.28, p=.867, η2=.00). This result did not change after 
controlling for IQ (F(1,95)=.33, p=.569, η2=.00) or visual-short term memory 
(F(1,95)=.04, p=.837, η2=.00). 
Non-EF Abilities 
We were not primarily interested in group-differences in non-EF 
performance, since these tasks were mainly included to control for non-EF 
in EF tasks. Moreover, the EF deficiency hypothesis of ADHD does not 
predict difficulties on non-EF tests. But some interesting group differences 
between ADHD and NC subjects were established, which is why we report 
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the results on these tasks. The ADHD group performed significantly worse 
on the California Verbal Learning Test than the NC group (F(1,96)=15.81, 
p=.000, η2=.14). On the other verbal short-term memory test (Digit Span-
Forwards), the ADHD group also showed worse performance than the NC 
group (F(1,96)=12.53, p=.001, η2=.12). The last significant group effect we 
found was for WAIS-Vocabulary. ADHD participants displayed less 
knowledge of the meaning of words than the NC group (F(1,96)=9.55, 
p=.003, η2=.09). For the remaining non-EF tasks, no significant differences 
or effects exceeding the ‘small’ range could be established. Like EFs, the 
formerly described differences in non-EF functioning may also be influenced 
by differences in IQ. Therefore, we exploratively controlled the medium to 
large effects for IQ. The large effect for verbal short-term memory on the 
California Verbal Learning Test was lowered to medium (F(1,95)=11.26, 
p=.001, η2=.11). For Digit Span-Forwards, the effect remained medium 
(F(1,95)=8.76, p=.004, η2=.08). The medium effect for Vocabulary turned 
into small when controlled for IQ (F(1,95)=5.36, p=.023, η2=.05). 
Co-morbid Disorders 
ADHD participants were divided into two groups based on their scores on 
the CIDI. When their CIDI scores denoted a current (in the past 6 months) 
anxiety or mood disorder, participants were classified as ‘ADHD with 
current anxiety or mood disorder’ (ADHD+; n=25). When participants did 
not receive a current CIDI anxiety or mood disorder diagnosis, they were 
classified as ‘ADHD without current anxiety or mood disorder’ (ADHD-; 
n=24). We conducted a MANOVA on these two groups to determine the 
effect of co-morbid anxiety and mood disorders on the best distinguishing 
neuropsychological variables: Stop Signal Reaction Time and Change 
Response of the Change Task, commission errors of the Continuous 
Performance Test, and the interference score of the Stroop Color Word Test. 
The overall effect of group was not significant (Wilks’ Λ=.92, F(4,44)=.90, 
p=.471, η2=.08), indicating that there were no overall differences in 
performance between ADHD participants with and without current co-
morbid anxiety and/or mood disorders. Univariate analyses confirmed this 
result for the four separate neuropsychological tasks (data available from 
the fist author). 
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Discriminant Analysis 
To determine whether functioning on EF tests could predict a diagnosis of 
ADHD, we conducted a discriminant analysis. Since we only had two 
groups, the number of discriminant functions was limited to one. We 
therefore computed a composite score for the four best discriminating 
dependent variables: Stop Signal Reaction Time and Change Response of 
the Change Task, commission errors of the Continuous Performance Test, 
and the interference score of the Stroop Color Word Test. In order to do so 
we added reversed z-scores for these variables, so that a higher score on the 
composite indicated better overall performance. The overall Wilks’ lambda 
was significant (Λ=.72, χ2(1,N=98)=31.09, p=.000). Group membership could 
be correctly classified based on the composite score in 74.5% of the cases. 
Thirty-six of 49 participants with ADHD were correctly classified, leading to 
a sensitivity of 73.5%. Thirty-seven of 49 NCs were correctly classified as 
such, indicating a specificity of 75.5%. In order to take into account chance 
agreement, we computed a kappa coefficient and obtained a value of .51, 
which can be considered moderate (Landis & Koch, 1977). 
DISCUSSION 
The main reason for conducting this study was to ascertain if adults with 
ADHD show deficits in inhibition and other areas of EF, as predicted by the 
theoretical model for the disorder postulated by Barkley (1997b), and if 
these deficits would hold after stringent controls for non-EF and IQ 
performance. Without controlling for IQ and non-EF performance, we found 
large effects in the areas of pre-potent response inhibition, interference 
control, and set shifting, and medium effects for verbal fluency, verbal 
working memory, and another test for pre-potent response inhibition. Other 
differences were either small in terms of effect size, or did not reach 
significance. After controlling for group differences in IQ, only the effects for 
inhibition remained large. Other effects disappeared or at least diminished. 
Similar effects were noted after controlling for non-EF demands of EF tasks: 
the effect for inhibition was still large; other effects were lessened or 
vanished. In the non-EF domains, we observed medium to large effects for 
verbal short-term memory. Other differences were either small in terms of 
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effect size, did not reach significance, or became negligible after controlling 
for IQ. 
Going back to our hypotheses as stated in the Introduction, the 
results of our study only partly confirm Barkley's theory of ADHD. Based on 
our data, we do agree with his notion of inhibition as the primary deficit in 
ADHD. But according to Barkley’s theory, this primary inhibition deficit 
would irrevocably lead to deficits in other domains of EF, as stated in our 
second hypothesis. This assumption is only partly supported by our 
findings. It should be noted, however, that we did not specifically adhere to 
Barkley’s subdivision of different EFs, which is something future studies 
should aim for. Our final hypothesis stated that problems in EFs for ADHD 
should remain distinct after stringent testing for non-EFs and IQ. However, 
after controlling for differences in IQ and non-EF performance, only the 
inhibition and set shifting difficulties remained. These results are in 
keeping with other important theoretical elucidations that imply inhibition 
deficiencies (but not EF in general) as the main explanatory factor for ADHD 
(Nigg, 2001; Schachar, Tannock, & Logan, 1993), although the specificity of 
the deficiencies for ADHD remains controversial (Oosterlaan, Logan, & 
Sergeant, 1998). Our study also substantiates recent reports on possible 
endophenotypes of ADHD (Castellanos & Tannock, 2002; Slaats-Willemse, 
Swaab-Barneveld, de Sonneville, Van der Meulen, & Buitelaar, 2003) that 
implicate inhibition as quantifiable intermediate construct between genetic 
make-up for the disorder and its behavioral manifestations. Also, our 
results are backed up by many neuro-imaging studies that have confirmed 
deviations in brain areas related to inhibition and set shifting in ADHD 
(e.g., Booth et al., 2005; Durston, 2003; Pliszka, Liotti, & Woldorff, 2000; 
Tamm, Menon, Ringel, & Reiss, 2004; Willis & Weiler, 2005). Besides this, 
our results endorse the importance of controlling for non-EF components of 
EF tasks when using the latter in research. In addition, the findings shed 
some light on the relationship between EF and IQ and on the related debate 
on whether EF results should be controlled for differences in IQ or not. The 
association between IQ and EF may be the strongest for EF tests with a 
strong verbal component. Our EF tasks with a strong verbal component 
(verbal fluency and verbal working memory) proved less robust for effects of 
IQ than our EF measures that involved less verbal abilities (set shifting and 
inhibition). Also, the correlation between verbal EF tasks and IQ (for 
instance the Controlled Oral Word Association Test; r=.46) was considerably 
larger than the correlation between IQ and non-verbal EF tasks (for 
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instance the Continuous Performance Test; r=-.22). This notion is backed 
up by several other studies (e.g., Ardila et al., 2000; Murphy et al., 2001; 
Weyandt, Mitzlaff, & Thomas, 2002). Part of our last hypothesis stated that 
there would be no differences in EF performance between ADHD 
participants with and without co-morbid anxiety and/or mood disorders. 
Our data confirmed this assumption. The EF disturbances in ADHD adults 
do not seem to be influenced by co-morbid anxiety and mood disorders. 
However, our design did not allow comparison with participants with pure 
mood or anxiety disorders. Since both these disturbances have been found 
to go hand in hand with neuropsychological disabilities themselves (e.g., 
Biederman et al., 2001; Lautenbaucher et al., 2002), the field of adult 
ADHD is now in urgent need of direct group comparisons between ‘pure’ 
ADHD, and ‘pure’ possible co-morbidities. 
The largest effects found in this study, were in the domain of 
inhibition. Even after covarying for IQ and non-EF performance, ADHD 
participants still showed worse performance in this area. We can therefore 
not subscribe the opinion of McLean et al. (2004), who recently concluded 
that inhibition problems might be something of the immature ADHD child 
brain. Only ongoing response inhibition did not yield any differences 
between the ADHD and NC groups. However, large variability in 
performance across groups raises questions about the reliability of the task 
at hand. Studies with child populations have reported similar problems 
(Geurts et al., 2004; Scheres et al., 2003). Another issue related to this form 
of inhibition, is the debate about whether it should be seen as inhibition of 
an ongoing response or as ongoing inhibition of a response. The latter might 
be represented by a task such as the Circle Drawing Test, whereas the 
former is better represented by a task used by Rubia et al. (2001), in which 
participants have to periodically interrupt a continuous movement. 
The only other large effect of group in EF was found in the domain of 
set shifting. NCs outperformed the ADHD participants on this ability, but 
only when it was operationalized by the Change Response of the Change 
Task. After covarying for IQ and non-EF performance, the results remained 
highly significant, although the effects fell just outside the 'large' range. Our 
results are in line with studies that used the Change paradigm in children 
with ADHD (Oosterlaan & Sergeant, 1998; Schachar, Tannock, Marriott, & 
Logan, 1995). When carefully looking at the skills necessary to shift set in 
the Change Task, one can understand why this would be problematic for an 
adult ADHD group that also shows difficulties with inhibition: the task 
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requires inhibition prior to the actual set shifting. This is probably the case 
in many more set shifting tasks; so set shifting may be a less separate EF 
domain from inhibition than assumed by Pennington & Ozonoff (1996). The 
correlation found in our study between the Change Response and the Stop 
Signal Reaction Time confirms this idea (r=.62; p=.000).  
When set shifting was operationalized as percentage perseverative 
errors on the Wisconsin Card Sorting Test, no differences between the 
ADHD and NC groups were established. This is actually in accordance with 
earlier work: Woods et al. (2002) reported in their review that out of six 
studies that used this test in a group of ADHD adults, only one (Taylor & 
Miller, 1997) established a difference with normal controls. Besides this, the 
Wisconsin Card Sorting Test has been shown more useful in identifying 
young children with ADHD than adolescents with the disorder (Seidman, 
Biederman, Faraone, Weber, & Ouellette, 1997), a trend that may well 
continue into adulthood. We feel that the uselessness of this test in an 
adult ADHD population has now been solidly proven. 
Medium effects of group were established in the domain of verbal 
working memory. On both tasks used for this domain, the ADHD group 
performed worse than the NC group. An interesting change in results was 
obtained after controlling for non-EF performance. When using the 
California Verbal Learning Test, as originally planned, the results were not 
substantially influenced, but when we exploringly covaried for performance 
on Digit Span-Forwards, the results on both verbal working memory tasks 
vanished. This effect is probably related to the purity of the measures used 
as covariate. The dependent measure from the California Verbal Learning 
Test represents short-term memory, as well as learning effects, rehearsal 
strategies, interference effects, and mnemonic strategies like chunking and 
grouping. Digit Span-Forwards can be considered a purer measure of verbal 
short-term memory. Apparently, verbal working memory deficits in adult 
ADHD are related to verbal short-term memory problems. This is actually 
opposite the recent suggestion that ADHD in children is mainly about 
working memory deficits (Martinussen, Hayden, Hogg-Johnson, & Tannock, 
2005). Whether this implies a developmental change in underlying 
mechanisms for the disorder, should be explored in further research. In the 
domain of spatial working memory, we established no effects of group, 
indicating that although spatial working memory problems have been noted 
in children with ADHD (Martinussen et al., 2005), this area is no longer 
posing difficulties in adult samples with the disorder. Alternatively, 
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especially the Self Ordered Pointing Test may have been too simple for 
adults, as indicated by re-analysis of the data with a repeated measures 
analysis, in which accompanying plots showed diverging lines for ADHD 
and NC participants at the hardest level of the task. 
Another medium effect was found for verbal fluency as measured by 
the Controlled Oral Word Association Test, which disappeared after 
controlling for IQ. Earlier studies have often reported fluency difficulties for 
adult ADHD groups (see Woods et al., 2002), but in the one study that 
controlled for IQ (Murphy et al., 2001) the significant difference 
disappeared, like it did in our study. For category fluency, we found no 
differences at all. In children with ADHD, several studies have also reported 
differences for letter fluency and not for category fluency (Grodzinsky & 
Barkley, 1999; Pineda, Ardila, & Rosselli, 1999). Explanations for this 
disparity can be found in the level of difficulty of both tasks (people can 
usually generate more exemplars for categories than for letters) and in the 
involvement of brain areas in both forms of fluency. Category fluency has 
been associated more with temporal lobe involvement (Kirchner, Brammer, 
Tous Andreu, Williams, & McGuire, 2001), whereas letter fluency is 
supposedly more related to frontal involvement (Stuss et al., 1998). These 
latter areas are also the ones linked to ADHD in several neuro-imaging 
studies (for a review see Durston, 2003). Woods et al. (2002) described 
fluency tasks as promising in discriminating ADHD adults, but based on 
our results and the results of Murphy et al. (2001), we feel that IQ may play 
a larger role in the differences on this task than has been assumed so far. 
Our test of non-verbal fluency did not yield significant group differences, in 
agreement with earlier studies in adults with ADHD (Barkley, Murphy, & 
Kwasnik, 1996; Rapport, Van Voorhis, Tzelepis, & Friedman, 2001). 
In the domain of planning we observed no differences between the 
ADHD and NC participants, which is in line with earlier work (Murphy, 
2002; Riccio, Wolfe, Romine, Davis, & Sullivan, 2004). This may partly be 
explained by the fact that the standard deviation for the beta coefficients 
was almost twice as large as the mean. However, re-analyzing the Tower of 
London data in a repeated measures design did not indicate a difference in 
increase of errors with increasing difficulty level between the two groups 
(data available from the first author). McLean et al. (2004) recently did find 
a significantly worse performance of an adult ADHD group on a 
computerized version of the Tower of London, but the abilities called for by 
this version of the task are slightly different than for our version. Two other 
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groups (Murphy, 2002; Riccio et al., 2004) used Tower tasks more 
comparable to the version used in our study, and they did not find a 
difference in performance between adult ADHD and NC participants. So 
planning as measured by Tower tasks does not seem to constitute a 
problem area in adult ADHD. 
For most of the non-EF abilities, we perceived no differences between 
the NC and the ADHD participants. However, some remarkable results were 
detected, even after controlling for IQ differences between groups. In line 
with earlier work (see Woods et al., 2002), the ADHD group performed worse 
than the NC group on verbal short-term memory. Judging from the 
established relationship between memory and inhibition (e.g., Anderson, 
2003), the reported short-term memory deficits are actually in line with the 
inhibition difficulties of the ADHD group. 
With respect to clinical implications of our data, our group 
comparisons and follow up discriminant analyses showed that the Conner’s 
Continuous Performance Test, the Change Task, and the Stroop Color Word 
Task together predicted correct group membership in almost 75% of the 
cases. These tests seem promising for use in the clinic, to support a 
possible diagnosis of ADHD, although future research should investigate 
the predictive value of the tests separately. Moreover, the discriminating 
power for other (related) disorders remains to be established. 
In conclusion, the results of this study showed large differences 
between adults with ADHD and normal controls in the EF areas of 
inhibition and set shifting, even after stringent controls for group 
differences in IQ, non-EF demands, and co-morbid anxiety and/or mood 
disorders. Differences in other areas of EF (fluency, working memory, and 
planning) did not prove robust for IQ and non-EF controls. These results 
indicate that it is important to control for non-EF abilities and IQ 
differences when using EF measures. They further denote that Barkley’s 
model may be correct in stating that inhibition is the primary deficit in 
ADHD, but that this defect does not automatically lead to insufficiencies in 
all other EFs. On the contrary: our study implies that adult ADHD may be 
mainly about inhibition. 
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ABSTRACT 
We examined the effect of methylphenidate (Mph) on inhibition and several other 
cognitive abilities in 43 adults with Attention Deficit Hyperactivity Disorder 
(ADHD) by use of Conners’ Continuous Performance Test (CPT) and the Change 
Task (ChT), an extension of the Stop Signal Test (SST). In a double blind, cross-
over, placebo controlled study with Mph, tests were administered during the third 
week of individually titrated treatment with Mph (maximum dose 1 mg / kg / day) 
and during the third week of treatment with placebo. We established large 
medication effects for commission errors, standard error of mean reaction time, 
and attentiveness on the CPT, as well as moderate medication effects for mean 
reaction time on the CPT and response re-engagement speed on the ChT. For Stop 
Signal Reaction Time (SSRT) on the ChT, we also established large effects of Mph, 
but only in a group of participants who showed slow SSRTs on placebo. Mph indeed 
ameliorates inhibition, which is the core problem of ADHD, and certain other 
cognitive abilities in adults with ADHD. 
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INTRODUCTION 
For decades, Attention Deficit Hyperactivity Disorder (ADHD) has been 
thought to affect only children. In the last fifteen years or so, however, 
researchers have established that children do not always outgrow their 
problems with attention, hyperactivity, and impulsivity once they reach 
adulthood. Rather, between 30 to 50% of children with ADHD still meet the 
requirements for the diagnosis in adulthood (Biederman, Mick, & Faraone, 
2000; Mannuzza, Klein, Bessler, Malloy, & LaPadula, 1998; Weiss, 
Hechtman, Milroy, & Perlman, 1985). This has lead to prevalence estimates 
for the United States of 1-6% of the general population (Wender, Wolf, & 
Wasserstein, 2001). Epidemiologic studies have confirmed these figures in 
adults applying for a driver’s license (Murphy & Barkley, 1996) and in 
college students (Heiligenstein, Conyers, Berns, Miller, & Smith, 1999). 
For a long time, attention problems and hyperactivity have been the 
most researched symptoms of this disorder, but recently impulsivity is 
increasingly seen as the symptom of greatest significance (Taylor, 1998). 
According to several theories, impulsivity or decreased inhibition of 
behavior even is the central impairment of ADHD (Barkley, 1997b; Nigg, 
2001; Pennington & Ozonoff, 1996; Schachar, Tannock, & Logan, 1993). A 
possible explanation for this shift may be found in the current thought that 
inhibitory control plays an important role in attentional systems, which 
makes the inattention in ADHD a secondary symptom. As Rubia, 
Oosterlaan, Sergeant, Brandeis and van Leeuwen (1998) stated it: "For 
example, failure to sustain attention may be due to failure to inhibit 
interfering activities and distractibility may be caused by not inhibiting 
attention to irrelevant information" (p. 25). The extensive empirical evidence 
for deficits in inhibition in children with ADHD is derived from studies 
using different inhibition paradigms, for instance the Stop Signal Test 
(SST). In a meta-analysis on SST data in ADHD children, Oosterlaan, 
Logan, and Sergeant (1998) demonstrated that children with ADHD exhibit 
significantly slower response inhibition times than normal control children. 
This finding was confirmed in a more recent review of SST studies in 
children (Sergeant, Geurts, & Oosterlaan, 2002). Another paradigm that has 
often been employed in successfully establishing inhibition deficits in 
children with ADHD is the Continuous Performance Test (CPT; Brandeis et 
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al., 1998; Kerns, McInerney, & Wilde, 2001) . For reviews of CPT studies in 
children with ADHD, see Corkum and Siegel (1993), Losier, McGrath, and 
Klein (1996), and Riccio, Waldrop, Reynolds, and Lowe (2001). Deficits in 
inhibition have also been established for adults with ADHD, using both the 
SST (Epstein, Johnson, Indira, & Conners, 2001; Murphy, 2002b; Ossmann 
& Mulligan, 2003; Wodushek & Neuman, 2003), and the CPT (Barkley, 
Grodzinsky, & DuPaul, 1992; Epstein, Conners, Sitarenios, & Erhardt, 
1998; Epstein et al., 2001; Ossmann & Mulligan, 2003; Riccio et al., 2001; 
Walker, Shores, Trollor, Lee, & Sachdev, 2000).  
The stimulant methylphenidate (Mph) is one of the most effective and 
safest medications for the treatment of ADHD in children. Approximately 
70% of ADHD children show a therapeutic response to stimulant 
medication (Schachter, Pham, King, Langford, & Moher, 2001; Wilens & 
Spencer, 2000). In adults with ADHD, stimulant medication has received far 
less attention than in children. In a recent review by Wilens, Spencer, & 
Biederman (2002) seven Mph studies were mentioned, in which the 
weighted mean clinical response to Mph treatment was 56%. In a recent 
meta analysis, Faraone, Spencer, Aleardi, Pagano, and Biederman (2004) 
mentioned a mean effect size of 0.9 for six double-blind placebo-controlled 
Mph treatment studies in adults with ADHD. 
Mph has been shown to improve inhibition on several laboratory tasks 
in children with ADHD, such as the CPT (for a review see Losier et al., 
1996), and the SST (Scheres et al., 2003; Tannock, Schachar, Carr, 
Chajczyk, & Logan, 1989; Tannock et al., 1995). Information on the effect of 
Mph on inhibition and other cognitive variables tested by the CPT in an 
adult ADHD population is limited. Riordan et al. (1999) established a 
decrease in visual distractibility with Mph on a CPT. Kuperman et al. (2001) 
mentioned improvement with Mph on attentiveness (one of the signal 
detection parameters) on a CPT in adults with ADHD, but no other 
parameters were reported. In the only study mentioning an effect of Mph on 
the inhibition parameter of a CPT, the effect was not significant (Gualtieri, 
Ondrusek, & Finley, 1985). The effect of Mph on the Change Task (ChT, 
which is an extended version of the SST) in an adult ADHD sample has not 
been reported thus far. Given the current emphasis on inhibition in ADHD, 
this shortage of studies into the effect of Mph on inhibition in adult ADHD 
is surprising. This is why in the present study, we hypothesized that Mph 
would improve inhibition in adults with ADHD, both on the CPT and the 
ChT, compared to placebo.  
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In addition to inhibition, the CPT and the ChT measure several other 
variables of cognitive functioning. The CPT provides information on 
processes related to response execution (speed and variability), as well as 
measures that are related to signal detection theory (perceptual sensitivity 
in discriminating targets from non-targets and response style). Another 
interesting feature of the CPT is that stimuli may be presented with 
different event rates, for instance 1, 2 or 4 s between stimuli. This allows for 
analysis of the involvement of behavioral activation in response execution.  
An optimal behavioral activation state influences motor adjustment, thus 
affecting response execution (Sanders, 1998). The influence of activation 
levelhas been repeatedly indicated in ADHD in children (Scheres, 
Oosterlaan, & Sergeant, 2001; Sergeant, 2000; Van der Meere, 1996).  
The ChT provides information on similar response execution 
processes as the CPT. Moreover, by instructing subjects to perform another 
action after they have inhibited their prepotent response, it also supplies 
information on response re-engagement processes. Performance on many of 
these variables has been shown to differ between children with ADHD and 
normal controls (see Losier et al., 1996; Oosterlaan et al., 1998, Riccio et al. 
2001). Similar information on adults with ADHD is sparse, but available 
studies indicate that they also may show difficulties on some of the abilities 
mentioned above, such as speed of response execution, and attentiveness 
(Epstein et al., 1998; Epstein et al., 2001).  
Besides its positive effect on the clinical symptoms of ADHD and on 
inhibition, stimulant medication seems to improve specific other cognitive 
abilities. In children , it has been shown to enhance response speed and 
accuracy (Klorman et al., 1988; Reid & Borkowski, 1984), response 
variability (Tannock et al., 1995), and response re-engagement (Barnett et 
al., 2001; Berman, Douglas, & Barr, 1999; Kempton et al., 1999; Solanto, 
1997; Tannock et al., 1995). Studies with Mph in adults with ADHD have 
suggested that the drug may also improve specific cognitive abilities in this 
group. Kuperman et al. (2001) showed advanced response re-engagement 
abilities and increased fluency with Mph. Other researchers have found 
evidence of increase in working memory ability (Kinsbourne, De Quiros, & 
Tocci Rufo, 2001), motor speed, and processing speed, as well as decreases 
in distractibility (Riordan et al., 1999). 
Our first hypothesis stated that Mph would improve inhibition in 
adults with ADHD, both on the CPT and the ChT, compared to placebo. In 
order to extend the knowledge of the effect of Mph on cognitive abilities, 
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other than inhibition, in adult ADHD, we further hypothesized that several 
cognitive processes (speed of response execution, variability of response 
execution, response re-engagement, attentiveness) measured by the CPT 
and the ChT would improve with Mph, compared to placebo. 
METHOD 
Participants 
Forty-three adults with ADHD between 20 and 55 years of age (M=38.9 
years; SD=10.1), 21 men and 22 women, participated in this study. Two of 
these participants were diagnosed with ADHD hyperactive/impulsive 
subtype, the other 41 were diagnosed with ADHD combined subtype. None 
of the participants had been treated with Mph prior to this study. The 
average IQ was 100.3 (SD=17.9; minimum 76, maximum 142). The 
participants were either self-referred or referred by other clinicians for 
assessment of ADHD to an outpatient clinic in the Netherlands. Prior to 
inclusion in the study, participants underwent a standardized clinical 
assessment consisting of a psychiatric evaluation by one of two experienced 
psychiatrists. The following instruments were used: a semi-structured 
clinical diagnostic interview for ADHD and co-morbid disorders; several 
sections from the Dutch version of the Diagnostic Interview Schedule 
(Robins et al., 1995): section L (for the retrospective diagnosis of ADHD in 
childhood), section N (for the retrospective diagnosis of oppositional defiant 
disorder), section O (for the retrospective diagnosis of conduct disorder), 
and section P (for current antisocial personality disorder); the Dutch version 
of the Composite International Diagnostic Interview (CIDI; version 2.1, 
lifetime; Robins et al., 1988) for Axis I psychiatric disorders; the Dutch 
version of the International Personality Disorder Examination (IPDE; 
Loranger, Sartorius, Andreoli, & Berger, 1994) for borderline and antisocial 
personality disorders. For current ADHD-symptoms during the last 6 
months, we used the Dutch version of the ADHD-Rating Scale (DuPaul, 
Power, Anastopoulos, & Reid, 1998), based on the 18 DSM-IV symptom 
criteria for ADHD. The level of associated impairment was assessed using 
the Dutch version of the Sheehan Disability Scale (SDS; Sheehan, Harnett-
Sheehan, & Rai, 1996) and the Global Assessment of Functioning Scale 
(GAF; APA, 1994). A medical history, a physical examination (blood 
pressure, pulse and weight), and laboratory assessments (complete blood 
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cell count, liver, kidney, thyroid, glucose function tests, and electro-
cardiogram) were also obtained.  
To be given a diagnosis of adult ADHD, subjects had to (1) currently 
meet at least 5 of 9 DSM-IV criteria of inattention and/or at least 5 of 9 
DSM-IV criteria of hyperactivity/impulsivity (based on the ADHD Rating 
Scale), (2) meet at least 6 of 9 DSM-IV criteria of inattention and/or at least 
6 of 9 DSM-IV criteria of hyperactivity/impulsivity in childhood (based on 
the DIS-section L), (3) describe a chronic persisting course of ADHD 
symptoms from childhood to adulthood, and (4) endorse a moderate to 
severe level of impairment attributed to ADHD symptoms. The cutoff point 
of 5 of 9 hyperactive/impulsive symptoms and/or 5 of 9 inattention 
symptoms for adult diagnosis of ADHD is in line with previous research 
(Biederman et al., 2000; Murphy & Barkley, 1996). In order to obtain 
information about lifetime ADHD symptoms and impairment, the 
participant, the partner (if available), and (if possible) the parents were 
interviewed. Information on school reports was examined in order to 
substantiate the diagnosis in childhood. We estimated the IQ of participants 
based on four subtests of the Dutch version of the Wechsler Adult 
Intelligence Scale-III: Vocabulary, Arithmetic, Block Design, and Picture 
Arrangement. The reliability of this short form has not been established for 
the WAIS-III yet, but for the WAIS-R these four tests have been found to 
estimate Full Scale IQ with greater accuracy than other variations (Boone, 
1990). Data for several diagnostic measures are provided in Table 4.1. 
 
Subjects with co-morbid psychiatric disorders were included, unless these 
disorders required to be treated first (for instance severe depression or 
anxiety) or when treatment with Mph was contra-indicated (for instance 
with hypertension). The number of eligible participants was 108. Before 
study entry, 15 people withdrew consent for the trial. We excluded 41 
participants: four with clinically significant medical conditions, one with 
abnormal baseline laboratory values, seven with other psychiatric 
conditions that required to be treated first, 11 because of current use of 
psychotropics, and 18 because of prior use of Mph or amphetamines. Other 
exclusion criteria were: a history of tic disorders, IQ below 75, any 
neurological condition that could interfere with a diagnosis of ADHD (such 
as concussion, meningitis, traumatic brain injury), suicidal behavior, 
psychosis, mania, physical aggression, and pregnancy or nursing. No 
participants had to be excluded based on these criteria. After study entry 
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and full diagnostic assessment, seven participants were ineligible: five due 
to current substance abuse, one due to hypertension, and one due to severe 
depression that urgently required treatment. In the end, 45 participants 
were randomized and completed the trial. Data of two participants could not 
be used for the neuropsychological part of the study due to incompletion 
(n=1) and positive urine screening for opiates (n=1). The study was approved 
by the local Medical Ethical Committee, and all subjects completed a 
written informed consent form before inclusion in the study. 
 
Table 4.1  
Group Characteristics on Diagnostic Measures 
 
measure value 
Number of currently endorsed DSM-IV criteria for ADHD M = 15.5 SD = 2.1 
Number of DSM-IV criteria for ADHD endorsed in childhood (DIS-L) 
 
M = 12.0 
SD = 4.1 
Sheehan Disability Scale (minimum 0, maximum 30) 
 
M = 22.8 
SD = 3.3 
Global Assessment of Functioning (minimum 0, maximum 100)* * M = 57.3 SD = 6.1 
Axis I co-morbid disorders (CIDI Lifetime) 
 any co-morbid disorder 
 multiple co-morbid disorders ( ≥ 2) 
 any anxiety disorder 
 any mood disorder 
 
79 % 
53 % 
51 % 
53 % 
Axis II co-morbid disorders  
 Antisocial Personality Disorder (IPDE) 
 Borderline Personality Disorder (IPDE) 
 
9 % 
16 % 
Note. CIDI = Composite International Diagnostic Interview; IPDE = International Personality Disorder Examination. 
* Scores above 70 indicate normal functioning. 
Materials 
Continuous Performance Test 
Computerized CPTs are often used to study vigilance in ADHD populations. 
Most CPTs require a subject to press a key in response to a target stimulus 
(for instance the letter X, or the letter A followed by an X) and to ignore non-
target stimuli. The version used in this study is the Conners’ Continuous 
Performance Test  (Conners, 1995), which differs from traditional (X and A-
X) CPT paradigms (Rosvold, Mirsky, Sarason, Bransome, & Beck, 1956). In 
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Conners’ CPT, the response required for the critical signal of X is to 
withhold a discrete and repetitive motor response, rather than to respond to 
it. For all other stimuli, a response of pressing the space bar is required. 
This means that omission errors indicate a failure to execute the required 
response, whereas commission errors suggest an inability to inhibit the 
prepotent response. Next to sustained attention, the main measurement 
objective of traditional CPTs, the  Conners’ CPT may invoke executive or 
controlled attention (Ballard, 2001). As far as we know, this version of the 
test has only been used in one study with Mph in an adult ADHD 
population (Kuperman et al., 2001). However, this study only reported 
medication effects on the dependent variable attentiveness (d’). 
The task consisted of six blocks of 60 trials. Each block contained 
three sub-blocks of 20 trials each. Stimuli presented were letters of 
approximately 1 inch in size. Ten percent of stimuli in each block were Xs, 
with a total of 36 Xs for the entire test. Other letters presented were A, B, C, 
D, E, F, H, I, L, M, N, O, T, Y, and Z. For each block, the sub-blocks had 
different inter-stimulus intervals (ISIs): 1, 2, or 4 s. The order of sub-blocks 
randomly varied between blocks. Each letter was displayed for 250 ms. The 
most often reported (and therefore also chosen for this study) dependent 
variables are: 1) the number of commission errors, measuring inhibitive 
behavior (high error rates indicate poor inhibitive control), 2) mean reaction 
time for hits (to measure the latency of the response execution process), 3) 
the standard error of the mean hit reaction time (an indication of the 
consistency with which respondents can focus their attention), 4) 
attentiveness (d’), which is an indication of the ability to discriminate 
between targets and non-targets, and 5) risk taking (β; an indication of a 
person’s response style: high values point to cautious response styles, 
whereas low values suggest more risk taking). Omission errors were not 
analyzed for this study, since the participants made hardly any errors of 
this type (M (placebo) = 2.4; M (Mph) = 1.8). 
Change Task 
The Change Task (ChT; Logan & Burkell, 1986) is an extension of the Stop 
Signal Test (SST; Logan, Cowan, & Davis, 1984). The SST measures 
response execution and response inhibition processes, while the extended 
ChT is also used to investigate response re-engagement. To our knowledge, 
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this test has not been used previously in any studies with adults with 
ADHD.  
The ChT used in this study consisted of go trials and stop trials. For 
both types of trials, an aeroplane was presented for 1000 ms at either the 
left or the right side of the screen. Immediately before stimulus onset, a 
fixation point (500 ms in duration) appeared at the center of the screen. A 
right-sided stimulus required subjects to press the right response button as 
quickly as possible. If the aeroplane was presented on the left, the left 
response button had to be pressed. Subjects were instructed to use the 
index and middle fingers of their dominant hand. Between trials the screen 
turned blank for 1500 ms. Stop trials were identical to go trials, but in 
addition a stop signal (a 1000 Hz tone, 50 ms in duration) was presented 
through stereo earphones. When a stop signal was presented, participants 
were to withhold their response (i.e., not to press any button with their 
dominant hand). In addition, they had to press a different button with their 
non-dominant thumb as quickly as possible. This is the Change Response, 
a measure of response re-engagement. Seventy-five percent of trials were 
go-trials, and 25% were stop trials. Trials were presented in blocks of 64 
trials. Stop signals were presented at predetermined intervals before the 
subject’s expected response. This provides the opportunity to ascertain the 
ability to inhibit a response at different points in the response execution 
process. The shorter the time interval between the stop signal and the 
expected response, the more difficult it becomes to inhibit this response. 
Intervals between stop signal and expected response were set at 50 ms, 200 
ms, 350 ms, or 500 ms with each interval occurring on 25% of the stop 
trials. The expected moment of response was based on the mean reaction 
time in the previous block. The task started with three practice blocks to 
familiarize participants with the paradigm. In the first block only go trials 
were presented (primary task). In the second practice block, 25% of trials 
were stop trials, which only required inhibition of response. In the last 
practice block, stop signals required both response inhibition and response 
re-engagement. After practice, participants were administered four 
experimental blocks of 64 trials each. Standardized instructions pressed 
participants not to wait for the stop signal, but to continue pressing the 
buttons as quickly as they could. 
The main dependent measure for this task is Stop Signal Reaction 
Time (SSRT). This is an estimate of the time it takes before the inhibition 
process is engaged. SSRT cannot be measured directly, but it can be 
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estimated using the Race Model (Logan, 1994). According to the Race Model 
response inhibition depends on the outcomes of a race between two sets of 
processes that operate independently. One set starts with the onset of the 
go-stimulus (the aeroplane at the left or right side of the screen) and results 
in the activation and execution of the response, whereas the other set starts 
with the onset of the stop signal and results in the onset of the inhibitory 
process (Logan & Cowan, 1984). The response is made or withheld, 
depending on which set of processes wins the race. In practice, SSRT is 
calculated as follows: first, reaction times on go-trials are rank ordered on a 
time axis. Then, the nth reaction time is picked, whereby n is defined by the 
product of the number of reaction times in the distribution and the 
probability of responding given a stop signal. This gives an estimate for the 
time at which the inhibition process runs to completion, relative to the 
onset of the primary task stimulus. Third, the delay between onset of the 
primary task stimulus and the stop signal is subtracted from the nth 
reaction time and thus SSRT is estimated. For more detailed information on 
the calculation of SSRT, the reader is referred to Logan et al. (1984). In 
addition to SSRT, other dependent variables included in the analyses were: 
1) the mean reaction time on go-trials of the primary task (measuring 
latency of response execution), 2) the standard deviation of the reaction 
times on go-trials of the primary task (measuring variability in the latency 
of the response execution process), 3) the mean reaction time on the 
Change Response of the task (an indication of the speed of the response re-
engagement process), and 4) the standard deviation of the Change Response 
latencies (to measure variability in the speed of the response re-engagement 
process). Another measure often reported in research using the SST is the 
slope of inhibition function. Recently however, Band, Van der Molen, and 
Logan (2002) indicated that this variable is not a reliable indicator of 
differences in inhibition. Therefore, this variable was not analyzed in the 
current study. 
Procedure 
Participants entered a double blind, placebo controlled, cross-over trial of 
Mph. The design of this trial and clinical outcomes are described in detail 
elsewhere (see Kooij et al., 2004). We designed the trial based on the 
medication study by Spencer et al. (1995). There were two 3-week treatment 
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periods for each participant, one period of three weeks for Mph and one 
period of three weeks for placebo, with 1 week of washout in between.  
The order of treatment (Mph-placebo or placebo-Mph) was 
randomized. Weekly supplies of Mph (10 mg per tablet) or placebo were 
prepared and dispensed by the hospital pharmacy in identically appearing 
tablets. Placebo tablets contained only a base granulate. Mph tablets 
contained only Mph granulate. Medication was prescribed in four times or 
five times a day dosing, depending on whether rebound occurred. Study 
medication was titrated up from low to high doses, to avoid exposure to 
high initial doses of active medication and to minimize side effects. 
Participants started with 0.5 mg/kg per day in week 1, followed by 0.75 
mg/kg per day in week 2, and up to 1.0 mg/kg per day in week 3, unless 
adverse effects emerged. A dose of 1.0 mg/kg has been shown to be a 
reasonable upper limit dosage for clinical purposes (Sachdev & Trollor, 
2000). To control for possible substance use during the trial, patients were 
asked unannounced twice to hand over a urine sample.  
Repeated administrations of the inhibition tasks described above were 
obtained in week 3 (highest dose of Mph, or placebo) and in week 7 (highest 
dose of Mph, or placebo). Testing started one hour and fifteen minutes after 
tablet intake. Mph peak concentrations in the brain are reached after 
approximately 60 minutes (Volkow et al., 1995). Maximal therapeutic effects 
are reached within approximately 2 hours after ingestion (Swanson, 
McBurnett, Christian, & Wigal, 1995; Wilens, Biederman, Spencer, & 
Prince, 1995). The behavioral half-life of the drug is approximately 3 hours 
(Solanto & Conners, 1982). Administration of the inhibition battery took 
approximately 1 hour, so testing was completed between the moment of 
peak Mph levels in the brain and the behavioral half-life value.  
Besides two treatment orders (Mph-placebo or placebo-Mph), 
inhibition tasks were also administered in two different test orders (CPT-
ChT or ChT-CPT), to be able to control for possible effects of fatigue and for 
effects of declining medication efficacy. 
Statistical Approach 
In order to check whether treatment order or test order interacted with the 
effect of treatment condition, separate MANOVAs were conducted for the 
dependent variables of the CPT and the ChT, with treatment condition (Mph 
or placebo) as within subject factor and treatment order (Mph-plac or plac-
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Mph) and test order (CPT-ChT or ChT-CPT) as between subjects factors. If 
no overall interactions between treatment condition and treatment order or 
test order were found, the effects of medication on the dependent variables 
were further analyzed with ANOVAs with treatment condition as within 
subject factor. If, however, overall interactions between treatment condition 
and treatment order or test order were significant, univariate cross-over 
results were interpreted only for those variables that did not show an 
interaction. For variables that did show a univariate interaction, only data 
from the parallel trial (the first three weeks of treatment) were analyzed in 
an ANOVA with treatment condition as between subjects factor. We 
adjusted our alpha level to .0125 (.05 devided by the number of processes 
tested) to compensate for the number of comparisons made.  
The data of one participant were excluded from the analyses for the 
ChT, because mean scores on several dependent variables deviated more 
than 1.5 times the interquartile range from the 25th or 75th percentile. 
RESULTS 
Group characteristics for the two treatment order groups are shown in 
Table 4.2. Statistical analyses confirmed that there were no differences 
between the two groups in number of participants, gender distribution, age, 
IQ, absolute dose (in mg/day), or relative dose (in mg/kg/day) of Mph at 
time of testing. 
 
Table 4.2 
Characteristics of Two Treatment Order Groups and of Total Group 
 Mph – Plac (n = 24) Plac – Mph (n = 19) Total group (N = 43) 
men/women 14/10 8/11 22/21 
age (M, SD) 38.5 (9.9) 38.3 (10.6) 38.4 (10.1) 
IQ (M, SD) 100.3 (17.6) 100.2 (18.7) 100.3 (17.9) 
dose (mg) (M, SD) 74.8 (15.6) 65.3 (16.9) 70.6 (16.7) 
dose (mg/kg) (M, SD) .97 (.13) .88 (.23) .93 (.18) 
Note. Mph = methylphenidate; Plac = placebo. 
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Main analyses 
Continuous Performance Test 
There was no interaction between treatment condition and treatment order 
(Wilks’ Λ=.77, F(5,35)=2.12, p=.086), nor between treatment condition and 
test order (Wilks’Λ=.93, F(5,35)=.49, p=.779). Therefore, the effects of 
treatment condition on the dependent variables of the CPT were further 
analyzed without taking either treatment order or test order into account. A 
MANOVA with treatment condition as within subject factor showed an 
overall significant effect of treatment (Wilks’ Λ=.60, F(5,38)=4.98, p=.001, 
η2=.40). Separate ANOVAs with treatment condition as within subject factor 
(see Table 4.3 for means and standard deviations) revealed a significant 
decrease of commission errors with Mph (F(1,42)=10.88, p=.002). The 
accompanying effect size (η2=.21) was large (Cohen, 1988). The  increase in 
mean reaction time with medication (F(1,42)=5.10, p=.029) was not 
significant. The accompanying effect size, however, was medium (η2=.11). 
Standard error of hits significantly decreased with Mph (F(1,42)=7.15, 
p=.011), with a large effect size (η2=.15). There was a significant 
improvement in attentiveness (d’; F(1,42)=8.17, p=.007). The effect size of 
the latter increase was large (η2=.16). Risk taking (β) did not show a change 
with medication (F(1,42)=.43, p=.837, η2=.00). 
 
Table 4.3 
Descriptives and Statistics for Continuous Performance Test Variables 
Variable Placebo (M, SD) 
Mph 
(M, SD) F p η
2 
mean hit reaction time 333.5 (48.7) 342.6 (48.7) 5.10 .029 .11 
standard error 6.0 (3.3) 4.9 (2.4) 7.15 .011 .15 
commissions 13.6 (7.6) 10.7 (7.2) 10.88 .002 .21 
attentiveness (d’) 3.1 (0.9) 3.4 (0.9) 8.17 .007 .16 
risk taking (β) .1 (.1) .1 (.1) .43 .837 .00 
Note. Mph = methylphenidate; Plac = placebo. 
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CPT Analyses of ISI 
For several variables (commission errors, mean hit reaction time, and 
standard error of reaction time) of the CPT, separate data are available for 
the three different ISIs. These variables were analyzed in ANOVAs with two 
within subject factors: ISI (three levels: 1, 2, or 4s) and treatment condition 
with two levels, to check if Mph has a different effect for different ISIs. 
Because of possible violations of the sphericity assumption, degrees of 
freedom and related p-values were corrected according to the Greenhouse-
Geisser method. For commission errors, there was no significant interaction 
between treatment condition and ISI (F(1.89,79.21)=.54, p=.940, η2=.00). 
Mph did not change the number of commission errors made over the 
different ISIs. As can be seen in Figure 1, there was a significant interaction 
effect of ISI and treatment condition for mean hit reaction time 
(F(1.75,73.53)=5.15, p=.011, η2=.11). Post hoc paired samples t-tests 
revealed that the difference between placebo and Mph was significant only 
for an ISI of 1 s (t(42)=3.95, p=.000). The accompanying effect size was 
medium (Cohen’s d=.60). Mph significantly slowed down the mean hit 
reaction time for an ISI of 1s.
Figure 1. Mean Hit Reaction Time (HRT) (in ms) on CPT as a Measure of ISI and 
Treatment Condition. 
Figure 2 displays the standard error of mean hit reaction time. For this 
variable we established a significant interaction of ISI and treatment 
condition (F(1.88,79.06)=5.07, p=.010, η2=.11). Post hoc paired samples t-
tests showed the effect of Mph to be significant only for an ISI of 4 s (t(42)=-
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3.14, p=.003). The matching effect size was close to medium (Cohen’s 
d=.48). So Mph lead to less variability in responding at a large ISI. 
Figure 2. Standard Error of Hit Reaction Time (SE HRT) (in ms) on CPT as a 
Measure of ISI and Treatment Condition. 
Change Task 
There was no significant interaction between medication treatment 
condition and test order (Wilks’ Λ=.91, F(5,34)=.67, p=.628). Therefore, the 
effects of medication for this test were further analyzed without taking test 
order into account. There was, however, a significant interaction between 
treatment condition and treatment order (Wilks’ Λ=.51, F(5,34)=6.60, 
p=.000). Univariate tests revealed significant interactions of treatment 
condition and treatment order for mean reaction time (F(1,38)=12.20, 
p=.001), and standard deviation of reaction times (F(1,38)=21.00, p=.000). 
Apparently, for these variables it made a difference whether Mph or placebo 
was administered first. For these variables, main effects of treatment 
condition were therefore analyzed only for the parallel trial (after three 
weeks of treatment, during the highest dose of Mph or placebo).  
The variables that did not show univariate interactions of treatment 
order and treatment condition were further analyzed with ANOVAs with 
treatment condition as within subject factor (see Table 4.4 for means and 
standard deviations). For SSRT, no decrease with medication was found 
(F(1,41)=3.08, p=.087, η2=.07). Inhibition as measured by this variable, did 
not improve with Mph. We did not establish a decrease in mean reaction 
time on the Change Response with Mph (F(1,41)=4.84, p=.033). The 
accompanying effect size, however, was medium (η2=.11). The standard 
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deviation of these Change Response reaction times was not different under 
medication or placebo (F(1,41)=.26, p=.615, η2=.01).  
For the two variables that showed significant interactions between 
treatment order and treatment condition, data for the first point of 
measurement (after three weeks) were compared in an ANOVA with 
treatment condition as a between subjects factor (see Table 4.4 for means 
and standard deviations). There was no significant effect of Mph on mean 
reaction time (F(1,40)=.91, p=.346, η2=.02), nor on the standard deviation of 
reaction times (F(1,40)=4.02, p=.052, η2=.09). 
 
Table 4.4 
Descriptives and Statistics for Change Task Variables 
Variable Placebo (M, SD) Mph (M, SD) F p η2 
SSRT 220.0 (56.4) 202.3 (50.5) 3.08 .087 .07 
MRT* 434.1 (82.7) 407.4 (95.9) .91 .346 .02 
SD RT* 96.9 (32.3) 78.2 (28.4) 4.02 .052 .09 
Change Response MRT 475.3 (89.7) 457.1 (71.1) 4.84 .033 .11 
Change Response SD RT 117.0 (43.4) 113.2 (43.8) .26 .615  .01 
Note. SSRT = Stop Signal Reaction Time; MRT = mean reaction time; SD = standard deviation; RT = reaction time. 
* Placebo: n = 19; Methylphenidate: n = 23 (parallel trial analysis only). 
Post-hoc analyses 
Several exploratory analyses were conducted to characterize the results 
more completely. Because of the exploratory nature of these analyses, alpha 
level was set at .05.  
In order for a medication effect to be not only statistically but also 
clinically significant, one would like medication to normalize scores on 
dependent variables. Ideally, one would compare the scores of participants 
with those of a normal control group or with a norm group. However, 82% 
of the norm group for the CPT used in our study was in the age range of 18-
30. This is much younger than our ADHD group. Therefore we decided to 
compare the mean of our medicated ADHD group with the group mean of a 
normal control sample from another study for the variable that showed the 
largest effect size in our study: commission errors on the CPT. The normal 
control participants (mean age 33.4 years, 50% males) in a study by 
Epstein et al. (2001) carried out the exact same version of the CPT as our 
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ADHD participants. A one sample t-test showed no differences (t(42)=1.65, 
p=.11) between the mean number of commission errors of our medicated 
ADHD sample (M=10.7) and the mean of the normal control sample (n=30, 
M=8.9), indicating a similar level of inhibition in both groups. When we 
compared our ADHD sample off medication (placebo scores) and the same 
normal control group, the difference was significant (t(42)=4.04, p=.00): the 
ADHD group showed worse inhibition capacities than the normal control 
group from Epstein et al. 
It is possible that medication effects are found only when there is 
room for improvement. To check this possibility, we compared medication 
effects (difference scores between placebo and Mph) on CPT commissions 
and on ChT SSRT for participants with placebo scores below and above the 
means of these variables. For CPT commissions, the group (n=18) who made 
a larger number of commission errors (compared to the mean placebo 
commission score) improved significantly more with Mph than the group 
who made a smaller number of errors (n=25; again compared to the mean 
placebo score; F(1,41)=8.21, p=.007,  η2=.17). For SSRT on the ChT, the 
effect of high versus low placebo scores was even larger. Participants who 
showed slower than average SSRTs on placebo (n=22) improved much more 
with medication than participants who responded faster than average to 
begin with (n=20; F(1,40)=25.15, p=.000, η2=.39). This latter result is in 
contrast with the non-significant results in the total sample. Apparently, 
Mph does significantly improve inhibition as measured by the ChT in 
participants who show low scores on SSRT to begin with. 
To check what the predictive value of improvement on cognitive tests 
is for clinical respondership, we conducted a discriminant analysis to 
determine whether the difference between placebo and medication scores 
for the two most often reported dependent variables for our 
neuropsychological tests (commission errors and SSRT) could predict 
clinical respondership. Clinical respondership for each participant was 
determined according to Kooij et al. (2004), who defined clinical response as 
a decrease of at least two points on the investigator based Clinical Global 
Impression Scale for ADHD over the total treatment period (three weeks), 
and a 30% or more symptom reduction on the selfreported ADHD Rating 
Scale. The overall Wilks’ lambda was significant for change in commission 
errors on the CPT (Λ=.79, χ2(2,N=43)=9.15, p=.010), but not for the SSRT of 
the ChT. Only the significant discriminant function was interpreted. Clinical 
respondership could be correctly classified based on decrease of 
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commission errors in 79% of the cases. Ten of 16 responders were correctly 
classified, leading to a sensitivity of 63%. Twenty-three of 26 non-
responders were correctly classified as such, indicating a specificity of 89%. 
Positive predictive power of the decrease in commission errors on clinical 
respondership was 78%, negative predictive power was 79%. In order to 
take into account chance agreement, we computed a kappa coefficient and 
obtained a value of .53, which can be considered moderate (Landis & Koch, 
1977).  
Finally, we performed a partial correlation analysis to check whether 
the amount of commission errors on the CPT during Mph was related to 
several clinical variables rather than to Mph, when placebo-commission 
errors were partialed out. There were no significant correlations between 
Mph-commission errors and any of the following variables: severity of ADHD 
(number of DSM-IV symptoms; r=-.14, p=.37), relative Mph dose at endpoint 
(in mg/kg; r=-.03, p=.86), absolute dose at endpoint (mg; r=-.00, p=.99), co-
morbid anxiety disorder (r=.27, p=.09), number of co-morbid disorders 
(r=.28, p=.07), or IQ (r=.06, p=.71). 
DISCUSSION 
The present study was designed to examine the effects of Mph on inhibition 
and other cognitive measures in a sample of adults with ADHD. The 
analyses indicated rather strong effects of Mph on inhibition and response 
measures on the CPT. However, no medication effects on inhibition and 
other response measures were found on the ChT. 
With respect to the CPT, the inhibition results confirm our hypothesis 
and they are in line with previous research in ADHD children (Losier, 1996). 
For adults, very few medication studies of commission errors on the CPT 
are available. Results by Gualtieri et al. (1985) indicate a decrease in 
commission errors on a CPT, although this decrease just fell short of 
significance. However, our study provides more reliable changes, since 
Gualtieri and colleagues tested after a single dose of Mph, rather than an 
entire week of medication. When breaking down commission errors into 
number of errors for different ISIs, the results indicate that the commission 
errors occur independently of event rate, both in the placebo and the Mph 
condition. This result may underline the suggestion that inhibition is not 
influenced by a behavioral activation level (Sergeant, Oosterlaan, & Van der 
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Meere, 1999). When we compared participants who made many commission 
errors in the placebo condition with the participants who made few errors in 
the placebo condition, the effect of medication was significantly larger in the 
group who performed worse to begin with. So the effect of Mph on inhibition 
is larger in a subgroup that shows more room for improvement. 
We hypothesized the effect of Mph on SSRT of the ChT to be stronger 
than what we actually found. Our finding cannot be compared with adult 
ADHD data, since the effect of Mph on SSRT of the ChT has not been 
studied in this population before. In children with ADHD, three studies 
reported substantial faster SSRTs with Mph (Scheres et al., 2003; Tannock 
et al., 1989, 1995), while Overtoom and colleagues (2003) did not observe 
changes in SSRT with Mph. Post hoc analyses of our data indicated that 
Mph does induce a large improvement in SSRT for a subgroup of our 
participants whose SSRT on placebo was slower (indicating worse 
inhibition) that the mean placebo SSRT score of the entire group. However, 
this does not explain why we did not find an improvement of SSRT in the 
entire ADHD group, whereas we did find a decrease of commission errors on 
the CPT. Possible explanations for this deviance will be explored later in this 
discussion. 
Other cognitive processes measured by the two paradigms used in 
this study include latency and variability of response execution processes 
(mean reaction time and variability in reaction times on both CPT and ChT), 
attentiveness (d’; CPT), response style (β; CPT) and response re-engagement 
(MRT and SD; only in the ChT). Reaction times did not change with 
medication on the CPT. This is in contrast with research in children 
(Klorman, Brumaghim, Fitzpatrick, & Borgstedt, 1991; Riccio et al., 2001) 
and adults with ADHD (Riordan et al., 1999), in which faster MRTs with 
medication have been established. Since the accompanying effect size of 
this result was medium, we decided to look into effects for different ISIs 
Here, we found the expected slowing of MRT with longer ISIs (ADHD 
subjects have been shown before to show slower RTs with longer ISIs, see 
Scheres et al. 2001). Only with the shortest ISI, however, did medication 
slow RT significantly. The overall slowing of MRT with medication seems to 
be best and solely explained by aslower MRT with the shortest ISI. 
Apparently, Mph allows ADHD participants to respond less impulsively at 
short ISIs. This is in accordance with research by Berman et al. (1999), 
which showed that Mph slowed down RT only on the most difficult, high 
load test conditions (the shortest ISI can be considered to be a high load). 
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This result implies that Mph may improve self-regulatory abilities, as 
suggested by Douglas (1988, 1999). In view of the non-significance of the 
MRT result, this statement is tentative, but worthy of further consideration, 
given the medium effect size. 
We also found that treatment with Mph decreased variability of mean 
reaction times on the CPT. On the ChT, this change was not significant, 
although the accompanying medium effect size implies that this may have 
been a power issue. This improvement in variability is in agreement with 
earlier studies in children with ADHD (Tannock et al., 1989, 1995). No 
comparable research is available for adults with ADHD. The overall 
decrease of variability in reaction times on the CPT could be broken down 
into different effects for different ISIs. Mph effects on variability seem to be 
larger for longer ISIs. This is propitious, since ADHD is known to lead to 
increasing variability in response execution with slow event rates (i.e., 
longer ISIs; Scheres et al., 2001; Van der Meere, Shalev, Borger, & Gross-
Tsur, 1995). Apparently Mph increased the behavioral activation level 
(Sanders, 1998), which allowed participants  to respond more evenly. 
Response re-engagement on the ChT (the Change Response) was not 
sped up significantly by Mph. This is in contrast with a recent study, 
showing that Mph enhanced task switching performance in ADHD children 
(Kramer, Cepeda, and Cepeda, 2001), and with earlier findings on the effect 
of Mph on the Change Response (see the Materials section for an 
explanation of the Change Response) in children with ADHD (Tannock et 
al., 1995). No data on the effect of Mph adult performance on this variable 
are available. Again, looking at the accompanying effect size for this result 
(η2=.11), this result may be worth considering further in a larger sample. 
Variability in response re-engagement reaction times was not affected by 
medication. No previous studies have reported on this measure in adults 
with ADHD, but based on decreased response variability in primary reaction 
times with Mph, one might expect this variability on a secondary task to 
decrease as well. This was indeed found in a child ADHD sample (Tannock 
et al., 1995). Possible explanations for this divergence will be explored later 
on in the discussion. 
Attentiveness (d’) on the CPT increased with medication, which is in 
keeping with medication studies in children with ADHD (Losier, 1996), and 
with studies in adults with ADHD (Kuperman et al., 2001). Risk taking (β) 
did not change with Mph treatment, which also in line with previous studies 
in children (Losier, 1996). In adults with ADHD, the effect of Mph on this 
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variable has not been reported before. It should be mentioned, however, 
that the standard deviation of this parameter was about as large as the 
mean, which makes interpreting any results with this variable difficult. It 
also raises questions about the accuracy of the calculation of this measure 
by the scoring program. Similar observations were made by Epstein et al. 
(1998). 
Exploratory analyses indicated that Mph may indeed normalize the 
number of commission errors made on the CPT by ADHD participants to 
the level of a normal control group. We only compared data for one 
dependent variable, so we cannot generalize this result to other cognitive 
abilities, but it is a promising result for clinical practice. Future research 
should compare other processes, preferably with a normal control group 
recruited especially for that study, since the normal control sample in the 
study by Epstein et al. (2001) was slightly younger than our ADHD sample. 
If other variables of the CPT also normalize with Mph, this may render this 
test suitable for quantitatively establishing the effect of Mph on an 
individual level. This would be a valuable contribution to the entire ADHD 
population (both children and adults), since changes in symptoms are now 
indicated by either observers, who may not always be as objective as 
necessary, or by patients themselves, who may not have an accurate 
perception of these changes (Barkley, Fisher, Smallish, & Fletcher, 2002). 
The clinical value of a decrease in commission errors is also substantiated 
by the receiver operating characteristic analyses we performed. We 
ascertained that the overall predictive value of the difference between 
placebo and medication commission errors on the CPT was 79%. The 
related sensitivity of 63% indicates that the decrease in commission errors 
from placebo to Mph has a moderate predictive value for clinical 
respondership. The specificity of this decrease seems to be better: 88% of 
participants who did not show a large decrease, were not clinical 
responders. Elwood (1993) argues that a more accurate measure of utility of 
neuropsychological variables is the positive and negative predictive power. 
Positive predictive power for the change in commission errors indicates that 
of those participants who showed large decreases in this type of errors, 78% 
were responders. Conversely, 79% of participants who showed a smaller 
decrease of commission errors, were correctly classified as non-responders.  
We found no significant correlations between medication commission 
errors on the CPT and several clinical variables, while partialing out placebo 
commission errors. This indicates that improvement in commission errors 
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with medication is not influenced to a significant extent by the severity of 
ADHD, the administered dose of Mph (either relative or absolute), the 
number of co-morbid disorders, co-morbid anxiety disorder, and IQ. Of 
course these analyses are only superficial, and no definitive conclusions 
can be drawn based upon these results. Larger groups of participants 
would allow for more substantial analyses into these issues. However, the 
results do suggest that the effect of Mph on commission errors on the CPT 
takes place rather independently of the variables mentioned. For all the 
exploratory analyses, it should be stressed that only a few variables were 
used in the analyses. So exploratory results only play up to future research: 
of course other variables and other tests should be evaluated before firm 
conclusions can be drawn. 
All in all, many of the effects found in our study are in accordance 
with previous Mph studies with either adults with ADHD and/or children 
with ADHD. However, two deviant results were established. The first deviant 
result is lack of reduced variability in the reaction times on the Change 
Response. This may be due to large within group variability for this 
variable. The decrease in mean reaction time of the Change Response is 
close to significance, while the decrease in the standard deviation of 
reaction times is not. Proportionally, however, these decreases are similar 
for both variables. The within group variance is, again proportionally seen, 
much larger for the standard deviation of mean reaction times on the 
Change Response than for the mean reaction time of the Change Response, 
which could easily lead to lack of significant ANOVA results. 
The second and main divergent result is a lack of robust decreases in 
SSRT on the ChT for the total ADHD group. Several explanations can be 
given for this deviation. A possible explanation can be found in the work of 
Tannock and colleagues (1995), who found an inverse U-shaped dose-
response curve for SSRT in a ChT: Mph induced the largest reduction in 
SSRT with a medium dose (0.6 mg/kg). Decreases in SSRT were not 
established with low (0.3 mg/kg) nor with high (0.9 mg/kg) doses. In our 
study, the mean relative dose (0.9 mg/kg) was similar to the high dose in 
Tannock’s study. Future research with different doses of Mph should prove 
whether medium doses improve inhibition on the ChT in adults with ADHD. 
Another elucidation for our absence of a robust reduction in SSRT 
may be offered by Scheres et al. (2003), who indicated that a Stop Task with 
a tracking mechanism may be more sensitive to medication effects than the 
version with a fixed intervals method, used here. The version with a 
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tracking mechanism assures a constant inhibition probability of 50%, 
which provides the most reliable estimation of SSRT (Band et al., 2003). 
When the percentage inhibition is lower or higher than 50%, estimations of 
SSRT may be underestimated or overestimated, respectively. The results of 
a recent study (Aron, Fletcher, Bullmore, Sahakian, & Robbins, 2003) 
indicate that Mph may indeed improve inhibition as measured with a 
tracking version of the SST in adults with ADHD. Our data evoke the 
important question of why Mph has a robust effect on commission errors on 
the CPT, and not on SSRT on the ChT, while both variables are supposed to 
measure inhibition. It may be the case that the two operationalizations of 
response inhibition actually tap into slightly different abilities. This 
suggestion is underpinned by the low correlation between SSRT and 
commission errors (r=.21). The nature of the two tasks also indicates several 
differences. First of all, in the CPT, the signal to withhold a response is 
given before the actual response is started up, while the ChT requires 
withholding a response that has already commenced in a large part of the 
trials. Secondly, there is a difference in the percentage of targets in both 
tasks. In the ChT, 25% of trials require withholding a response, while this is 
only called for in 10% of the trials in the CPT. This discrepancy may cause 
differences in the state of arousal that participants are in while performing 
both tasks, which may influence the effect of Mph on both tasks. 
A third difference between the two tasks is the nature of the stop 
signal. In the CPT, this signal is visual, and similar to the target signals. In 
the ChT, the stop signal is auditory. It has been suggested that children 
with ADHD have particular difficulties with processing information in the 
auditory modality (Riccio, Hynd, Cohen, Hall, & Molt, 1994). If this is also 
the case in adult ADHD, this factor may interfere with improvement on the 
ChT with medication. Besides this difference in nature of the stop signal, 
the mere fact that processing of the stop signal requires a different modality 
than processing of the stimulus itself may cause a difference in medication 
effect in comparison with the CPT. 
Yet another, important difference can be found in the level of difficulty 
of both tasks. Inhibition on the ChT requires withholding a response while 
being in a more or less alerted state. The participant is anticipating a plane 
on either side of the screen and has to actually pay continuous attention in 
order to give the correct response in this two-choice reaction time task. 
With the CPT, it seems easier to drift into a semi-alert state of attention, 
since this is a simple go-nogo task. Every stimulus requires the same 
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response, i.e., pressing the space bar. Besides this difference in difficulty, 
the ChT requires response re-engagement after inhibition of the primary 
response. This also makes the inhibition process in this task a different, 
and more difficult process from inhibition in the CPT. Tannock et al. (1995) 
have indeed found smaller Mph effects on SSRT in the more demanding 
ChT, compared to the easier SST (used in their 1989 study). Increased 
cognitive load may reduce the magnitude of the effect of stimulants. This is 
in line with previous research, where performance decrements at high doses 
have been found on tasks that were complex, or on the most difficult level of 
tasks (Berman et al., 1999; Douglas, 1988; Tannock & Schachar, 1992). 
This underscores the importance of studying the effects of different doses in 
adults with ADHD, since the optimal dose for ameliorating behavioral 
symptoms, may not necessarily the most effective dose for several cognitive 
abilities (Cantwell & Swanson, 1997). 
We tried to establish the effect of Mph on inhibition in adults with 
ADHD. Although our data suggest positive effects of the drug on inhibition, 
we did not test whether this holds for all forms of inhibition. As noted by 
Evenden (1999), “there is not one unitary impulsivity or only one type of 
impulsive behavior” (p. 348). Different researchers have proposed different 
taxonomies for subdividing inhibition (Barkley, 1997b; Nigg, 2001). So 
further studies are necessary to determine which form of inhibition is 
improved by Mph and to better operationalize  different forms of inhibition.  
In sum, current findings showed that, in adults with ADHD, Mph has 
large beneficial effects on inhibition as measured by the CPT. It also has a 
large effect on inhibition as measured by the ChT, but only in those 
subjects who show slow inhibition times off-medication. In addition to 
improving inhibition, Mph decreases variability in response execution 
processes on  the CPT, and it improves the ability to distinguish signal from 
noise on the CPT. Thus, Mph does not only effectively ameliorate clinical 
symptoms in an adult ADHD population, as shown by several researchers 
(for reviews, see Wilens et al., 2002 and Faraone et al., 2004), but its 
positive effects can also be demonstrated on several cognitive processes 
important in daily life. 
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ABSTRACT 
Study Objectives: To investigate parameters of sleep, activity, and circadian 
rhythm, as well as the effects of methylphenidate on these variables, in adults 
with Attention Deficit Hyperactivity Disorder (ADHD). 
Design: 1) Baseline group comparison; 2) Double blind, placebo controlled cross-
over medication trial. 
Setting: Data collection took place during the daily lives of participants. 
Participants: 39 normal controls and 33 adults with ADHD for baseline 
comparisons; 31 adults with ADHD in the medication trial. 
Interventions: Treatment with placebo and methylphenidate during the 
medication trial. 
Measurements & Results: Actigraphy and sleep log data were collected for seven 
consecutive nights and days to obtain baseline values for ADHD and normal 
controls. Repeated measurements during placebo and methylphenidate treatment 
were conducted for the ADHD group. 
1) Baseline comparisons indicated higher daytime activity, lower Sleep Efficiency, 
longer Sleep Onset Latency, and shorter average Sleep Bout Duration in the ADHD 
group, as well as a higher Interdaily Stability and a lower Intradaily Variability. 
Subjectively, participants with ADHD rated their sleep quality lower than normal 
controls. 
2) Methylphenidate led to delays in Bedtime, Sleep Onset Latency, and decreased 
Sleep Times. However, during this shorter sleep, participants showed fewer 
nocturnal awakenings, less wakefulness, and longer average Sleep Bout Duration. 
Intradaily Variability also increased. 
Conclusions: Our data suggest that sleep problems are inherent in adult ADHD, 
and that they are neither caused by nor worsened with stimulant treatment in this 
population. On the contrary, stimulants improve the quality of sleep in adults with 
ADHD. 
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INTRODUCTION 
Actigraphs are small devices, usually worn around the wrist, that detect 
and store movement for later analysis of levels of activity, sleep and wake 
parameters, and circadian rhythm parameters (Ancoli-Israel et al., 2003). 
These measurement goals make actigraphy a useful tool for objectively 
studying Attention Deficit Hyperactivity Disorder (ADHD), since this 
disorder is by definition associated with hyperactivity, but also with sleep 
problems (e.g., Cohen-Zion & Ancoli-Israel, 2004; Corkum, Tannock, & 
Moldofsky, 1998; O'Brien & Gozal, 2004; Van der Heijden, Smits, & 
Gunning, 2005). Actigraphy has indeed been utilized in studying children 
with ADHD, but it has hardly ever been employed in adults with the 
disorder. We therefore present the present extensive actigraphy study of 
daytime and nighttime activity, sleep/wake parameters, and circadian 
rhythms in carefully diagnosed adults with ADHD, as well as the effects of 
medication, in order to provide tentative answers to the four research 
questions described below. 
 
Are adults with ADHD more active (as measured by actigraphs) 
during the day and/or during the night than normal controls? 
When looking at daytime activity, children with ADHD showed higher levels 
than normal controls (Dane, Schachar, & Tannock, 2000; Halperin, Matier, 
Bedi, Sharma, & Newcorn, 1992; Halperin et al., 1993; Porrino, Rapoport, 
Behar, Sceery et al., 1983). Inoue et al. (1998) suggested that children with 
ADHD can be distinguished from normal controls based on actigraphy 
scores during neuropsychological testing (70% sensitivity and 82% 
specificity). We know of only one study to use daytime actigraphy in an 
adult population with suspicion of childhood ADHD. The patient group in 
this study could be distinguished from normal controls by higher activity 
counts from the actigraphs (Tuisku et al., 2003). However, the patient group 
in this study was classified as 'Antisocial Violent Offenders': our study is 
the first to explore daytime activity in adult participants with a primary 
diagnosis of ADHD. 
With respect to nighttime activity, Cohen-Zion & Ancoli-Israel (2004) 
discussed four studies (Corkum, Tannock, Moldofsky, Hogg-Johnson, & 
Humphries, 2001; Dagan et al., 1997; Gruber, Sadeh, & Raviv, 2000; 
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Porrino, Rapoport, Behar, Sceery et al., 1983) that utilized actigraphs in a 
child ADHD sample and they concluded that the evidence is inconclusive, 
although most studies reported more nighttime activity and increased 
nighttime variability in activity levels. Two more recent additional studies 
confirmed these findings (Crabtree, Ivanenko, & Gozal, 2003; Gruber & 
Sadeh, 2004). We are aware of two studies in which actigraphy was used to 
evaluate activity during the night in an adult ADHD population. In one of 
these, adults with ADHD showed a higher mean activity level during the 
night than normal controls (Kooij, Middelkoop, Van Gils, & Buitelaar, 
2001), whereas in the other study the difference was not significant 
(Middelkoop, Van Gils, & Kooij, 1997). Both studies reported a higher 
movement index (percentage of epochs with an activity count > 0) during 
the night. 
 
Are there differences in actigraphic sleep parameters between 
adults with and without ADHD? Besides the nighttime actigraphy 
results mentioned with the former research question, problems with sleep 
are frequently reported in children with ADHD (Cohen-Zion & Ancoli-Israel, 
2004; Corkum et al., 1998; O'Brien & Gozal, 2004; Van der Heijden et al., 
2005). Especially subjective (parental) reports of sleep problems in children 
with the disorder are highly prevalent, although results of more objective 
measurements of sleep (like polysomnography) are equivocal: there does not 
seem to be one specific disturbance of sleep architecture related to the 
disorder. In addition to sleep architecture differences, ADHD has been 
associated with a higher prevalence of sleep disorders like Periodic Limb 
Movement and Sleep Disordered Breathing (see reviews mentioned above). It 
has even been suggested that sleep problems in children with ADHD may 
be the primary condition that results in secondary symptoms of 
hyperactivity and inattention, rather than ADHD being the primary 
condition associated with specific sleep problems (Cohen-Zion & Ancoli-
Israel, 2004).  
Research into sleep problems in adults with ADHD is scarce. Several 
studies have indicated that also in adults, sleep disorders may be 
misdiagnosed as ADHD (Ball, Wooten, & Crowell, 1999; Naseem, 
Chaudhary, & Collop, 2001). In adult men with Antisocial Personality 
Disorders, Lindberg et al. (2004) found a strong positive correlation between 
childhood ADHD scores and abnormal sleep architecture as measured by 
polysomography. Kass, Wallace, and Vodanovich (2003) also established a 
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relation between scores on an adult ADHD questionnaire and scores on 
several sleep problem questionnaires. But we know of no direct studies of 
sleep characteristics of carefully diagnosed adults with ADHD, let alone of 
actigraphic sleep characteristics.  
 
Are there differences in circadian rhythm parameters between 
adults with ADHD and normal controls? Actigraphy also yields 
information on the amplitude, phase and stability of the circadian (24-hour) 
pattern of activity, which may reflect functionality of the hypothalamic 
suprachiasmatic nucleus, the biological clock of the brain. There is hardly 
any research into circadian rhythms in ADHD, especially not in adults with 
the disorder. Gruber et al. (2000) and Crabtree et al. (2003) reported that 
instability of sleep onset time and sleep duration is characteristic for ADHD 
in children but they did not evaluate the circadian patterning of rest-activity 
rhythms. Van der Heijden et al. (2005) suggested that the chronic sleep 
onset insomnia often encountered in children with ADHD may be a 
circadian rhythm sleep disorder. They also established a delayed melatonin 
secretion (linked to the biological clock: Webb & Puig-Domingo, 1995) in 
children with ADHD, possibly indicative of a delayed sleep phase. 
 
What are the effects of treatment with methylphenidate on the 
above-mentioned activity, sleep and circadian rhythm parameters 
in adults with ADHD? Methylphenidate (Mph) has been the preferential 
treatment for ADHD for decades, both for children (e.g., Brown et al., 2005) 
and for adults (e.g., Kooij et al., 2004; Spencer et al., 2005). Very few 
studies have investigated the effects of this stimulant on hyperactivity by 
means of actigraphy, but the few available outcomes indicated a decrease in 
activity during the day with treatment in children with ADHD (Konrad, 
Gunther, Heinzel-Gutenbrunner, & Herpertz-Dahlmann, 2005; Miller & 
Kraft, 1994; Porrino, Rapoport, Behar, Ismond, & Bunney, 1983). We know 
of no daytime medication effect studies in the adult ADHD population, but 
the one available actigraphy treatment study reporting effects of stimulants 
during the night showed a decrease of nighttime activity level with 
medication in comparison to placebo (Kooij et al., 2001).  
In addition to the above mentioned sleep problems in un-medicated 
children with ADHD, insomnia is a frequent side effect of stimulant 
medication (e.g., Ahmann et al., 1993; Efron, Jarman, & Barker, 1997; 
Stein et al., 2003). Other sleep disturbances with stimulant treatment have 
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also been indicated by parental reports (Day & Boerio Abmayr, 1998; Stein 
et al., 2002; Stein, 1999). However, some researchers have established a 
decrease rather than an increase in sleep problems with stimulant 
medication and some have even suggested that sleep problems may 
represent features of the behavioral phenotype of ADHD rather than 
adverse side effects of medication (Efron et al., 1997; Kent, Blader, 
Koplewicz, Abikoff, & Foley, 1995; Mick, Biederman, Jetton, & Faraone, 
2000; O'Brien, Ivanenko et al., 2003; Tirosh, Sadeh, Munvez, & Lavie, 
1993). Two of the earlier actigraphy studies (Stein et al., 1996; Tirosh et al., 
1993) on the effects of stimulants on sleep in children with ADHD have 
mainly noted differences in Total Sleep Time, which decreased with 
medication. In a recent study (Schwartz et al., 2004) children with ADHD 
showed longer sleep onset latency, less sleep efficiency and shorter total 
sleep time with treatment than with placebo. Medication studies of specific 
sleep actigraphy parameters in adults with ADHD are not available. 
METHODS  
Participants 
ADHD participants 
We included data of 33 adults with ADHD, 16 men and 17 women. The 
average age was 37.9 years (SD 10.3), and the average IQ was 104.1 (SD 
18.5). One of the participants was diagnosed with ADHD 
hyperactive/impulsive subtype, the other 32 were diagnosed with ADHD 
combined subtype. Thirty-one of these participants entered the medication 
trial after a baseline comparison. One female participant had to be excluded 
from the medication trial due to use of a weight control supplement that 
contained a stimulating substance (ephedra), and one male participant was 
excluded because of a positive opiate urine screening during the first week 
of the trial. The average age for the 31 participants of the medication trial 
was 37.8 (SD 10.6), the average IQ was 104.1 (SD 18.2). None of the 
participants had been treated with methylphenidate (Mph) prior to this 
study. The participants were self-referred or referred by other clinicians for 
assessment of ADHD to an outpatient clinic in The Netherlands. Details of 
the diagnostic procedure and the instruments used have been provided 
elsewhere (see Chapter 4 of this thesis; Kooij et al., 2004). In brief, 
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participants underwent a standardized clinical assessment by a 
psychiatrist. Next to a semi-structured clinical diagnostic interview for 
ADHD and co-morbid disorders, several structured interviews and 
questionnaires were used to assess ADHD and co-morbid psychiatric 
disorders. To be given a diagnosis of adult ADHD, subjects had to  
(1) currently meet at least 5 of 9 DSM-IV criteria of inattention and/or at 
least 5 of 9 DSM-IV criteria of hyperactivity/impulsivity (this cutoff point is 
in line with previous research by Biederman et al., 2000; Kooij et al., 2004; 
Murphy & Barkley, 1996), (2) meet at least 6 of 9 DSM-IV criteria of 
inattention and/or at least 6 of 9 DSM-IV criteria of hyperactivity/-
impulsivity in childhood, (3) describe a chronic persisting course of ADHD 
symptoms from childhood to adulthood, and (4) endorse a moderate to 
severe level of impairment attributed to ADHD symptoms.  
Normal Control Participants 
Thirty-nine normal control (NC) participants, 18 men and 21 women, 
participated in the baseline comparison study. The average age was 37.8 
years (SD 9.5), and the average IQ was 109.31 (SD 15.4). Controls were 
matched to ADHD participants on age and gender on group level. Details of 
the diagnostic procedure and the instruments used have been provided 
elsewhere (see Chapter 3 of this thesis). In brief, we only included NCs that 
did not a) show any evidence of ADHD or other psychiatric diagnoses, b) use 
any drugs or psychotropic medications, c) consume more alcohol than 
considered safe by official Dutch guidelines, d) ever in their life receive a 
psychiatric diagnosis (including substance abuse), and e) seek help for 
mental health problems (including burn out) during the last three years. IQ 
as estimated with a short version of the WAIS-III had to be above 75. 
The local Medical Ethical Committee approved the study, and all 
subjects completed a written informed consent form before inclusion in the 
study. 
Procedure 
All participants wore the actigraph for seven consecutive nights and days to 
obtain baseline values. The ADHD participants then entered a double blind, 
placebo controlled, cross-over trial of Mph. The design of this trial and 
clinical outcomes are described in detail elsewhere (see Chapter 4 of this 
thesis; Kooij et al., 2004). In brief, there were two 3-week treatment periods 
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for each participant, one period of three weeks for Mph and one period of 
three weeks for placebo, with 1 week of washout in between. The order of 
treatment (Mph-placebo or placebo-Mph) was randomized. Study 
medication was titrated up from low to high doses, to avoid exposure to 
high initial doses of active medication and to minimize side effects. 
Participants started with 0.5 mg/kg per day in week 1, followed by 0.75 
mg/kg per day in week 2, and up to 1.0 mg/kg per day in week 3, unless 
adverse effects emerged. Repeated measurements with the actigraphs took 
place during week 3 (highest dose of Mph, or placebo) and during week 7 
(highest dose of Mph, or placebo). All recordings were obtained between 
July 2000 and February 2003. 
Materials  
Actigraphy 
We used the Actiwatch Activity Monitoring System, developed by Cambridge 
Neurotechnology. We set our epoch length to 1 min, in accordance with the 
2002 Practice Parameters for the use of actigraphy (Littner et al., 2003). 
Epoch length refers to the period of time the Actiwatch accumulates activity 
data before saving the sampling and resetting the counter to zero. We 
instructed participants to wear the Actiwatch on their non-dominant wrist, 
as recommended by Littner et al. (2003) and Sadeh and Acebo (2002).  
Calculation of actigraphic sleep variables 
Objective estimates of sleep were calculated from the actigraphy recordings 
using the Actiwatch Sleep Analysis software (version 1.19, 2001, Cambridge 
Neurotechnology, Cambridge, UK), which compares favorable to other such 
packages in reliably estimating sleep (Chang et al., 1999). The patterning of 
periods of rest and activity during the night is correlated - but not identical 
- to periods of sleep and wakefulness: estimates are useful though (El Baz, 
Quera-Salva, Oakley, Lecendreux, & Gajdos, 1998), and will be referred to 
as 'sleep’ and ‘wakefulness’ throughout this paper. We obtained the 
following objective sleep variables for each subject at each condition by 
averaging over the recorded nights: the Bedtime and Get Up Time (actual 
clock hour) are derived from the sleep logs and together determine the 
Time In Bed (in hours). Within this time frame, Sleep Start and Sleep 
End (actual clock hour) occur, which together determine the period of 
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Assumed Sleep Time (in hours). Since sleep is not one continuous 
process from Bedtime to Get Up Time, but is interrupted by short 
awakenings, which may or may not be perceived consciously, a somewhat 
lower Actual Sleep Time (in hours) results. This may also be expressed as 
Actual Sleep %, being the percentage of sleep between Sleep Start and 
Sleep End. Likewise, the arousals – also denoted as (number of) Wake 
Bouts - make up some Actual Wake Time (in hours), which again may be 
expressed as Actual Wake %. Sleep Efficiency is the percentage of sleep 
between Bedtime and Sleep End. Sleep Onset Latency (in hours) is the 
time it takes from Bedtime to Sleep Start. The duration of periods of sleep 
and wakefulness can be averaged to generate a mean Sleep Bout 
Duration and a mean Wake Bout Duration (both in hours). These 
variables give an impression of the structure of sleep. The Sleep Bout 
Duration measures the average length of uninterrupted sleep between two 
consecutive awakenings. Sleep bouts of long duration are related to a high 
sleep efficiency, the occurrence of 'deep', i.e. slow-wave sleep, and are 
negatively related to nocturnal awakenings (Gimeno, Sagales, Miguel, & 
Ballarin, 1998; Middelkoop, Van Hilten, Kramer, & Kamphuisen, 1993). The 
Wake Bout Duration provides another indication of sleep depth and 
continuity: long arousals are more disruptive to sleep than very brief ones. 
Calculation of actigraphic circadian sleep-wake rhythm variables 
Not only the occurrence of activity during the major sleep period, but also 
the patterning of periods of rest and activity over days and nights may 
provide useful information. We calculated a number of nonparametric 
circadian rhythm variables, which compare favorable to other methods for 
rhythm quantification including cosine fitting, complex demodulation, the 
Lomb-Scargle periodogram and autoregression (Van Someren et al., 1999). 
The Interdaily Stability (IS) quantifies the strength of coupling of the 
sleep-wake rhythm to the 24-hour regularity in the environment. A low IS is 
indicative of a weak circadian rhythm. The Intradaily Variability (IV) 
quantifies the fragmentation of periods of rest and activity. A high IV is 
indicative of many transitions between periods of rest and activity, as 
opposed to one sustained period of activity during the day and one 
sustained period of rest during the night. For details on calculation of these 
variables, the reader is referred to Witting, Kwa, Eikelenboom, Mirmiran, & 
Swaab (1990). A measure indicating the activity level during the major sleep 
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period is L5, defined as the mean activity level during the sequence of the 5 
least active hours in the 24-hour average activity profile. L5 provides an 
indication of restfulness and regularity of sleep periods with lower values 
indicating a more regular and restful ‘core’ sleep period. L5-Onset 
indicates the clock hour at which this major restful phase commences. A 
measure indicating the activity level during the major wake period is M10, 
defined as the sequence of the 10 most active hours in the 24-hour average 
activity profile. M10 provides an indication of how active and regular the 
major wakefulness periods are. M10-Onset indicates the clock hour at 
which this major active phase commences. Finally, the Relative 
Amplitude (RA) quantifies the difference between daytime (M10) and 
nighttime (L5) activity levels. A low RA indicates little difference between the 
activity levels during the major rest and activity phases and/or extreme 
irregularity: both indicative of a weak circadian rhythm. Details on 
calculation of these variables have been given elsewhere (Van Someren et 
al., 1996; Van Someren, Kessler, Mirmiran, & Swaab, 1997; Van Someren 
et al., 1999). 
Sleep & Activity Log 
In accordance with the 2002 Practice Parameters for the use of actigraphy 
(Littner et al., 2003), we asked participants to complete a Sleep & Activity 
Log twice a day, for each day they wore the actigraph. The log contained 
questions about subjective experience of different aspects of sleep, rated on 
a five point Likert scale (e.g., ‘How well rested did you feel today?’, ‘How well 
did you sleep?’). Higher scores were indicative of poorer subjective 
experience of sleep aspects. The log also contained questions about 
activities during the day, use of medication, alcohol, caffeinated beverages, 
and cigarettes, and bed- and wake times. In the log participants noted 
periods they did not wear the actigraph, due to showering and other water-
related activities. These periods of time were manually discarded from the 
data before analysis. 
Statistical approach 
Since it has been noted previously that sleep-wake rhythms may differ with 
age, gender and season (see Sadeh & Acebo, 2002), and given that we 
obtained data throughout the year, it was desirable to include these factors 
as covariates. Season is a circular variable, which has previously 
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successfully been linearized into the two variables: day-length and rate of 
change in day-length (Van Someren, 1997; Van Someren et al., 1996). 
Having solved this difficulty, the fact remains that in a repeated measures 
design – investigating the effect of Mph and placebo on the sleep-wake 
rhythm – these season variables are time-varying covariates, i.e. not fixed 
per subject, but changing over the repeated observations in the subjects in 
a differential way due to the staggered entry of subjects in the protocol. A 
solution was found in the application of hierarchical regression analysis 
(i.e., random coefficient analysis) to account for the interdependency of the 
data points inherent to the hierarchical structure of the design, i.e. 
sequential observations within subjects (MLwiN software, Centre for 
Multilevel Modelling, Institute of Education, London, UK: Twisk, 2003). 
Although not strictly necessary, we consistently applied this method to first 
investigate differences between baseline assessments of ADHD participants 
and control subjects. 
 
For all variables mentioned above we obtained effect estimates from the 
following regression equation: 
 
Outcome_Variablej =  
ß0j + ß1j*ADHD + ß2j*Male + ß3j*Age + ß4j*Daylength + ß5j*DaylengthChange 
 
where ß0j – ß5j are the effect estimates for the intercept, the effect of ADHD, 
gender, age, and season, optimized to fit the observations of all j subjects.  
 
We subsequently investigated the effect of Mph in the ADHD participants on 
the same variables. For all variables we obtained effect estimates from the 
following regression equation: 
 
Outcome_Variableij =  
ß0j + ß1ij*Mph + ß2ij*Male + ß3ij*Age + ß4ij*Daylength + ß5ij*DaylengthChange + ß6ij*Placebo + ß7ij*Time 
 
where ß0 – ß7 are the effect estimates for the intercept, the effect of Mph, 
gender, age, season, placebo, and time in study (whether methylphenidate 
was taken during the first or second period of the trial), as optimized to fit 
all i observations of all j subjects.  
Effect estimates with two-tailed Wald–statistic p-values < 0.05 were 
regarded as significant; non-significant terms were excluded from the 
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regression equation and a next iteration of fitting the resulting sparser 
equation commenced. 
RESULTS 
Baseline comparisons 
A two-way contingency table analysis proved that there were equal numbers 
of female and male participants in the ADHD group and the NC group 
(Pearson’s χ2(1,N=72)=.04, p=.84). Independent-samples t-tests demon-
strated that there were no differences between the two groups in age 
(t(1,70)=.04, p=.97) or IQ (t(1,70)=-1.31, p=.19).  
Table 5.1 first presents the grand means and standard errors for all 
variables (column 1) of the ADHD participants at baseline (column 2) and 
controls (column 3). Subsequently, the intercept and effects of the factors 
finally included in the regression analysis are shown in columns 4 to 9.  
 
As can be expected for ADHD, the daytime activity level M10 was 52 
counts or 17% higher in the ADHD group compared to control subjects. No 
differences were found in nighttime activity levels. 
After having accounted for the variance due to age, gender and 
season, the actigraphic sleep variables indicated less sound sleep in the 
ADHD group. Compared to NCs, ADHD participants showed a 3.5% lower 
Sleep Efficiency, a six minute (67%) longer Sleep Onset Latency, and a six-
minute (34%) shorter average Sleep Bout Duration uninterrupted by 
wakefulness. 
The circadian variables on the other hand did not indicate 
disturbances of circadian organization of the sleep-wake cycle. On the 
contrary, compared to NCs, participants with ADHD showed a 0.07 points 
(13%) increased IS and a 0.13 points (16%) decreased IV, respectively 
indicative of a more repeatable daily schedule of activities and more 
consolidated periods of rest and activity.  
The subjective variables indicated that ADHD participants felt less 
well-rested in general (0.82 or 36%) as well as directly after waking up (0.72 
or 30%), and that they rated their sleep quality lower (0.61 or 31%) than 
control subjects. This is in agreement with the objectively lower sleep 
efficiency in comparison with normal subjects. Moreover, ADHD 
participants showed an eight-minute (65%) longer subjective sleep onset
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latency and 0.60 points (36%) more difficulty falling asleep. These findings 
are well in agreement with the objectively increased sleep latency of six 
minutes. 
Medication comparisons 
Table 5.2 exhibits the results of the regression analyses on the effect of Mph 
after having accounted for the variance due to age, gender and season. 
Neither Placebo treatment nor Time in study affected any of the variables, 
and therefore these factors were not included in the table. Table 5.2 shows 
the grand means and standard errors of the collapsed observations at 
baseline and with placebo (column 2) and of the observations during Mph 
treatment (column 3). The columns further to the right show the beta 
coefficients of the intercept and of the effects of Mph treatment, gender, age, 
and season.  
 
There was no change in activity level during the day (M10) with 
medication. The actigraphic sleep variables indicated that Mph is 
associated with delays in Bed Time (19 min), Sleep Onset Latency (5 min or 
34%) and Sleep Start (24 min). Consequently, the Assumed Sleep Time was 
reduced by 25 min (6%) and the Actual Sleep Time by 20 min (5%). 
However, during this shorter sleep period, sleep appeared to be more 
consolidated as indicated by a decrease in the number of nocturnal 
awakenings (-3.8 or 14%) and a lower percentage of wakefulness (-0.9 or 
8%), as well as by the .3 min (21%) increased average duration of 
uninterrupted sleep bouts. The circadian variables showed, that treatment 
delayed the onset of the major five least active hours (L5) by 18 min, in 
accordance with the delayed bedtime and sleep start reported above. 
Besides this, treatment increased the fragmentation of periods of rest and 
activity (IV) by 0.07, or 9%. Subjectively, Mph only reduced the nocturnal 
awakening rating by 0.36 or 31%, which is in agreement with the objective 
decrease in wake time and percentage.  
In line with previous observations, the covariates gender, age and 
season accounted for a significant part of the variance in the sleep-wake 
rhythm. Whereas a full description of these effects is outside the scope of 
the present paper, the most significant findings (p<0.001) will briefly be 
discussed here. With regards to the most prominent gender effects, males 
went to bed more than half an hour later than females in the overall 
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analysis including both control subjects and the baseline assessments of 
the ADHD subjects. Concerning age effects, in the ADHD group the Sleep 
Efficiency increased by 0.20% per year of age, the number of awakenings 
decreased by 0.4 per year of age, and the duration of Uninterrupted Sleep 
Bouts increased by 16 seconds per year of age. Concerning seasonal effects, 
in the ADHD group Sleep End and Get Up Time were advanced by ± eight 
minutes with every hour increase in day-length, indicating a much earlier 
awakening in the summer in comparison to the winter.  
Explorative analyses of co-morbidity 
To obtain a first indication of the influence of co-morbid disorders on 
actigraphic parameters in the ADHD group, we calculated correlations 
between the actigraph parameters that showed significant differences in the 
baseline analyses and the participants’ scores on the Hamilton Depression 
Scale (Hamilton, 1960) and the Hamilton Anxiety Scale (Hamilton, 1959). 
These rating scales were part of the extensive diagnostic procedure for 
ADHD and co-morbidity. The correlations between the scales and the 
actigraphy parameters ranged between |.02| and |.27|. None of the 
correlations reached significance (data available form the first author). 
DISCUSSION 
We designed the current study to obtain some first answers to questions 
concerning activity, sleep, and circadian rhythms as measured with 
actigraphs in an adult ADHD population. Answers to our first research 
question ('Are adults with ADHD more active during the day and/or during 
the night than normal controls?') can be found in comparison of daytime 
activity level and nighttime activity level. Participants with ADHD were 
indeed more active during the day than NCs. To our knowledge, this study 
is the first to objectively establish a higher daytime activity level in adults 
with ADHD. Our results are in agreement with the few studies conducted in 
the child ADHD population (Dane et al., 2000; Halperin et al., 1992; 
Halperin et al., 1993; Porrino, Rapoport, Behar, Sceery et al., 1983). We did 
not find a difference in nighttime activity L5 between our ADHD 
participants and the NCs. This result deviates from what we would expect 
based on the literature on children with the disorder (for reviews see Cohen-
Zion & Ancoli-Israel, 2004; Corkum et al., 1998), in which it is suggested 
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that one of the more consistent findings with regard to sleep problems in 
this population is increased nighttime activity. Data on adults with ADHD 
are equivocal, with one study (Kooij et al., 2001) reporting more nighttime 
activity and the other (Middelkoop et al., 1997) not. However, direct 
comparison with these studies is difficult since different dependent 
variables were reported. Moreover, sample size in both studies was small, so 
our data may prove more reliable. A possible explanation for the difference 
between children and adults could be found in the fact that adults choose 
their own bedtime and daytime activities, which may lead to less activity 
during the night. There is some tentative evidence that hyperactivity is most 
profound in structured and restricted activities (Dane et al., 2000; Porrino, 
Rapoport, Behar, Sceery et al., 1983), which would compare more favorably 
to daytime schedules of adults, but probably not to their evening and 
nighttime activities. It may also be that activity in the five least active hours 
of the average 24-hour rest-activity profile provides a view of activity during 
the core sleep period, but is not sensitive enough to quantify whole-night 
nocturnal activity, as is indeed suggested by the findings discussed below. 
Moreover, a recent polysomnography study indicated that it is mainly 
during light sleep (rather than deep sleep) that children with ADHD show 
more movements than normal controls (Kirov et al., 2004). 
With respect to our second research question ('Are there differences 
in actigraphic sleep parameters between adults with and without ADHD?'), 
our results indicate that this is indeed the case. Participants with ADHD 
showed less sound sleep than normal controls, as reflected by lower sleep 
efficiency, longer sleep onset latency, and shorter average duration of sleep 
bouts uninterrupted by wakefulness. These objective sleep problems are 
subscribed by subjective ratings of participants. Our results are 
conformable to the two studies that have utilized actigraphs in an adult 
ADHD population: Middelkoop et al. (1997) also found lower subjective 
ratings of sleep (as did Kooij et al., 2001) and shorter average duration of 
uninterrupted immobility periods. Middelkoop et al. (1997) and Kooij et al. 
(2001) did not find longer sleep onset latencies, but those results were 
based on subjective ratings only. In children with ADHD, actigraphy studies 
have shown mixed results, but longer sleep onset latencies have been 
reported frequently (for reviews see Corkum et al., 1998 and Cohen-Zion & 
Ancoli-Israel, 2004).  
Our third research question ('Are there differences in circadian 
rhythm between adults with ADHD and normal controls?') also leads to a 
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positive answer, although this answer differs from what one would 
intuitively expect in this population. We found that participants with ADHD 
showed a more repeatable daily schedule of activities and more consolidated 
periods of rest and activity than the NCs. In children with ADHD, there 
have been some suggestions of deviant circadian patterns (e.g., Crabtree et 
al., 2003; Gruber & Sadeh, 2004; Gruber et al., 2000; Van der Heijden et 
al., 2005). The fact that our data do not point towards deviant circadian 
patterning in adults with the disorder may be related to some form of 
compensation of adults with ADHD. They may be trying to impose external 
structure to counterbalance their lack of internal structure, as has been 
reported to occur in healthy aging as well (Monk, Reynolds, Machen, & 
Kupfer, 1992). Alternatively, it may be that there was just less difference in 
high and low activity levels in the ADHD group, because their daytime 
activity was near maximal most of the time. Indeed, it has been previously 
found in demented elderly that IS and IV appear less disturbed if daytime 
activity levels are high (Van Someren et al., 1996). Future studies with 
different methodologies (e.g., temperature measurements, melatonin 
secretion measurements) should shed further light on circadian patterning 
in participants with ADHD: do they go to bed later because they are too 
restless to sleep or because they show a phase delay in their circadian 
rhythm? 
Our fourth research question was 'What are the effects of treatment 
with Mph on activity, sleep parameters, and circadian rhythm in adults 
with ADHD?'. With respect to activity, we established no changes with 
medication in daytime or nighttime activity level. As far as we know, there 
are no studies to back up our results with respect to daytime activity in 
adults or children with ADHD, but Kooij et al. (2001) did find a decrease in 
nighttime activity level with stimulant treatment in an adult ADHD sample. 
However, this latter sample was small (eight participants) and the 
associated p-level was .10. Moreover, the design of that study was open-
label rather than controlled, so we feel that we stand stronger when we 
conclude that Mph does not change day- or nighttime activity level in adult 
participants with ADHD. Neither of the two available stimulant treatment 
studies in children with ADHD (Stein et al., 1996; Tirosh et al., 1993) 
reported any changes purely in nighttime activity level with treatment, so 
our data are in agreement with the few available results in a child 
population.  
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Mph did delay the onset of the least active period. This result is in 
accordance with the effects of medication on the sleep parameters, which 
were a delay in bedtime and sleep start, and longer sleep onset latency. As a 
result, assumed and actual sleep was reduced. However, the quality of sleep 
seemed to be better during the shorter nights, which was reflected in fewer 
nocturnal awakenings and an increase in the average duration of 
uninterrupted sleep bouts. The one study known to us that evaluated 
stimulant effects on actigraphic sleep estimates in adult ADHD participants 
(Kooij et al., 2001) did not report any effects of medication on total time in 
bed, sleep latency time, or number of awakenings. Like we mentioned before 
though, our study can be viewed as an extension towards more reliable 
results. In agreement with our findings, child ADHD studies have reported 
longer sleep onset latency and shorter total sleep time as measured by 
actigraphy after stimulant treatment (Schwartz et al., 2004; Stein et al., 
1996; Tirosh et al., 1993). An interesting result in our study was 
improvement of sleep quality, as reflected by fewer nocturnal awakenings 
and an increase in the average duration of uninterrupted sleep bouts, in 
spite of longer sleep onset latency and shorter total sleep time. These 
results are contradictory to the results of Schwartz et al. (2004), where both 
quality and quantity of sleep deteriorated with medication. A possible 
explanation for our results can be found in the timing of the last dose of 
medication, which was at 8 p.m. This makes the possibility of rebound (and 
thus worse sleep) less likely. In children, stimulants are often given during 
the day, to facilitate behavior during school hours, and not in the evening. 
This might increase the chance of rebound early in the evening, and lead to 
bedtime resistance and sleep problems (Garland, 1998). Kent et al. (1995) 
reported that children with ADHD derived substantial symptom reduction 
from Mph administered late in the afternoon, with no untoward negative 
effects on sleep.  
Subjectively, participants indicated that they woke up fewer times 
during the night with medication, which is in agreement with the objective 
results. In the only actigraphy study on effects of stimulants on sleep in 
adult ADHD (Kooij et al., 2001), subjective rating of the quality of sleep 
improved. It is interesting to see that the changes with medication in sleep 
parameters are hardly reflected in changes in the subjective ratings of sleep 
as given by the ADHD participants, whereas at baseline ADHD participants 
seemed capable of rating their own sleep fairly well. This may be related to 
the previously noted difficulty that adults with ADHD have with observing 
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changes in their own behavior, symptoms, or side effects of medication 
(Barkley et al., 2002).  
With regard to the effects of medication on circadian rhythms, we 
found an increased fragmentation of rest and activity periods (IV). The value 
was still below that of NCs in the baseline comparison, so if anything, the 
increase might be seen as an effect towards normalization of fragmentation.  
Age, gender and seasonal effects were included in the analyses 
because of the earlier established influence of these variables on sleep-wake 
parameters. Within the ADHD group it was most striking that females 
showed a higher mean activity count during the day than males. This is 
rather surprising, since in children with ADHD it has been thought that 
girls more often show the inattentive subtype, with less profound motor 
hyperactivity, whereas boys are supposedly more often affected by the 
hyperactive/impulsive subtype of the disorder (Berry, Shaywitz, & Shaywitz, 
1985; Brown, Madan-Swain, & Baldwin, 1991; Gaub & Carlson, 1997). 
There is tentative evidence both for lack of differences at the symptom level 
between sexes in adult ADHD (Biederman et al., 1994; DuPaul et al., 2001), 
and for over-representation of the hyperactive/impulsive subtype among 
adult women with the disorder (Kooij et al., 2004), so the difference in 
activity level warrants further investigation. Possibly, differences in co-
morbid disorders between sexes influence the activity level as well.  
The most outstanding result with respect to influence of age was that 
sleep seems to become more consolidated (as indicated by increased sleep 
efficiency, fewer wake bouts, and longer sleep bouts) in the ADHD group 
with age. These are remarkable findings given the literature on increasing 
sleep problems with age in the healthy population (Van Someren, 
Burmester, Alusi, & Lane, 2000). This may be related to hyperactive 
symptoms declining faster with age than inattentive symptoms (Biederman 
et al., 2000), if in fact mainly the hyperactive symptoms are related to sleep 
problems in ADHD, which has not been established yet. 
 
Our study has some limitations that should be taken into account in future 
investigations of activity and sleep parameters as measured by actigraphy 
in adult ADHD. It would be important to carefully examine the effect of co-
morbid disorders. Explorative correlation analyses in our study indicated 
that objective actigraph parameters may not be related to severity of 
depression or anxiety as measured by the Hamilton scales. This is only a 
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very rough indication of course, which should be further investigated in 
direct group comparisons. 
A second issue that should be explored in future studies, is the 
relationship between adult ADHD and sleep disorders, which may either 
mimic the behavioral complex of ADHD (Chervin, Dillon, Bassetti, Ganoczy, 
& Pituch, 1997; O'Brien, Holbrook et al., 2003; Yuan & Pelayo, 1999) or co-
occur with the disorder (e.g., Gaultney, Terrell, & Gingras, 2005; Morrish, 
King, Pilsworth, Shneerson, & Smith, 2002). Relating these should shed 
more light on the important matter of which is caused by which: are sleep 
problems caused by ADHD, are symptoms of ADHD the result of being 
sleepy, or are the two the result of one underlying brain defect, as is 
suggested by Brown & McMullen (2001)?  
Further important topics are: the long-term effects of stimulant 
treatment on sleep parameters (see Schachar, Tannock, Cunningham, & 
Corkum, 1997), daytime sleepiness (see Golan, Shahar, Ravid, & Pillar, 
2004), the effects of sleep disturbances on problems in cognitive functioning 
that have been related to ADHD (e.g., Frazier, Demaree, & Youngstrom, 
2004; Hervey, Epstein, & Curry, 2004; Chapter 2 and 3 of this thesis), 
issues with respect to clinical responders versus non-responders (Schwartz 
et al., 2004), and ADHD subtypes (Corkum, Moldofsky, Hogg-Johnson, 
Humphries, & Tannock, 1999; LeBourgeois, Avis, Mixon, Olmi, & Harsh, 
2004). 
 
In conclusion, we established higher daytime activity, indications of lower 
sleep quality and lower subjective rating of sleep quality in adults with 
ADHD in comparison with NCs. However, participants with ADHD showed a 
more repeatable daily schedule of activities and more consolidated periods 
of rest and activity than NCs. Treatment with Mph prolonged sleep onset 
latency and decreased total sleep time in comparison with placebo, but 
quality of sleep seemed to improve with stimulant treatment. Our data 
suggest that sleep problems are inherent in adult ADHD, and that they are 
neither caused by or worsened with stimulant treatment in this population. 
On the contrary, stimulants improve the quality of sleep in adults with 
ADHD. 
112 | Chapter 5 
ACKNOWLEDGEMENTS 
This research was supported by grants from Mental Health Institute GGZ 
Delfland, Health Insurance Company DSW, Nationaal Fonds Geestelijke 
Volksgezondheid (National Foundation for Mental Health), and De 
Hersenstichting (Brain Foundation).  
We thank Alex de Jager, Judith Rietjens, Susan ter Linden, Mariska 
Duijvelshof, Stijn Van Lanen, and Alain Vasbinder for their help in 
collecting the data. We thank the Board of Scientific Activities of the Reinier 
de Graaf Hospital in Delft for their financial contribution to the preparation 
of the study medication. We thank Paul Van der Linden for his help with 
the randomization procedure. We thank Huub Middelkoop for providing 
suggestions for the sleep & activity log. 
   
 
 
Genes & neurocognitive performance:
are the two related in adult ADHD?
Boonstra, A.M., Kooij, J.J.S., Buitelaar, J.K., Oosterlaan, J., Sergeant, J.A., Heister, 
J.G.A.M., & Franke, B. Genes and neurocognitive performance: are the two 
related in adult ADHD? Manuscript submitted for publication. 
114 | Chapter 6 
ABSTRACT 
Objective: To establish a first connection between key genetic polymorphisms and 
neurocognitive performance in adults with ADHD in order to aid the search for 
endophenotypes. 
Method: We genotyped 45 adults with ADHD at four key candidate polymorphisms 
for the disorder (DRD4 48 bp repeat, DRD4 120 bp duplicated repeat, SLC6A3 40 bp 
VNTR, and COMT Val158Met). We then subgrouped the sample for each 
polymorphism (DRD4 48 bp by presence or absence of 7-repeat allele; DRD4 120 bp 
by presence or not of two L alleles; SLC6A3 by presence or absence of 10-repeat 
allele; COMT by genotype Val/Val, Val/Met, and Met/Met) and compared the 
performance of the subgroups on a large battery of neurocognitive tests. 
Results: The COMT Val158Met polymorphism was related to differences in IQ and 
reaction time, both of the DRD4 polymorphisms (48 bp repeat and 120 bp 
duplication) showed an association with verbal memory skills, and the SLC6A3 40 
bp VNTR polymorphism could be linked to differences in inhibition. 
Conclusions: Our findings tentatively point towards possible endophenotypes for 
adult ADHD. Suggestions for future research are discussed. 
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INTRODUCTION 
It has long been clear that although close to 80% of the variability within 
Attention Deficit Hyperactivity Disorder (ADHD) is explained by genetic 
factors (see Faraone et al., 2005 for a review), the disorder does not follow 
simple Mendelian rules in its patterns of inheritance, but is most likely 
influenced by small effects of several genes. This complex nature of the 
disorder has lead researchers to search for simpler constructs that lie 
between genes and the complex syndrome of interest, called intermediate 
phenotypes or endophenotypes. These may serve as markers for risk of 
psychiatric psychopathology in the same way cholesterol levels serve as 
marker for heart disease (Aron & Poldrack, 2005). Theoretically, because 
the endophenotype is influenced by fewer genetic and environmental risk 
factors than the disorder as a whole, its use would result in greater 
statistical power to detect the effects of individual genes. However, to be 
most successful, endophenotypes for psychiatric disorders must meet 
certain criteria, including association with a candidate gene or gene region, 
heritability that is inferred from relative risk for the disorder in relatives, 
and disease association parameters (Gottesman & Gould, 2003). A possible 
way to support association with candidate genes or gene regions is by 
studying the relationship between cognitive functions that have been 
related to a disorder and the genes or genetic regions that have been 
implicated (Doyle, Faraone et al., 2005; Doyle, Willcutt et al., 2005). 
In ADHD much of the research into neurocognitive performance has 
focused on the concept of executive functioning (EF). EF is a very wide-
ranging construct, with as many as 33 different definitions posed in the 
literature (Eslinger, 1996). One possible definition is that of Welsh and 
Pennington (1988): “... the ability to maintain an appropriate problem 
solving set for attainment of a future goal (p. 201)”. Following this 
definition, Pennington and Ozonoff (1996) have included the following 
cognitive domains to be shared under the wings of EF: fluency (the ability to 
generate different solutions for a problem), planning (the ability to plan the 
steps needed to reach a solution for a problem), working memory (the ability 
to keep information online while performing), inhibition (the ability to 
inhibit or withhold ones actions), and set shifting (the ability to shift to 
another action or problem solving set when necessary). Many studies have 
116 | Chapter 6 
confirmed EF deficits in both children and adults with ADHD (see Hervey et 
al., 2004; Sergeant et al., 2002; Woods et al., 2002 for reviews). 
With respect to genes and genetic regions that have been implied in 
ADHD, most of the research has been concentrated on the disorder in 
children (for a recent review see Faraone et al., 2005). Since the first 
association study by Cook et al. (1995), many researchers have confirmed a 
relationship between ADHD and the dopamine transporter gene (DAT1 or 
SLC6A3, as it is currently known; Curran et al., 2001; Faraone, Doyle, 
Mick, & Biederman, 2001; Maher, Marazita, Ferrell, & Vanyukov, 2002). In 
SLC6A3, a 40 base pair repeat polymorphism in the 3’ untranslated region 
of the gene (Vandenbergh et al., 1992) has been studied mostly, indicating 
overrepresentation of the 10-repeat allele in ADHD. An association with 
dopamine receptor genes, such as DRD4 and (more recently) DRD5 (Lowe et 
al., 2004), has also been established. Research regarding DRD4 has focused 
on two polymorphisms in the gene that seem to influence the function and 
regulation of the gene product (Asghari et al., 1995; Asghari et al., 1994; 
D'Souza et al., 2004): a 48-bp repeat in exon 3 of the gene (Van Tol et al., 
1992) with the 7-repeat allele found to be over-represented in ADHD 
patients (e.g., Faraone et al., 2001; Faraone et al., 2005), and a 120-bp 
tandem duplication polymorphism in the 5’ flanking region (Seaman, 
Fisher, Chang, & Kidd, 1999). A gene involved in the breakdown of 
dopamine, the catechol-o-methyltransferase gene (COMT) with the 
functional polymorphism Val158Met (Lachman et al., 1996), has been 
implicated in ADHD as well (Eisenberg et al., 1999). Although this genetic 
research was performed with children with ADHD, similar patterns have 
been tentatively implicated in adults with ADHD (Faraone, 2004; Muglia, 
Jain, Macciardi, & Kennedy, 2000). 
Studies examining the association between candidate genes and 
established neurocognitive dysfunctions in ADHD, have led to a putative 
connection between the 7-repeat allele of the DRD4 gene and an inaccurate, 
impulsive response style on several neurocognitive tasks (Swanson et al., 
2000; Langley et al., 2004; Manor et al., 2002). The polymorphism on 
SLC6A3 has been associated with sustained attention performance (Loo et 
al., 2003). The functional polymorphism on the COMT gene, Val158Met, has 
been implicated in prefrontal functioning in healthy volunteers (Malhotra et 
al., 2002), although this relationship has not been confirmed in children 
with ADHD (Mills et al., 2004). 
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As far as we know, there have been no studies into the relationship between 
genetics and neurocognitive functioning in adults with ADHD. This seems 
logical in line with the fewer studies that have been conducted in this age 
group, but injudicious in light of the suggestion of the persistence 
hypothesis, which states that genes may play a larger role in the persistent 
form of ADHD (Faraone, 2004). This is why we pursued the following 
explorative coupling of several genetic polymorphisms in adults with ADHD 
and their performance on a large battery of neurocognitive tasks, divided 
into the five domains of EF mentioned above, to aid the search for possible 
endophenotypes of the disorder. 
METHOD 
Participants 
Forty-five adults with ADHD, 25 men and 20 women, participated in this 
study. The average age was 39.1 years (SD 9.9), and the average IQ was 
101.0 (SD 18.2). Two of the participants were diagnosed with ADHD 
hyperactive/impulsive subtype, the other 43 were diagnosed with ADHD 
combined subtype. The participants were self-referred or referred by other 
clinicians to an outpatient clinic in The Netherlands for assessment of 
ADHD. Prior to inclusion in the study, participants underwent a 
standardized clinical assessment consisting of a psychiatric evaluation by 
one of two experienced psychiatrists. The participants were originally 
recruited for a larger baseline comparison study of neurocognitive test 
performance (see Chapter 3 of this thesis), a clinical trial with 
methylphenidate (Kooij et al., 2004), and a study into the effects of 
methylphenidate on tests of inhibition (see Chapter 4 of this thesis). An 
extensive description of the diagnostic procedures and exclusion criteria 
can be found in these papers.  
The local Medical Ethical Committee approved the study, and all 
subjects completed a written informed consent form before inclusion in the 
study. 
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Materials 
DNA isolation and genotyping 
EDTA blood was collected from all adult ADHD cases. High molecular DNA 
was isolated by a routine procedure (Miller, Dykes, & Polesky, 1988). 
The 48 base pair (bp) repeat polymorphism in DRD4 was genotyped as 
described by Lichter et al. (1993). Using 31.25 ng of genomic DNA as 
template PCR was performed with 0.4 µM forward primer (5’-
GCGACTACGTGGTCTACTCG-3’) and reverse primer 
(5’-AGGACCCTCATGGCCTTG-3’), 0.25 mM dNTPs, 0.11 mM 7-deaza GTP 
(Amersham Biosciences Roosendaal, The Netherlands), 1 U AmpliTaq Gold 
DNA polymerase (Applied Biosystems, Nieuwerkerk a/d IJssel, The 
Netherlands), 60 mM Tris-HCl (pH 8.5), 15 mM (NH4)2SO4, 10% DMSO (v/v) 
and 2 mM MgCl2. Analysis of the PCR products on a 1.5% agarose gel 
showed bands at 378 bp (2 repeats), 426 bp (3 repeats), 474 bp (4 repeats), 
522 bp (5 repeats), 570 bp (6 repeats), 618 bp (7 repeats) or 666 bp (8 
repeats). 
The 120 bp tandem duplication (insertion/deletion) polymorphism in 
the DRD4 gene was genotyped using a PCR-based method essentially as 
described by Seaman et al. (1999). PCR was on 62.5 ng genomic DNA using 
0.4 µM of forward primer (5’-GTTGTCTGTCTTTTCTCATTGTTTCCATTG-3’) 
and 0.4 µM reverse primer (5’-GAAGGAGCAGGCACCGTGAGC-3’), 0.25 mM 
dNTPs, 0.5 U Taq DNA polymerase (Invitrogen, Breda, The Netherlands) in a 
PCR buffer containing 10 mM Tris-HCL pH 8.0, 50 mM KCl, 0.1% Triton X-
100 (v/v), 0.015% gelatin (w/v), 5% DMSO (v/v) and 1.5 mM MgCl2 . PCR 
products were analyzed on a 1.5% agarose gel. The amplification yielded 
distinct bands at 429 bp (short ‘S’ allele) and 549 bp (long ‘L’ allele). 
The 40 bp VNTR in the SLC6A3 (DAT1) gene was genotyped as 
described by Michelhaugh, Fiskerstrand, Lovejoy, Bannon, & Quinn (2001). 
Genomic DNA (62.5 ng) was amplified with 0.4 µM of forward primer (5’-
TGTGGTGTAGGGACGGCCTGAGAG-3’) and reverse primer  
(5’-CCTTGAGCCGTGACCTCCAGGAA-3’) and 0.25 mM dNTPs, 0.5 U Taq 
DNA polymerase (Invitrogen) in a PCR buffer containing 60 mM Tris-HCl 
(pH 8.5), 15 mM (NH4)2SO4, 10% DMSO (v/v) and 3.5 mM MgCl2. Analysis 
of PCR products was on a 2% agarose gel, producing bands at 443 bp (9 
repeats), 483 bp (10 repeats) or 523 bp (11 repeats). 
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Genotypes for the COMT Val158Met polymorphism were determined 
by pyrosequencing (Fakhrai-Rad, Pourmand, & Ronaghi, 2002) according to 
the protocol of the manufacturer (Pyrosequencing AB, Uppsala, Sweden). 
For the PCR amplification from 120 ng of genomic DNA a three primer 
system was used, with 0.2 µM forward primer (5’-
GGAGCTGGGGGCCTACTGTG-3’ (Malhotra et al., 2002), 0.02 µM reverse 
primer carrying a universal tail  
(5’-AGCGCTGCTCCGGTTCATAGATTGGCCCTTTTTCCAGGTCTGA-3’, the 
universal part is underlined) and 0.18 µM biotinylated universal reverse 
primer (5’-AGCGCTGCTCCGGTTCATAGATT-3’). The reaction also contained 
3 mM dNTP and 2 U AmpliTaq Gold DNA polymerase in GeneAmp PCR Gold 
buffer with 1.5 mM MgCl2 (Applied Biosystems). The sequence primer used 
for the pyrosequence reaction was 5’-GATGGTGGATTTCGC-3’. 
Pyrosequencing was performed on a PSQTM96 System (Pyrosequencing AB). 
The cycling conditions for most of the PCR assays were similar, 
starting with 5 min at 92°C, followed by 35 cycles (45 in the case of COMT 
Val158Met) of 1 min 92°C, 1 min at the optimized annealing temperature 
(58°C for the DRD4 120 bp tandem duplication and for the 40 bp VNTR in 
SLC6A3, 59.8°C for the COMT Val158Met polymorphism) and 1 min at 
72°C, then followed by an extra 5 min 72°C. The cycling conditions for the 
48 bp repeat polymorphism in DRD4 started with 10 min at 92 °C, followed 
by 40 cycles of 45 sec at 95°C, 45 sec at 54°C and 75 sec at 72°C, with a 
final extension for 10 min at 72°C. The amplifications were performed in a 
PTC-200 Multicycler (MJ-Research via Biozym, Landgraaf, The 
Netherlands). 
Neurocognitive tests 
The neurocognitive tests used in this study were originally chosen for the 
formerly mentioned study into differences in neurocognitive functioning 
between adults with ADHD and normal control participants. An extensive 
description of the tests and the results of the comparison between ADHD 
and normal controls can be found in Chapter 3 of this thesis. An overview 
of the used materials is provided in Table 6.1. 
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The tests for EF were divided into five domains, following the grouping by 
Pennington & Ozonoff (1996). The first domain, fluency, was assessed with 
three tests: 'Woordopnoemen' (WO; Luteijn & Van der Ploeg, 1983), a Dutch 
verbal fluency test for categories; Controlled Oral Word Association 
(COWAT; Benton & Hamsher, 1989), a verbal fluency test for letters, and 
the Ruff Figural Fluency Test (RFFT; Ruff, 1988), a test for non-verbal 
fluency. For the second domain, planning, we used the Tower of London – 
Revised (TOL; Schnirman et al., 1998). The third domain, working 
memory, was divided into verbal working memory and non-verbal working 
memory. Verbal working memory was assessed by means of two subtests 
from the Dutch version of the Wechsler Adult Intelligence Scale-III (WAIS; 
Wechsler et al., 2000): Digit Span-Backwards (WAIS-DS-B) and Letter 
Number Sequencing (WAIS-LNS). Visual Memory Span-Backwards (VMS-B) 
from the Wechsler Memory Scale-Revised (Wechsler & Stone, 1987) and the 
Self Ordered Pointing Task (SOP; Petrides & Milner, 1982) were included to 
assess non-verbal working memory. For the fourth domain of EF, 
inhibition, we included four tests. The first was the Change Task (ChT; 
Logan & Burkell, 1986). This is an extension of the Stop Signal Test (Logan 
et al., 1984) and can be used to investigate response inhibition (with the 
Stop Signal Reaction Time; SSRT), as well as set shifting or cognitive 
flexibility (with the Change Response; CR). The second test for inhibition 
was Conners’ Continuous Performance Test (CPT; Conners, 1995). We also 
used the Circle Drawing Test (CDT; Bachorowski & Newman, 1985; 
Bachorowski & Newman, 1990), and the Stroop Color Word Test (SCWT; 
Stroop, 1935; Dutch version: Hammes, 1971). The fifth and last domain 
included in this study was set shifting, as measured by the Change 
Response of the Change Task (see above) and the Wisconsin Card Sorting 
Test (WCST; Grant & Berg, 1948).  
We also included several neurocognitive tests for functions that are 
required to perform EF tests, but that are not tapping EF functions per se. 
In this manner, we aimed to control for performance on these abilities in 
the performance on EF tasks. Moreover, this would enable us to answer 
questions of the specificity of EF dysfunctions for ADHD. Which control test 
is used for which EF measure and for which function is clarified in Table 
6.1. We administered a short version of the Dutch Wechsler Adult 
Intelligence Scale-III (WAIS-III; Vocabulary, Arithmetic, Block Design, and 
Picture Arrangement) to estimate IQ. The subtests Vocabulary (WAIS-V) and 
Block Design (WAIS-BD) were also included as control tasks for other EFs. 
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Other control tests were: Benton Visual Retention Test-Copy (BVRT-C) and 
Memory (BVRT-M; Sivan, 1992); Purdue Pegboard (PP; Tiffin, 1968); Visual 
Memory Span-Forwards (VMS-F) from the Wechsler Memory Scale-Revised 
(Wechsler & Stone, 1987); 'Verbale Leer- en Geheugen Test' (VLGT; Mulder 
et al., 1996, which is a Dutch adaptation of the California Verbal Learning 
Test by Delis et al., 1987); Finger Tapping Test (FTT; Halstead, 1947); 
'Sorteren' (SORT; English: sorting; Luteijn & Van der Ploeg, 1983). 
Procedure 
We tested participants during two sessions on two separate days, one 
morning session of approximately three hours and one afternoon session of 
approximately three hours. Two 15-minute breaks were included in each 
session. We used standardized instructions for each of the tasks. Tasks 
were administered and scored by a trained psychologist or by master 
students trained by this same psychologist. 
Statistical Approach 
For each different polymorphism, Hardy-Weinberg equilibrium of the 
genotype distribution was analyzed. Study participants were then grouped 
according to genotype or presence of at least one risk allele, based on 
results from earlier studies. Table 6.2 provides an overview of the different 
polymorphisms and the frequency of genotypes. 
We then compared the subgroups with respect to their neurocognitive 
test performance. We checked normal distribution of each variable prior to 
group comparison with a Shapiro-Wilks test. If a polymorphism subdivided 
into two subgroups (all but COMT) was normally distributed we compared 
groups by means of independent sample t-tests, corrected for unequal 
variances where necessary. In case of non-normality we first checked for 
extreme scores, which were excluded when behavioural observations during 
testing prompted this. If this did not lead to normal distribution of the 
variable, we tried normalizing the distribution by transformation. If this still 
did not lead to normality, group differences were assessed non-
parametrically with a Mann-Whitney U test. In case of three subgroups 
(COMT), we followed the same procedure as outlined above, but tested the 
variables with an ANOVA followed by post-hoc comparisons, or, in case of 
non-normality, with a Kruskall-Wallis non-parametric analysis of variance, 
followed by Mann-Whitney U group comparisons. 
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Table 6.2 
Frequencies of genotypes per polymorphism investigated 
DRD4 
48 bp repeat 
DRD4 
120 bp ins/del 
SLC6A3 
VNTR 
COMT 
Val158Met 
2/2 n = 1 L/L n = 27 10/10 n = 19 Val/Val n = 10 
2/3 n = 1 L/S n = 15 10/9 n = 24 Val/Met n = 21 
2/4 n = 7 S/S n = 3 9/9 n = 1 Met/Met n = 14 
2/5 n = 1  11/10 n = 1  
2/7 n = 4    
3/3 n = 1    
3/4 n = 1    
4/4 n = 16    
4/5 n = 1    
4/7 n = 10    
4/8 n = 1    
6/7 n = 1    
N = 45 N = 45 N = 45 N = 45 
Note. 48 bp repeat = 48 base pair (numbers indicate the number of repeat units per allele); COMT = Catechol-
O-Methyltransferase; DRD4 = Dopamine Receptor D4; L = long allele; Met = Methionine; S = short allele; SLC6A3 
= Solute Carrier family 6, member 3, dopamine transporter (the numbers indicate the number of repeat units); 
Val = Valine; VNTR = variable number of tandem repeats. 
 
In light of chance capitalization we should actually have chosen to lower 
our alpha. However, because of small samples (and hence little power to 
detect small effects), the novelty of subject, and the exploratory nature of 
the study we decided to maintain an alpha level of .05 (two-sided). In this 
way, at least we hoped to establish some future directions for investigation. 
As can be seen below, degrees of freedom differed slightly for some tests. 
This was due to missing data because of technical difficulties, clerical 
errors, or extreme scores.  
RESULTS 
We observed no deviations from Hardy-Weinberg equilibrium for the 
genotyping results for DRD4, SLC6A3, and COMT (data not shown). Allele 
frequencies were similar to those observed in other samples of individuals of 
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Caucasian ethnic background according to the Alfred database 
(http://alfred.med.yale.edu/alfred/index.asp), except for a slightly higher 
frequency of the 2-repeat allele in DRD4 in our sample.  
Based on the results from the baseline neurocognitive study (see 
Chapter 3), tests could be divided into two different categories: one in which 
adults with ADHD actually performed worse than normal control (NC) 
participants and one in which there was no difference between the two 
groups. We describe the results according to this division. 
Tests on which ADHD adults performed worse than NCs 
DRD4, 48 bp repeat  
For this polymorphism, we compared the following two groups: 1) 
participants with at least one 7-repeat allele (n=15), and 2) participants 
without any 7-repeat alleles (n=30). This subdivision is in line with earlier 
cognitive research on this polymorphism  (Swanson et al., 2000; Langley et 
al., 2004) and based on the idea that the 7-repeat allele, specifically, affects 
protein function (Asghari et al., 1995). A significant difference between the 
two groups was found for verbal short-term memory, as measured with 
WAIS-DS-F (t(43)=2.18, p=.035). On this measure, the group with 7-repeat 
allele(s) performed better than the group without 7-repeat alleles. Statistics 
for additional (non-significant) results can be found in Table 6.3. 
DRD4, 120 bp duplicated repeat 
The following groups were formed for this polymorphism, based on whether 
participants had short (S) or long (L) alleles: 1) L/L, and 2) L/S + S/S. The 
group division was based on research indicating that the long allele has 
lower transcriptional activity and results in reduced DRD4 production in 
vitro (D'Souza et al., 2004). A significant difference between the two groups 
was found in the area of verbal memory, as measured by the VLGT, with the 
L/L group performing better than the other group (t(43)=3.57, p=.001). 
Statistics for additional tests are provided in Table 6.4. Comparing just L/L 
with L/S did not significantly change results (data available from the first 
author). 
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Table 6.3 
Descriptives and Statistics for DRD4 48 bp 
Test M (SD) Statistics 
IQ 1) 94.00 (17.30) 
2) 104.47 (17.86) 
t(43) = -1.87 ns 
WAIS-DS-F 1) .96 (.09)* 
2) .90 (.08) 
t(43) = 2.18 a 
WAIS-DS-B 1) 5.80 (1.42) 
2) 5.87 (1.55) 
t(43) = -.14 ns 
CPT  
 
1) 15.20 (6.68) 
2) 14.83 (7.67) 
t(43) = .16 ns 
VLGT 1) 51.73 (10.56) 
2) 54.70 (8.45) 
t(43) = -1.02 ns 
SCWT 1) 5.90 (1.06)* 
2) 5.91 (1.18) 
t(43) = -.05 ns 
ChT-CR 1) 22.61 (2.30)* 
2) 22.33 (2.09) 
t(43) = .41 ns 
ChT-SSRT 1) 231.34 (64.63) 
2) 228.05 (66.03) 
t(42) = .16 ns 
Note. 1) = DNA contains at least one 7-repeat allele; 2) = no 7-repeat alleles; ChT = 
Change Task (CR = Change Response; SSRT = Stop Signal Reaction Time); CPT = 
Continuous Performance Test; DRD4 = Dopamine Receptor D4; SCWT = Stroop Color 
Word Test; VLGT = 'Verbale Leer & Geheugen Test'; VMS-B = Visual Memory Span-
Backwards; WAIS = Wechsler Adult Intelligence Scale (DS-F = Digit Span-Forwards; 
DS-B = Digit Span-Backwards). 
* = Raw scores were transformed to obtain normality. 
ns = p > .05. a = p < .05. 
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Table 6.4 
Descriptives and Statistics for DRD4 120 bp 
Test M (SD) Statistics 
IQ 1) 10.06 (.87)** 
2) 9.94 (.97) 
t(40) = .51 ns 
WAIS-DS-F 1) .93 (.09)** 
2) .89 (.08) 
t(43) = 1.76 ns 
WAIS-DS-B 1) 5.89 (1.58) 
2) 5.78 (1.40) 
t(43) = .42 ns 
CPT  
 
1) 13.89 (7.52) 
2) 16.56 (6.80) 
t(42) = -1.21 ns 
VLGT 1) 57.26 (7.19) 
2) 48.39 (9.47) 
t(43) = -1.21 a 
SCWT 1) 1.51 (.16)** 
2) 1.55 (.17) 
t(43) = -.81 ns 
ChT-CR 1) 500.63 (88.94) 
2) 484.58 (68.14) 
t(41) = .63 ns 
ChT-SSRT 1) 238.34* 
2) 196.93 
z = -.63 ns 
Note. 1) L/L; 2) L/S + S/S; ChT = Change Task (CR = Change Response; SSRT = Stop 
Signal Reaction Time); CPT = Continuous Performance Test; DRD4 = Dopamine 
Receptor D4; SCWT = Stroop Color Word Test; VLGT = 'Verbale Leer & Geheugen 
Test'; VMS-B = Visual Memory Span-Backwards; WAIS = Wechsler Adult Intelligence 
Scale (DS-F = Digit Span-Forwards; DS-B = Digit Span-Backwards). 
* = For variables that were not normally distributed, we present the median. 
** = Raw scores were transformed to obtain normality. 
ns = p > .05. a = p < .01. 
 
SLC6A3 (DAT1), 40 bp VNTR  
For this polymorphism, we compared individuals homozygous for the 10-
repeat allele to those with any other genotype. The choice for this 
subdivision was based on the fact that the 10-repeat allele is the risk factor 
for ADHD (e.g., Curran et al., 2001), associated with higher expression 
and/or activity of the transporter in vitro and in vivo (Cheon, Ryu, Kim, & 
Cho, 2005; Fuke et al., 2001; Heinz et al., 2000; Mill, Asherson, Browes, 
D'Souza, & Craig, 2002). A significant difference between the two subgroups 
was found in the area of inhibition, as measured by SSRT of the ChT, with 
subgroup 1 (10/10) showing faster inhibition than the other subgroup (9/9 
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+ 9/10 + 11/10) (t(42)=-2.52, p=.016). Additional (non significant) statistics 
can be found in Table 6.5. Leaving out the two genotypes observed only in a 
single person (9/9 and 11/10) did not significantly change the results (data 
available from the first author). 
 
Table 6.5 
Descriptives and Statistics for SLC6A3 VNTR 
Test M (SD) Statistics 
IQ 1) 101.68 (18.56) 
2) 100.46 (18.24) 
t(43) = .22 ns 
WAIS-DS-F 1) 8.00 (1.33) 
2) 8.46 (1.61) 
t(42) = -1.00 ns 
WAIS-DS-B 1) 5.58 (1.43) 
2) 6.04 (1.54) 
t(43) = -1.02 ns 
CPT  
 
1) 12.84 (6.53) 
2) 16.50 (7.53) 
t(43) = -1.70 ns 
VLGT 1) 53.58 (9.94) 
2) 53.81 (8.81) 
t(43) = -.08 ns 
SCWT 1) 1.50 (.20)* 
2) 1.54 (.14) 
t(29.77) = -.79 ns  
ChT-CR 1) 469.79 (69.85) 
2) 511.93 (84.94)  
t(41) = -1.73 ns 
ChT-SSRT 1) 201.24 (57.01) 
2) 248.51 (63.76) 
t(42) = -2.52 a 
Note. 1) = 10/10; 2) = 9/9 + 9/10 + 11/10; ChT = Change Task (CR = Change 
Response; SSRT = Stop Signal Reaction Time); CPT = Continuous Performance Test; 
SCWT = Stroop Color Word Test; SLC6A3 = Solute Carrier family 6, member 3, 
dopamine transporter; Val = Valine; VNTR = variable number of tandem repeats; 
VLGT = 'Verbale Leer & Geheugen Test'; VMS-B = Visual Memory Span-Backwards; 
WAIS = Wechsler Adult Intelligence Scale (DS-F = Digit Span-Forwards; DS-B = Digit 
Span-Backwards). 
* = Raw scores were transformed to obtain normality. 
ns = p > .05. a = p < .05. 
 
COMT, Val158Met 
The Val158Met polymorphism induces a temperature sensitive 
conformational change in the protein encoded by the COMT gene, causing 
reduced activity in the Met allele, which is associated with changes in the 
availability of dopamine (Lachman et al., 1996). For this polymorphism we 
compared the following groups: 1) Val/Val, 2) Val/Met, and 3) Met/Met, 
following former studies (Malhotra et al., 2002; Mills et al., 2004; Taerk et 
al., 2004). As shown in Figure 1 the three groups differed significantly in 
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their Full Scale IQ (F(2,41)=6.058, p=.005). Post-hoc comparisons corrected 
for multiple comparisons with Tukey's HSD method revealed that the 
Val/Met subgroup had a significantly higher Full Scale IQ than the Val/Val 
subgroup (p=.003). Statistics for additional comparisons are provided in 
Table 6.6. 
 
 
 
 
 
 
Figure 1. Full Scale IQ per genotype for COMT Val158Met. 
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Table 6.6 
Descriptives and Statistics for COMT Val158Met 
Test M (SD) Statistics 
IQ 1) 84.67 (7.58) 
2) 107.10 (17.45) 
3) 100.50 (17.92) 
F(2, 41) = 6.058 a 
post-hoc comparison: 
2 > 1 a 
WAIS-DS-F 1) 9.30 (2.54) 
2) 8.48 (1.50) 
3) 7.71 1.79 
F(2, 42) = 2.460 ns 
WAIS-DS-B 1) 5.70 (1.89) 
2) 6.05 (1.20) 
3) 5.64 (1.65) 
F(2, 42) = .359 ns 
CPT  
 
1) 12.00 (6.85) 
2) 16.24 (6.91) 
3) 15.14 (8.00) 
F(2, 42) = 1.163 ns 
VLGT 1) 47.50* 
2) 55.00 
3) 57.00 
X2 (2, N = 45) = 1.52 ns 
SCWT 1) 33.50* 
2) 35.00 
3) 27.50 
X2 (2, N = 45) = 1.06 ns 
ChT-CR 1) 540.16 (152.97) 
2) 609.66 (84.48) 
3) 480.17 (70.74) 
F(2, 42) = 1.065 ns 
ChT-SSRT 1) 216.77 (71.50) 
2) 239.71 (59.10) 
3) 207.45 (50.21) 
F(2, 40) = 1.299 ns 
Note. 1) Val/Val; 2) Val/Met; 3) Met/Met; ChT = Change Task (CR = Change 
Response; SSRT = Stop Signal Reaction Time); COMT = = Catechol-O-
Methyltransferase; CPT = Continuous Performance Test; SCWT = Stroop Color Word 
Test; VLGT = 'Verbale Leer & Geheugen Test'; VMS-B = Visual Memory Span-
Backwards; WAIS = Wechsler Adult Intelligence Scale (DS-F = Digit Span-Forwards; 
DS-B = Digit Span-Backwards). 
* = For variables that were not normally distributed, we present the median. 
ns = p > .05. a = p < .01. 
 
Tests on which there was no difference from NCs 
For the tests on which an earlier study (see Chapter 3 of this thesis) did not 
indicate significant differences between adults with ADHD and normal 
controls, we established four significant associations with the tested 
polymorphisms. Firstly, for the COMT polymorphism there were differences 
in the sub-test Block Design of the WAIS-III (F(2,42)=5.05, p=.011), for 
which Bonferroni corrected post-hoc results revealed that both the Val/Met 
and the Met/Met genotypes performed better than the Val/Val genotype. 
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The second difference was found for hit reaction time of the CPT (χ2 (2, 
N=45)=7.91, p=.019), where post-hoc testing with Mann-Whitney U tests 
showed that the Val/Val genotype sub-group responded slower than both 
other groups, which did not differ significantly from each other. Thirdly, we 
established significant differences between groups for the sub-test Block 
Design of the WAIS-III between participants with and without 7-repeat 
alleles in DRD4 (t(43)=-2.21, p=.032): the group without 7-repeat alleles 
performed better than the group with one or two 7-repeat alleles. The latter 
group also scored more perseverative errors on the WCST than the former 
group (z=-2.35, p=.019). Remaining comparisons did not yield significant 
results (data not shown).  
DISCUSSION 
We conducted the present study to provide a first impression of the 
relationship between four key polymorphisms for ADHD and performance 
on a broad range of neurocognitive abilities in adults with the disorder. In 
light of the many statistical comparisons we made and the low power to 
detect smaller effects, these results should be viewed with caution, but they 
can serve as point of departure for future research into endophenotypes for 
ADHD.  
We started our analyses with tasks on which adults with ADHD had 
been shown to differ from healthy controls in a former study (see Chapter 
3). A significant result for the DRD4 48 bp polymorphism was found for 
short-term verbal memory as measured by the WAIS-DS-F, with the group 
with a copy of the 7-repeat allele performing better than the group without a 
7-repeat allele. This may seem counterintuitive (better performance in the 
subgroup displaying the genetic risk factor for ADHD), but Swanson et al. 
(2000) also reported that a 7-repeat-present subgroup of children with 
ADHD showed normal behavior (although on reaction times, not verbal 
memory). Although a role of this polymorphism was indicated in the 
susceptibility for adult ADHD (Muglia et al., 2000), we know of no studies 
into the relationship with cognition in adult ADHD groups. Cognitive 
studies in children with ADHD have shown mixed results, though most 
have indicated an association of the 48 bp repeat polymorphism with 
reaction times and inhibition, rather than verbal memory (Langley et al., 
2004; Manor et al., 2002; Swanson et al., 2000). 
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For the DRD4 120bp polymorphism we established a difference 
between subgroups for verbal memory as measured by the VLGT, with the 
group with two L alleles performing better than the group with the L/S and 
the S/S genotypes. For the other verbal memory task (WAIS-DS-F), the 
result was non-significant. However, the associated p-value (.085) suggested 
that research with larger groups might show a difference on this task as 
well. We are not aware of any other studies exploring the relationship 
between this polymorphism and cognitive tasks in ADHD. The 
polymorphism has been studied in a healthy control population (Fossella et 
al., 2002), for association with several attention and EF tasks. No relation 
was found with these tasks, which concurs with our findings. 
For the SLC6A3 (DAT1) VNTR polymorphism, the subgroup with a 
10/10 homozygous genotype showed significantly faster inhibition on the 
Change Task than the group with all other genotypes. Interestingly, results 
on other inhibition tasks showed trends in the same direction (CPT 
commission errors: p=.096; Change Response of Change Task: p=.09). 
Again, our results seem counterintuitive, since ADHD is clearly associated 
with problems in response inhibition control (Nigg, 2001; Pennington & 
Ozonoff, 1996; Sergeant et al., 2002). One would therefore expect the group 
with two risk alleles (10/10) for ADHD to perform worse rather than better 
on inhibition tasks compared to other genotypes. Findings with respect to 
this polymorphism and cognition in children with ADHD are equivocal 
(Fossella et al., 2002; Loo et al., 2003; Oh, Shin, Oh, & Noh, 2003). Fossella 
et al. (2002) have raised the intriguing explanation that both higher and 
lower than average levels of synaptic dopamine may lead to neurocognitive 
impairment, which could explain this counterintuitive result. This is 
actually in line with a clinical trial documenting an inverted U-shaped 
response curve across low to high doses of methylphenidate (Tannock et al., 
1995). More studies are clearly needed to clarify this topic.  
For the COMT polymorphism, we found that the group with two Val 
alleles had the lowest IQ of the three subgroups that were compared. For 
none of the other tests differences between genotype subgroups were found. 
The latter is in agreement with studies in children with ADHD (Mills et al., 
2004; Taerk et al., 2004). Although we know of no direct evidence linking IQ 
with the COMT polymorphism, there are indications that co-occurrence of 
ADHD and low IQ has genetic origins (Kuntsi et al., 2004). Moreover, the 
COMT gene has been reported to correlate with working memory (Egan et 
al., 2001; Goldberg et al., 2003), which is highly correlated with intelligence 
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(Deary, 2001). Future research should aim to confirm the influence of Val-
homozygosity on the co-occurrence of ADHD and lower IQ. 
 We continued our comparison with tests on which adults with ADHD 
did not differ from normal controls in our former study to find out if 
genotypic subgroups of ADHD adults perform differently. Moreover, such 
data can indicate which polymorphisms are related to traits that are not 
directly associated with ADHD. Again, we found a link between the COMT 
polymorphism and IQ in the sub-test Block Design of the WAIS-III, on 
which the Val/Val genotype performed worse than both other subtypes. 
There are no findings in the ADHD literature to back up our results, but a 
tentative relationship between catechol-O-methyltransferase and visuo-
spatial performance has been established (Gasparini, Fabrizio, Bonifati, & 
Meco, 1997). The COMT polymorphism was also found to be associated with 
hit reaction time on the CPT. Again, it was the Val/Val genotype that 
responded slower than the other groups. One study of reaction times of 
ADHD children in relation to COMT did not find any differences between 
genotypes (Mills et al., 2004). Other studies in ADHD samples are not 
known to us, but Nolan, Bilder, Lachman, and Volavka (2004) established 
slower reaction times in schizophrenic patients with Val homozygosity, 
compared to other genotypes, suggesting that the polymorphism is indeed 
related to response speed. Thirdly, the group without 7-repeat alleles in 
DRD4 performed better than the group with 7-repeat alleles on Block 
Design. We know of no studies that can support or explain this finding. A 
final difference was also found between the 7-repeat and the no-7-repeat 
groups, with the no-7-repeat group scoring fewer perseverative errors on the 
WCST than the 7-repeat group. Again, there are no direct results to explain 
this finding, but there are indications that mental flexibility as measured by 
the WCST may be an indicator of familial predisposition to ADHD (Slaats-
Willemse, 2003).  
Our results should be interpreted bearing several limitations in mind. 
We have already ventilated caution with respect to the issue of chance 
capitalization; our data should be merely viewed as a starting point for 
further investigation. Also, it should be kept in mind that the association of 
the selected genes with ADHD in adults is still in its infancy. Future studies 
should extend ours in several respects. First of all, there are suggestions 
that the relationship between genes and ADHD may differ for each subtype 
of the disorder (Eisenberg et al., 1999; Waldman et al., 1998). Since our 
sample consisted mainly of patients with the combined subtype, this issue 
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remains open for further study. Secondly, gender may play a role in 
differentiating the impact of genotypes on cognition (Fossella et al., 2002; 
Nigg, Blaskey, Stawicki, & Sachek, 2004). Further investigation should also 
focus on the influence of co-morbidity, which often accompanies ADHD in 
adults (Biederman, 2004). Next, there are several suggestions in the 
literature that a strong candidate for endophenotyping ADHD can be found 
in variability in speed of responding (Castellanos et al., 2005; Castellanos & 
Tannock, 2002; Kuntsi & Stevenson, 2001). This has not been investigated 
in adults with the disorder as of yet. Finally, there are several other genes 
that are now being investigated in relation to (adult) ADHD, but have not 
been included in our study, such as the genes encoding the dopamine D5 
receptor (Manor et al., 2004), the serotonin transporter (Kent et al., 2002), 
and some adrenergic receptors (De Luca et al., 2004). 
 
To summarize, we have tentatively shown a relationship between 
several key genetic polymorphisms and neurocognitive performance in adult 
ADHD: the COMT Val158Met polymorphism seems to be related to 
differences in IQ and reaction time (with higher IQ scores and faster 
reaction time in the presence of the low expressed COMT allele), both of the 
DRD4 polymorphisms (48 bp and 120 bp) showed a connection with verbal 
memory skills (with reduced availability or function of the receptor 
associated with better performance), and the SLC6A3 40 bp VNTR 
polymorphism could be linked to differences in inhibition (with the 
supposedly highly expressed genotype performing best). These results may 
aid the search for possible endophenotypes for ADHD, since they are in line 
with suggestions for endophenotypes for the disorder in children (e.g., 
Castellanos et al., 2005; Doyle, Faraone et al., 2005; Doyle, Willcutt et al., 
2005). 
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As stated in Chapter 1 of this thesis, diagnostic validity refers to the extent 
to which diagnostic categories are related to the clinical reality of patients. 
Valid diagnoses help in knowing something about the etiology of the 
patient’s disorder, in making treatment decisions, and in predicting the 
course of the patient’s problems (Blashfield, 1989). Since specific etiologies 
or specific biological defects that cause susceptibility for a disorder are still 
rarely available for psychiatric illnesses, “the trick is to find indirect 
indicators that a diagnostic definition maps closely onto the ‘real’ 
underlying disorder” (Robins & Barrett, 1989, p. vi). 
Although the validity of the diagnosis ADHD in children has been 
firmly established over the years (for a review see Faraone, 2005), the 
validity of the same disorder in adults is still somewhat indistinct (Barkley, 
1998; Shaffer, 1994; Spencer et al., 1994). The current thesis therefore 
comprised several clinical studies to underpin the validity of ADHD in 
adults, based on proposals for such research made over the years 
(Andreasen, 1995; Kendler, 1980, 1990; Robins & Guze, 1970). 
Next to adding to the validity of the diagnosis, the studies presented 
in this thesis also play a part in building theoretical knowledge at several 
levels of the disorder. Neuropsychological findings contribute to the 
description and therefore the phenotype of patients with the disorder, and 
to possible endophenotypes as well (Doyle, Faraone et al., 2005; Doyle, 
Willcutt et al., 2005). Especially with the use of an extensive battery of 
tests, with the inclusion of control tasks for functions that may underlie 
performance on executive functioning (EF) measures, and with the 
utilization of experimental tasks from cognitive psychology, the results 
added to the already existing neurocognitive literature in the field. A similar 
contribution was expected from the actigraphy data. Actigraphs are a very 
new research tool in the field of adult ADHD and their use may provide us 
with some interesting new venues as well as adding to the description of the 
phenotype or endophenotype of the disorder. In researching the effects of 
psychostimulants, the most widely used medications in ADHD, on 
neuropsychological tests and actigraphic parameters, the papers also build 
the knowledge of the disorder in ways that have not often been utilized in 
adults with the disorder. Last but not least, we hoped to contribute to the 
latest development in the research field of ADHD: the genetics of the 
disorder. By looking for the relationship between genetic polymorphisms 
and performance on neurocognitive tests we hoped to assist in the search 
for endophenotypes to aid the venture of laying out the genetics of ADHD. 
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NEUROPSYCHOLOGICAL FINDINGS 
The meta-analysis presented Chapter 2 was conducted to establish a 
quantitative account of the differences in EF between adults with ADHD 
and normal controls (NC). Non-EF dependent variables from the EF tasks 
were included in the analyses, in order to determine whether deficits are 
specific to EF or not. Although the data revealed significant mean effect 
sizes for several EF tasks, similar results were obtained for non-EF 
measures. This result raises doubts about the current emphasis on EF 
research in ADHD and it calls into question models of ADHD that depend 
heavily upon EF for their explanatory power, such as the model by Barkley 
(1997b). 
However, before we can decide in favour of or against the EF 
hypothesis of ADHD, the field is in need of some important methodological 
changes with respect to the operationalization of the concept. It seems, now 
more than ever, necessary to develop reliable and valid measures of EF and 
to study psychometric properties of existing tests. Although a recent paper 
addressed validity issues of some frequently used novel laboratory 
measures in ADHD-research (Nichols & Waschbusch, 2004), the validity 
and reliability of many more traditional neuropsychological measures still 
remain in doubt. Next to validity and reliability, researchers need to focus 
on studying and improving the (negative and positive) predictive power of 
neuropsychological measures used for assessment of ADHD, especially 
when the final goal is use of laboratory tests in diagnosing patients 
(McGough & Barkley, 2004). As long as we do not have improved EF 
measures at our disposal, researchers could improve their efforts by using 
tests that include different levels of difficulty (like the Tower of London), or 
that manipulate different functions at the same time, so that interactions 
and dissociations can be studied. Another way of improving research in this 
area, is by including control tasks for skills that are not related to EF per 
se, but that are necessary to perform an EF test anyway. It would also be 
an improvement to use tasks that are based on theoretical accounts of 
specific cognitive processes, rather than tasks that have been defined as EF 
task based on lesion studies, since the latter may not be sufficiently 
sensitive to detect the often more subtle dysfunctions in psychiatric 
disorders. 
 
138 | Chapter 7 
Apparently, the field was ready for meta-analyzing neuropsychological test 
data in adult ADHD, because several meta-analyses appeared within a 
relatively short period of time. The first one (Hervey et al., 2004) adhered to 
less strict in- and exclusion criteria than we did and included 
neuropsychological tests in general, not only EF tasks. However, their 
conclusion was in line with ours in that results did not indicate a domain-
specific neuropsychological deficit. That is, all domains revealed at least 
some degree of impairment on at least a subset of the tests considered 
within each domain. A general pattern that emerged in this paper as well as 
in ours was that adults with ADHD performed more poorly on tests in 
which there was a verbal presentation of stimuli rather than a visual 
presentation.  
In the second meta-analysis (Schoechlin & Engel, 2005) it was 
suggested that mainly complex attention variables and verbal memory 
discriminate between ADHD patients and controls, although significant 
effect sizes were found in eight out of ten chosen function domains. In 
contrast to results reported in children, executive functions were not 
generally reduced in adult ADHD patients, according to these authors. 
However, only planning (Tower of London) and controlling of actions 
(Wisconsin Card Sorting Test) were considered to be part of the EF domain. 
So it seems rather far-fetched to conclude that no EF deficits were found in 
adults with ADHD.  
Nevertheless, this result and the mere fact that three meta-analyses 
could appear within one year while utilizing completely different 
subdivisions of functions, really underscores the need for clear and 
unequivocal taxonomy of the domain of executive functioning. It seems 
rather peculiar that still every paper dealing with EF needs to address the 
‘umbrella-ness’ of the term and needs to refer to the 33 different definitions 
counted for the term by Eslinger (1996). Not only the operationalizations of 
EF are in pressing need of revision and improvement, as mentioned earlier, 
but also the concept itself urgently calls for clarification to aid the progress 
of the field. 
 
The empirical study in Chapter 3 was conducted to ascertain if adults with 
ADHD show deficits in inhibition and other areas of EF, as predicted by the 
theoretical model for the disorder postulated by Barkley (1997b), and if 
these deficits would hold after stringent controls for non-EF and IQ 
performance. Results showed large differences between adults with ADHD 
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and normal controls in the EF areas of inhibition and set shifting, even after 
stringent controls for group differences in IQ, non-EF demands, and co-
morbid anxiety and/or mood disorders. Differences in other areas of EF 
(fluency, working memory, and planning) did not prove robust for IQ and 
non-EF controls. These results indicate that it is important to control for 
non-EF abilities and IQ differences when using EF measures. They further 
denote that Barkley’s model may be correct in stating that inhibition is the 
primary deficit in ADHD, but that this defect does not automatically lead to 
insufficiencies in all other EFs. On the contrary: our study implied that 
adult ADHD may be mainly about inhibition, since set shifting also calls on 
inhibition before being able to actually shift sets. In the non-EF domains, 
we observed medium to large effects for verbal short-term memory. Judging 
from the established relationship between memory and inhibition (e.g., 
Anderson, 2003), these short-term memory deficits are actually in line with 
the inhibition difficulties of the ADHD group. 
 
The conclusion of Chapter 3, that adult ADHD may be mainly about 
inhibition, is actually substantiated by some very recent papers. Lijffijt, 
Kenemans, Verbaten, & Van Engeland (2005) conducted a meta-analysis of 
stopping performance in ADHD, in which it was concluded that deficient 
inhibitory motor control might be less crucial in children than in adults 
with ADHD. A recent empirical study by Bekker, Overtoom et al. (2005), 
who used the Stop Task and the Change Task, established a core deficit in 
behavioral inhibition in adults with ADHD. Further research by Bekker and 
colleagues however, brought to light a very interesting suggestion about the 
inhibition difficulties in ADHD adults. By applying a method for analyzing 
ERP data that had not been utilized before, they were able to discriminate 
between ERPs to stop signals and ERPs to other stimuli in close temporal 
proximity to the stop signal (such as the go-stimulus). In applying this 
method they revealed a smaller P3 in adults with ADHD in comparison to 
normal controls, thought to reflect deficient inhibitory control (Bekker, 
Overtoom et al., 2005). Next to this effect, they established that normal 
controls show a larger early response in the auditory cortex (N1) when stop 
signals lead to successful inhibition, relative to failed stops, signifying 
increased attention (Bekker, Kenemans, Hoeksma, Talsma, & Verbaten, 
2005). This difference was completely absent in adults with ADHD, which 
lead the authors to conclude that impaired stopping in adults with ADHD 
may actually be brought about by dysfunctional attentional processing 
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(Bekker, Overtoom et al, 2005). Does this mean the field of ADHD is back at 
square one, when attention was the main function related to the disorder? 
Probably not, but it does shed another light on theories that rely heavily on 
inhibition for their explanatory power. Barkley (1997b) suggested that 
dysfunctional inhibition caused attention problems, whereas it may actually 
be vice versa. 
 
In general, the results of Chapter 2 and Chapter 3 underlined the incon-
sistency that has characterized the search for the core deficit of ADHD over 
the years. Regardless of which theory or which core deficit is taken as the 
goal of an empirical or review study, the results are never unequivocal: one 
study does find the theorized deficit while the other one does not, there 
always is substantial overlap in performance between ADHD and control 
groups, effects in meta-analyses are never as large as one might expect for a 
core deficit, and never have we been able to find a task on which every 
person with ADHD fails. In an interesting study, Nigg, Willcutt, Doyle, and 
Sonuga-Barke (2005) underscored this last point. These authors re-
analyzed neuropsychological test data from a large sample of children with 
ADHD by calculating for each individual child whether or not it scored 
below the 90th percentile score on each neuropsychological measure 
utilized. Generally, no more than half of the children could be reasonably 
classified as impaired based on these analyses. These data suggested that 
any reasonable cut-off would leave many children with ADHD as unaffected 
or else classify an inordinate number of control children as affected. Up 
until now, researchers have sought explanations for these inconsistencies 
in various corners, such as methodological issues, diagnostic issues, 
psychometric properties of the tasks, etcetera. For instance, a very recent 
empirical study (Riccio et al., 2005) failed to establish any differences in EF 
tasks between adults with ADHD and normal controls, and explained this 
result by stating that the sample may not have been representative for the 
adult ADHD population since it was predominantly white, of average to 
above-average ability, and well-educated.  
However, during the past year, different notes are struck. The search 
for a single core cognitive deficit underlying ADHD seems to be rendered out 
of date (Pennington, 2005), and researchers are more and more suggesting 
that the clinical and neurocognitive heterogeneity that seems to 
characterize the disorder supports the likelihood that multiple 
neurodevelopmental pathways underpin this disorder. For instance, 
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Willcutt, Doyle, Nigg, Faraone, and Pennington (2005) conducted a meta-
analytic review of EF tasks in children with ADHD and concluded that EF 
difficulties appear to be only one of several important weaknesses that 
comprise the overall multifactorial neuropsychological etiology of ADHD. So 
rather than stating that the EF hypothesis of ADHD is incorrect or that the 
psychometric properties of EF tests are insufficient, it is carefully suggested 
that not all individuals with ADHD show the same difficulties. Of course, 
this had already been appreciated in the DSM-IV, by denoting three 
different clinical subtypes of the disorder, but recent theories and studies 
point in the direction of different subtypes within the clinical subtypes 
denoted in DSM-IV. 
Different authors have suggested different multifactorial models for 
the disorder. Sonuga-Barke (Sonuga-Barke, 2002; Sonuga-Barke, 2003, 
2005) contrasted the cognitive theory of an inhibitory deficit with the more 
motivational model of dysfunctional processing of delayed reward to suggest 
a ‘dual-pathway model’ for ADHD, in which some children with the disorder 
fail to inhibit because they are not able to do so and others because they 
prefer not to. These dissociable forms of ADHD are believed to be under-
pinned by alterations in different dopaminergic systems.  
Sagvolden, Johanson, Aase, and Russell (in press) have extended the 
dual-pathway model by Sonuga-Barke into a ‘dynamic developmental 
behavioral theory’ of ADHD. This model also focuses on the hypothesis that 
altered dopaminergic function plays a pivotal role by failing to modulate 
non-dopaminergic signal transmission appropriately. Three hypo-
functioning dopamine branches are related to the three main symptom 
groups of ADHD. An interesting component of this model is that ADHD 
symptoms are explicitly believed to be the result of the interplay between 
individual predispositions and the surroundings, which brings back 
environmental influences into theories of ADHD. This latter suggestion is 
receiving more emphasis with the shift toward genetic research in the field, 
since it is clear that genetic factors will never explain 100% of the variance 
within disorders. 
While Sonuga-Barke and Sagvolden are clear in the number of 
subtypes they propose, Nigg (Nigg, 2001, 2003, 2005; Nigg et al., 2005) has 
developed a multiple pathway model, distinguishing more than two possible 
neuropsychological subtypes of the combined subtype of ADHD. His 
theoretical work started out with dividing between motivational and 
executive inhibition, stating that “Although (…) the evidence is strong for 
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deficits in some forms of executive response inhibition in ADHD combined 
type, it remains unclear that this is the primary mediating or causal deficit” 
(Nigg, 2001, p.583). In 2003, he still held on to these two separate possible 
pathways for explanation of the combined type of ADHD, but in a couple of 
very recent papers (Nigg, 2005; Nigg et al., 2005) it is suggested that there 
may be multiple neuropsychological subtypes of ADHD. These subtypes 
could find their basis in several theoretical accounts for the disorder that 
have been around for a while (e.g., EF, state regulation & motivation, and 
processing of temporal information) and possibly even more yet to be 
discovered ones. 
Thus, many important theorists in the field have articulated the idea 
of multiple developmental pathways to ADHD. However, the implications of 
this possibility for resolving the puzzle of ADHD causality have not been 
incorporated into the field’s research agenda. Doing so calls for several 
changes in policy, such as direct comparison of different theoretical options 
within one group, as was done by Solanto et al. (2001), and a more 
individual approach to dysfunction, as was suggested in the paper by Nigg 
et al. (2005). Doyle and colleagues (Doyle, Faraone et al., 2005; Doyle, 
Willcutt et al., 2005) have made some further suggestions for future 
research that are very much in line with our ideas mentioned earlier, i.e., 
increasing predictive power of neuropsychological tests, utilize 
computerized experimental measures borrowed from cognitive neuro-
science, and including control measures. 
GENETIC FINDINGS 
The recent suggestions for multiple developmental pathways in ADHD have 
not only been prompted by the clinical and neuropsychological 
heterogeneity of the disorder, but also by the direction that more 
fundamental research into the disorder has taken. It has long been clear 
that although close to 80% of the variability within ADHD is explained by 
genetic factors (see Faraone et al., (2005) for a review), the disorder does not 
follow simple Mendelian rules in its patterns of inheritance, but is most 
likely influenced by small effects of many genes. This complex nature of the 
disorder has lead researchers to search for simpler constructs that lie 
between genes and the complex syndrome of interest, called endo-
phenotypes.  
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Recent studies and reviews (Castellanos et al., 2005; Doyle, Faraone et al., 
2005; Doyle, Willcutt et al., 2005) have indicated several putative 
endophenotypes for ADHD in children, but in adults with the disorder, far 
fewer genetic and endophenotypic studies have been performed. This seems 
logical in line with the fewer studies that have been conducted in this age 
group in all, but is injudicious in light of the suggestion of the persistence 
hypothesis, which states that genes may play a larger role in the persistent 
form of ADHD (Faraone, 2004). We therefore conducted the study described 
in Chapter 6 to provide a first impression of the relationship between 
genetic make-up of adults with ADHD and their performance on a broad 
range of neurocognitive abilities.  
We first compared ADHD participants with different polymorphisms 
on certain genes on tests that they had performed worse on in the 
comparison with normal controls in Chapter 3. Results tentatively pointed 
towards a relationship between several genetic polymorphisms and 
neurocognitive functioning in adult ADHD: the COMT Val158Met 
polymorphism seemed to be related to differences in IQ and reaction time, 
both of the DRD4 polymorphisms (48 bp and 120 bp) showed a connection 
with verbal memory skills, and the SLC6A3 40 bp VNTR polymorphism 
could be linked to differences in inhibition. 
We continued our comparison with tests on which adults with ADHD 
did not differ from normal controls in Chapter 3. Although it may not seem 
interesting to compare adults with ADHD with different genotypes on a 
polymorphism on the latter category of tests, it may be the case that a 
genotypic subgroup of ADHD adults does perform differently. Moreover, 
these data indicate which polymorphisms are related to traits that are not 
directly associated with ADHD. The COMT polymorphism seemed to be 
associated with visuo-spatial performance and response speed. The 7-
repeat polymorphism of the DRD4 gene appeared to be related to visuo-
spatial performance as well, and to set shifting. 
All in all, we found some tentative candidate genes for EF deficits in 
adults with ADHD as well as candidate genes for EF functioning in general, 
which may strengthen the evidence for possible endophenotypes in adult 
ADHD. However, since this was the first study to look at the relationship 
between genes and neurocognitive performance in adult ADHD, our data 
should be merely viewed as a starting point for further investigation.  
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ACTIGRAPHY FINDINGS 
In Chapter 5 the reader could find the results of an extensive actigraphy 
study in an adult ADHD sample, designed to obtain some first answers to 
questions concerning activity, sleep, and circadian rhythms. For the 
external validity of the disorder, mainly the results of the baseline 
comparison are relevant. With respect to activity, these results indicated 
that participants with ADHD were indeed more active during the day than 
NCs, but not during the night. However, sleep parameters did indicate 
differences between NC and ADHD during the night. Actigraphy ratings 
indicated less sound sleep in the ADHD group than in normal controls, 
which was corroborated by subjective ratings. Circadian rhythm parameters 
also indicated differences between groups, but these results were 
counterintuitive, since participants with ADHD showed a more repeatable 
daily schedule of activities and more consolidated periods of rest and 
activity than the NCs. 
Since this study was one of the first to utilize actigraphs in an adult 
sample with ADHD, our results are tentative and they naturally show some 
limitations that should be taken into account in future investigations of 
activity and sleep parameters as measured by actigraphy in adult ADHD. 
Nevertheless, our results have proven that also in adult ADHD research, 
actigraphy can prove a useful and comparatively easy and cheap method of 
investigation. 
EFFECTS OF METHYLPHENIDATE ON INHIBITION 
The study depicted in Chapter 4 was designed to examine the effects of 
methylphenidate (Mph) on inhibition and other cognitive measures in a 
sample of adults with ADHD. The findings showed that, in adults with 
ADHD, Mph has large beneficial effects on inhibition as measured by the 
Continuous Performance Test (CPT). It also has a large effect on inhibition 
as measured by the Change Task (ChT), but only in those subjects who 
show slow inhibition times off-medication. In addition to improving 
inhibition, Mph decreases variability in response execution processes on the 
CPT, and it improves the ability to distinguish signal from noise on the CPT. 
Finally, Mph has a positive effect on response re-engagement, as measured 
by the ChT. Thus, Mph does not only effectively ameliorate clinical 
symptoms in an adult ADHD population, as shown by several researchers 
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(for a review, see Wilens et al., 2002) and also by a recent study of our own 
research group (Kooij et al., 2004), but its positive effects can also be 
demonstrated on several cognitive processes important in daily life. 
These results may render the CPT suitable for quantitatively 
establishing the effect of Mph on an individual level. This would be a 
valuable contribution to the entire ADHD population (both children and 
adults), since changes in symptoms are now indicated by either observers, 
who may not always be as objective as necessary, or by patients 
themselves, who may not have an accurate perception of these changes 
(Barkley et al., 2002).  
Future studies should investigate effects of methylphenidate on other 
neurocognitive functions in adults with ADHD, since this is still a relatively 
unexplored area. However, it also seems to be important to turn to 
alternative medications that are now being used more and more for ADHD, 
such as extended-release methylphenidate (Greenhill, Findling, & Swanson, 
2002; Wolraich et al., 2001), bupropion (Kuperman et al., 2001; Wilens et 
al., 2001), and atomoxetine (Michelson et al., 2003). Especially in light of 
very recent suggestions of dopaminergic nerve ending damage in primates 
with the use of amphetamine (Ricaurte et al., 2005), medications other than 
stimulants may merit further research. 
EFFECTS OF METHYLPHENIDATE ON ACTIGRAPHY  
The actigraphy study explicated in Chapter 5 also included effects of 
medication. We established no changes with Mph in daytime or nighttime 
activity level. Nighttime activity level was not different form normal controls 
at baseline to start with, but daytime level was. Mph does not seem to 
influence this. However, Mph did change the baseline difficulties found in 
sleep parameters. Treatment with Mph prolonged sleep onset latency and 
decreased total sleep time in comparison with placebo, but quality of sleep 
seemed to improve with stimulant treatment. Our data suggested that sleep 
problems are inherent in adult ADHD, and that they are neither caused by 
or worsened with stimulant treatment in this population. On the contrary, 
stimulants improved the quality of sleep in adults with ADHD. 
Again, since this was one of the first studies to look at the effect of 
medication on actigraphy parameters in adults with ADHD, the results 
should be viewed with caution.  
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VALIDITY OF ADHD IN ADULTS 
In Chapter 1 of this thesis it was stated that one of the main goals of the 
studies presented was substantiation of the validity of the diagnosis ADHD 
in adults. One of the problems with this goal is formed by the many 
different definitions that have been provided in the literature for the term 
‘validity’. Although it is far beyond the scope of this discussion to clarify this 
problem, it needs to be touched upon, because it hampers the conclusions 
that can be made accordingly. In the introduction, we mentioned the 
criteria of Robins & Guze (1970). In line with their criteria, developed 
mainly as validators for the external validity of a diagnosis, we have 
substantiated the external validity of ADHD in adults by showing that 
people with this disorder can be distinguished from people without the 
disorder on several laboratory measures that were not originally part of the 
diagnostic procedure: neuropsychological tests of executive functioning and 
actigraphs. Moreover, the fact that within the ADHD group, we could 
establish differences in neuropsychological functioning related to genetic 
findings also contributes to the external validity of the disorder. According 
to Robins & Guze’s division, our findings with respect to the effects of 
methylphenidate on neurocognitive functioning and actigraphy parameters 
also substantiate the external validity of the disorder in adults. Cloninger 
(1989) directly related the five phases denoted by Robins & Guze to 
psychometric types of validity. In his view, the data presented in this thesis 
would substantiate the concurrent validity (neuropsychology, actigraph, 
and genetic findings), and the predictive validity (methylphenidate findings). 
Both of these two types of validity come under criterion related validity, 
according to Cloninger.  
Anyhow, our studies have indeed contributed to the validity of the 
diagnosis ADHD in adults. However, there are several aspects of especially 
internal validity (Herpers & Buitelaar, 1996) that we have not addressed in 
this thesis. In keeping with Robins & Guze (1970), we did not look at 
clinical description (unless one counts neurocognitive functioning as part of 
the clinical description, which might be a future prospect, judging from the 
suggestions that have been made for neuropsychological subtyping of the 
disorder), family study, and exclusion of other disorders. According to 
Cloninger (1989) these phases of validating a disorder correspond with the 
following psychometric types of validity: content validity (clinical 
description), criterion related validity (family study), and discriminant 
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validity (delimitation of other disorders). Although no data to back up these 
types of validity are presented in the present thesis, another thesis is 
currently being prepared in our research group in which several of these 
issues will be dealt with. For example, the study by Kooij et al. (submitted) 
on reliability and validity of instruments used for assessing ADHD in adults 
will add to the content validity. The paper on epidemiological data (Kooij et 
al., 2005) will underpin the internal validity of ADHD in adults by showing 
that the symptom structure in adults with ADHD is very similar to that 
found in children with the disorder. A third article will substantiate the 
discriminant validity of the disorder, by looking at different possible co-
morbid disorders (Kooij, Boonstra, Huijbrechts, & Buitelaar, in 
preparation). A final point with respect to validity of the diagnosis ADHD in 
adults that needs to be raised is the fact that the diagnostic criteria of the 
DSM-IV have not been validated for adults (McGough & Barkley, 2004). 
GENERAL CONCLUSION AND FUTURE DIRECTIONS 
With the papers presented in this thesis we have contributed to the 
supporting of the external (concurrent and predictive) validity of the 
diagnosis ADHD in adults. Our neuropsychological and actigraphy findings 
have added to the description of the disorder outside of the clinical 
symptomatology and in doing so, they have helped build the phenotypic as 
well as the endophenotypic picture of the disorder in adults. In the coupling 
with genetic data, the neuropsychological results have also added to 
endophenoptypes of adult ADHD, as well as to directions for future genetic 
studies of the disorder. Future research should focus on strengthening the 
tentative conclusions with respect to endophenotypes and actigraphic data. 
Especially the endophenotypes in adults ADHD should be a promising 
venue, in light of the persistence hypothesis mentioned earlier.  
Further work lies in confirming suggested theoretical elucidations for 
the disorder in adults. Although we would certainly expect the theories to 
hold for the adult manifestation of the disorder, it remains to be seen how 
the different developmental pathways lead into adulthood and if neuro-
psychological subtypes show different distributions in adulthood than in 
childhood, as do the clinical subtypes. Moreover, several theoretical 
suggestions that have been subjected to research in children with ADHD, 
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have not even been touched upon in adults with the disorder (delay 
aversion, effects of reward, temporal instability).  
Additional important issues can be found in area of discriminant 
validity of the disorder. In light of the huge percentage of co-morbidity in 
adult ADHD (e.g., Biederman, 2004), it is high time that more clinical group 
comparisons are made. Although there are suggestions that neurocognitive 
findings in ADHD in children are independent of co-morbid disorders (e.g., 
Nigg, Hinshaw, Carte, & Treuting, 1998; Rucklidge & Tannock, 2002; 
Seidman, Biederman, Monuteaux, Doyle, & Faraone, 2001; Willcutt et al., 
2005), neurocognitive findings are by no means specific for the disorder. 
Besides this, there are ample suggestions for the effects of clinical subtypes 
and gender in children with ADHD (e.g., Hinshaw, Carte, Sami, Treuting, & 
Zupan, 2002; Nigg et al., 2004), but these have hardly been studied in 
adults with the disorder.  
An important improvement of the research in the ADHD field can be 
found in performing longitudinal research. We keep comparing adults with 
children in a cross sectional fashion, hoping to thus build the validity of the 
disorder in adults and trying to substantiate theoretical issues for the 
lifespan, but the real litmus test for these issues is of course found in 
different research designs. Only then can patterns and predictors for adult 
ADHD really be substantiated (Kessler et al., 2005).  
Underlying these suggestions are methodological issues that deserve 
attention. As suggested before the field of EF is in urgent need of more 
agreement on its taxonomy and terminology, and of tests that show better 
predictive power. Especially when different neuropsychological subtypes are 
indeed established, the need for tests with sound psychometric properties 
increases even more, since neurocognitive testing might then take a larger 
place in the diagnostic procedure than it does now. Until then, we would 
have to agree with McGough and Barkley (2004) that adult ADHD remains a 
clinical diagnosis. 
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The current thesis encompassed a number of empirical, clinical studies into 
various aspects of ADHD in adults. Each study has its own background in 
the literature in terms of theoretical perspectives and prior data. Beyond 
that, the common theme of the studies and thereby the overall aim of this 
thesis was to further substantiate the external validity (especially the 
concurrent and predictive validity) of the diagnosis ADHD in adults. 
Chapter 2 
Several theoretical explanations of ADHD in children have focused on 
executive functioning as the main explanatory neuropsychological domain 
for the disorder. In order to establish if these theoretical accounts are 
supported by research data for adults with ADHD, we compared 
neuropsychological executive functioning and non-executive functioning 
between adults with ADHD and normal controls in a meta-analytic design. 
We compared thirteen studies that 1) included at least one executive 
functioning measure, 2) compared the performance of an adult ADHD group 
with that of an adult normal control group, 3) provided sufficient 
information for calculation of effect sizes, and 4) used DSM-III-R or DSM-IV 
criteria to diagnose ADHD. We found medium effect sizes both in executive 
functioning areas (inhibition and set shifting) and in non-executive 
functioning domains (consistency of response, word reading, and color 
naming). It seems that neuropsychological difficulties in adult ADHD may 
not be confined to executive functioning. The field is in urgent need of 
better-designed executive functioning tests, methodological improvements, 
and direct comparisons with multiple clinical groups to answer questions of 
specificity. 
Chapter 3 
Forty-nine carefully diagnosed adults with Attention Deficit Hyperactivity 
Disorder were compared to 49 normal controls matched for age and gender 
on a large battery of tests in five domains of executive functioning 
(inhibition, fluency, planning, working memory, and set shifting) and 
several other neuropsychological functions to control for non-executive test 
demands. After stringent controls for non-executive function demands and 
IQ, adults with ADHD showed problems in inhibition and set shifting, but 
not in any of the other domains tested. These results imply that adult 
ADHD may be mainly a disorder of inhibition. 
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Chapter 4 
We examined the effect of methylphenidate (Mph) on inhibition and several 
other cognitive abilities in 43 adults with Attention Deficit Hyperactivity 
Disorder (ADHD) by use of Conners’ Continuous Performance Test (CPT) 
and the Change Task (ChT). In a double blind, cross-over, placebo-
controlled study with Mph, tests were administered during the third week of 
individually titrated treatment with Mph (maximum dose 1 mg/kg/day) and 
during the third week of treatment with placebo. We established large 
medication effects for commission errors, standard error of mean reaction 
time, and attentiveness on the CPT, as well as moderate medication effects 
for mean reaction time on the CPT and response re-engagement speed on 
the ChT. For Stop Signal Reaction Time (SSRT) on the ChT, we also 
established large effects of Mph, but only in a group of participants who 
showed slow SSRTs on placebo. Mph indeed ameliorates inhibition, which is 
the core problem of ADHD, and certain other cognitive abilities in adults 
with ADHD. 
Chapter 5 
In Chapter 5 we aimed to investigate parameters of sleep, activity, and 
circadian rhythm, as well as the effects of methylphenidate on these 
variables, in adults with Attention Deficit Hyperactivity Disorder (ADHD). 
Actigraphy and sleep log data were collected for seven consecutive nights 
and days to obtain baseline values for 33 adults with ADHD and 39 normal 
controls. Repeated measurements during placebo and methylphenidate 
treatment were conducted for the ADHD group in a double blind cross-over 
trial. Baseline comparisons indicated higher daytime activity, lower Sleep 
Efficiency, longer Sleep Onset Latency, and shorter average Sleep Bout 
Duration in the ADHD group, as well as a higher Interdaily Stability and a 
lower Intradaily Variability. Subjectively, participants with ADHD rated 
their sleep quality lower than normal controls. Treatment with 
methylphenidate led to delays in Bedtime, Sleep Onset Latency, and 
decreased Sleep Times. However, during this shorter sleep, participants 
showed fewer nocturnal awakenings, less wakefulness, and longer average 
Sleep Bout Duration. Intradaily Variability also increased. Our data suggest 
that sleep problems are inherent in adult ADHD, and that they are neither 
caused by or worsened with stimulant treatment in this population. On the 
contrary, stimulants improve the quality of sleep in adults with ADHD. 
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Chapter 6 
The study in this chapter was conducted to establish a first connection 
between key genetic polymorphisms and neurocognitive performance in 
adults with ADHD in order to aid the search for endophenotypes. We 
genotyped 45 adults with ADHD at four key candidate polymorphisms for 
the disorder (DRD4 48 bp repeat, DRD4 120 bp duplicated repeat, SLC6A3 
40 bp VNTR, and COMT Val158Met). We then subgrouped the sample for 
each polymorphism (DRD4 48 bp by presence or absence of 7-repeat alleles; 
DRD4 120 bp by presence or not of two L alleles; SLC6A3 by presence or 
absence of a 10-repeat allel; COMT by genotype Val/Val, Val/Met, and 
Met/Met) and compared the performance of the subgroups on a large 
battery of neurocognitive tests. The COMT Val158Met polymorphism was 
related to differences in IQ and reaction time, both of the DRD4 
polymorphisms (48 bp repeat and 120 bp duplication) showed an 
association with verbal memory skills, and the SLC6A3 40 bp VNTR 
polymorphism could be linked to differences in inhibition. Our findings 
tentatively point towards possible endophenotypes for adult ADHD. 
 
With the papers presented in this thesis we have contributed to the 
supporting of the external (concurrent and predictive) validity of the 
diagnosis ADHD in adults. Our neuropsychological and actigraphy findings 
have added to the description of the disorder outside of the clinical 
symptomatology and in doing so, they have helped build the phenotypic as 
well as the endophenotypic picture of the disorder in adults. In the coupling 
with genetic data, the neuropsychological results have also added to 
endophenoptypes of adult ADHD, as well as to directions for future genetic 
studies of the disorder.  
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Dit proefschrift bevat een aantal empirische, klinische studies naar 
verschillende aspecten van Attention Deficit Hyperactivity Disorder (ADHD, 
in het Nederlands Aandachtstekortstoornis met hyperactiviteit) bij 
volwassenen. Elk onderzoek heeft zijn eigen achtergrond in de weten-
schappelijke literatuur in termen van theoretische perspectieven en al 
bekende gegevens. Hiernaast is het gemeenschappelijke thema, en daarmee 
het doel, van de onderzoeken in dit proefschrift het verder onderbouwen van 
de externe validiteit (met name de ‘concurrent’ validiteit en de predictieve 
validiteit) van de diagnose ADHD bij volwassenen. 
Hoofdstuk 2 
In verschillende theoretische verklaringen van ADHD bij kinderen wordt de 
nadruk gelegd op executief functioneren als belangrijkste neuro-
psychologische domein voor de stoornis. Om vast te stellen of een dergelijke 
theoretische uitleg gesteund wordt door empirische gegevens voor 
volwassenen met ADHD, hebben we in dit hoofdstuk executief functioneren 
en non-executief functioneren van volwassenen met ADHD en normale 
controles vergeleken in een meta-analytische onderzoeksopzet. We hebben 
dertien onderzoeken vergeleken waarin 1) ten minste één test voor executief 
functioneren werd gebruikt, 2) een groep volwassenen met ADHD werd 
vergeleken met een groep volwassen normale controles, 3) voldoende 
informatie werd verschaft voor het berekenen van effect groottes en 4) 
gebruik werd gemaakt van DSM-III-R of DSM-IV criteria voor het stellen van 
de diagnose ADHD. We vonden medium effect groottes in zowel het domein 
van executief functioneren (inhibitie en flexibiliteit) als het non-executieve 
functiedomein (regelmaat van reageren, lezen van woorden en benoemen 
van kleuren). Het lijkt erop dat neuropsychologische problemen in 
volwassenen met ADHD niet beperkt blijven tot het gebied van executief 
functioneren. Dit onderzoeksgebied is echter hard toe aan beter ontworpen 
tests voor executief functioneren, methodologische verbeteringen en directe 
vergelijking tussen verschillende klinische groepen om vragen met 
betrekking tot specificiteit te kunnen beantwoorden. 
Hoofdstuk 3 
In dit hoofdstuk vergeleken we 49 zorgvuldig gediagnosticeerde volwassenen 
met ADHD met 49 normale controles, gematched op leeftijd en geslacht, op 
een groot aantal tests in vijf gebieden van executief functioneren (inhibitie, 
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vloeiendheid, planning, werkgeheugen en flexibiliteit) en enkele andere 
neuropsychologische functies ter controle voor non-executieve testeisen. Na 
strenge controles voor de non-executieve testeisen en IQ, toonden 
volwassenen met ADHD problemen met inhibitie en flexibiliteit, maar niet in 
de andere geteste domeinen. Deze resultaten wijzen erop dat ADHD in 
volwassenen met name een stoornis in inhibitie is. 
Hoofdstuk 4 
We onderzochten het effect van methylfenidaat (Mph) op inhibitie en enkele 
andere cognitieve functies in 43 volwassenen met ADHD met behulp van de 
Conners’ Continuous Performance Test (CPT) en de Change Task (ChT). In 
een dubbelblind, cross-over, placebo gecontroleerd medicatieonderzoek met 
Mph, werden de tests afgenomen in de derde week van individueel 
getitreerde behandeling met Mph (maximale dosis 1 mg/kg/dag) en in de 
derde week van behandeling met placebo. We stelden grote effecten van 
medicatie vast voor commissie fouten, standaardfout van de gemiddelde 
reactietijd en ‘attentiveness’ op de CPT en voor ‘response re-engagement’ 
snelheid op de ChT. Voor de Stop Signal Reaction Time (SSRT) op de ChT 
vonden we ook grote effecten van Mph, maar alleen in een groep deelnemers 
die met placebo lage SSRT’s lieten zien. Mph verbetert zoals verwacht 
inhibitie, het kernprobleem van ADHD, en enkele andere cognitieve 
vaardigheden in volwassenen met ADHD. 
Hoofdstuk 5 
Hoofdstuk 5 was bedoeld om parameters van slaap, activiteit en circadiane 
ritmes en de effecten van Mph hierop te onderzoeken in een groep 
volwassenen met ADHD. Actigrafische data en logboek data werden 
gedurende zeven opeenvolgende dagen en nachten verzameld bij 33 mensen 
met ADHD en 39 normale controles, om baseline gegevens te verkrijgen. In 
de ADHD groep werden vervolgens herhaalde metingen gedaan onder 
behandeling met placebo en Mph, in een dubbelblind cross-over design. 
De baseline vergelijkingen wezen op hogere activiteit gedurende de dag 
in de ADHD groep. Daarnaast vonden we een verlaagde slaap effectiviteit, 
een langere latentie van inslapen en kortere gemiddelde slaapblokken. 
Bovendien wezen de resultaten op een hogere stabiliteit binnen dagen en 
een lagere variabiliteit tussen dagen in de ADHD groep. Subjectieve 
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metingen duidden op een lagere kwaliteit van slaap in de ADHD groep dan 
in de controle groep. 
Behandeling met Mph leidde tot later naar bed gaan, langere latentie 
van inslapen en een kortere slaapduur. Gedurende deze kortere slaapduur 
werden de deelnemers echter minder vaak wakker, duurden de perioden dat 
ze wakker waren korter en slaapblokken langer. De variabiliteit tussen 
dagen nam toe. 
Deze data suggereren dat slaapproblemen inherent zijn aan ADHD in 
volwassenen en dat ze niet veroorzaakt worden door of verergeren met 
behandeling met Mph. In tegendeel, stimulantia verbeteren de kwaliteit van 
slaap in volwassenen met ADHD. 
Hoofdstuk 6 
Het onderzoek in dit hoofdstuk werd uitgevoerd om een eerste verband 
tussen enkele genetische polymorfismen en neurocognitieve vaardigheden 
in volwassenen met ADHD vast te stellen, om zo de zoektocht naar 
endofenotypen te ondersteunen. We stelden van 45 volwassenen met ADHD 
het genotype vast op vier van de voornaamste kandidaat polymorfismen 
voor de stoornis (DRD4 48 bp repeat, DRD4 120 bp duplicated repeat, 
SLC6A3 40 bp VNTR en COMT Val158Met). Vervolgens deelden we de groep 
per polymorfisme in naar genotype (DRD4 48 bp op grond van aan- of 
afwezigheid van 7-repeat allelen, DRD4 120 bp naar aan- of afwezigheid van 
twee L allelen, SLC6A3 naar aan- of afwezigheid van een 10-repeat allel en 
COMT naar genotype Val/Val, Val/Met of Met/Met) en vergeleken we de 
prestatie van de subgroepen op een groot aantal neurocognitieve tests. 
Het COMT Val158Met polymorfisme was gerelateerd aan verschillen in 
IQ en reactietijd, de beide DRD4 polymorfismen (48 bp repeat en 120 bp 
duplicated repeat) vertoonden een associatie met verbaal geheugen 
vaardigheden en het SLC6A3 40 bp VNTR polymorfisme kon gekoppeld 
worden aan verschillen in inhibitie. Deze bevindingen duiden onder 
voorbehoud van replicatie op mogelijke endofenotypen voor ADHD in 
volwassenen. 
 
Met de onderzoeken die in dit proefschrift werden gepresenteerd hebben we 
bijgedragen aan de onderbouwing van de externe (‘concurrent’- en 
predictieve) validiteit van de diagnose ADHD bij volwassenen. Onze 
neuropsychologische en actigrafische data hebben bijgedragen aan de 
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beschrijving van de stoornis buiten de klinische symptomen om en op deze 
manier hebben ze geholpen om het fenotypische en endofenotypische beeld 
van de stoornis in volwassenen te bepalen. In de koppeling met genetische 
data hebben de neuropsychologische gegevens ook bijgedragen aan 
toekomstig genetisch onderzoek van de stoornis. 
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Dank aan ex-collega's die vriendinnen zijn geworden en met wie er gelukkig 
intussen veel meer te bespreken valt dan dat eeuwige onderzoek: Anouk, 
Fabiënne, Hilde, Karin en Saskia, wat ben ik blij met jullie gewerkt te 
hebben! 
 
Als laatste (maar niet als minste!) dank aan alle familie, vrienden en andere 
geliefden die jaar in jaar uit belangstellend bleven vragen naar het eindpunt 
 182 | Woorden van Dank 
van dit eeuwig durende project waardoor ik het altijd maar zo 
‘drukdrukdruk’ had. Wellicht ijdele hoop, maar misschien komt er nu meer 
tijd voor de andere dingen die het leven zo de moeite waard maken! Dank 
aan jullie allen voor ‘standing by me’. In het bijzonder dank aan Pieter en 
Bregje, voor levenslange steun & vertrouwen en het ‘prikkelen van de geest’. 
Aan Hidde, voor het (inmiddels grote) broer zijn, de vele geweldige vakanties 
en voor het ‘paranimfen’: mocht het tot een handgemeen komen, dan ben ik 
met jou naast me in elk geval verzekerd van goede fysieke steun! En aan 
Marleen, mijn andere steun & toeverlaat. Niet alleen bij de promotie, maar 
ook in het leren leven in een andere stad dan Amsterdam: moppie, je ben‘n 
kanjer! Dank toch ook aan Charles. Dit boekje is af en het doet me meer 
verdriet dan ik kan zeggen dat het andere onafgemaakt op de plank blijft 
liggen. Als laatste dank aan Wendell. Voor de vlinders die de laatste loodjes 
verlichtten en voor het tegenwicht van al mijn denken. 
 
 
 
 
Marije 
 
21 januari 2006 
   
Curriculum Vitae | 183 
CURRICULUM VITAE 
 
Marije Boonstra werd op 30 maart 1971 geboren in Amsterdam. In 1996 
rondde zij gelijktijdig haar studie Kinder & Jeugd Psychologie (specialisatie 
klinische neuropsychologie) en de European Graduate School for Child 
Neuropsychology af. Na een postdocorale stage in de Verenigde Staten begon 
zij in 1999 aan het promotietraject dat uiteindelijk leidde tot het onderzoek 
dat beschreven staat in dit proefschrift. Sinds 2003 is zij als universitair 
docent ontwikkelingspsychologie verbonden aan de Erasmus Universiteit in 
Rotterdam. Ze verzorgt daar onderwijs in het derde bachelor jaar en in de 
master. 
 
Marije Boonstra was born in Amsterdam on March 30th 1971. In 1996 she 
graduated both as a master in Developmental Psychology (specialization: 
clinical neuropsychology) and from the European Graduate School for Child 
Neuropsychology. After an internship in the United States, she started her 
PhD research (leading to the present thesis) in 1999. Since 2003 she is 
working as an assistant professor in Developmental Psychology at the 
Erasmus University in Rotterdam, teaching in the third bachelor year and in 
the master phase. 

   
 
 
